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Checkpoint kinase 1 (Chk1) is a key player in the DNA damage response 
signalling pathway and the mode of Chk1 activation whereby it undergoes ATR-




is well characterised. It has been 
suggested that phosphorylation at the ATR sites relieves the auto-inhibitory action 
conferred by the C-terminal negative regulatory domain on the catalytic core of 
Chk1. In this study, we show that Chk1 activity can also be stimulated by docking 
to an N-terminal region of the growth regulator p21
waf1 
and this docking domain is 
necessary for efficient Chk1-dependent phosphorylation of p21 at Ser
146
. In 
addition, Chk1 and p21 are shown to form a transient interaction by 
immunoprecipitation. Interestingly, although the isolated p21 docking domain can 
activate Chk1 in trans, a mutant where the C-terminal 70 amino acids are 
truncated is refractory to stimulation whereas mutation of the ATR phospho-
acceptor sites does not affect docking dependent activation.  Furthermore, when 
the amino acid sequence of the p21 docking domain was aligned with the sequence 
of Chk1, homology to the F region on the kinase domain was identified. 
Mutation of two conserved tryptophan residues within the homology region 
appears to release the C-terminus from intramolecular interactions rendering it 
susceptible to cleavage and refractory to allosteric stimulation. Furthermore, small 
peptides based on this region of Chk1, like the p21 docking domain, are able to 
activate Chk1 in trans and disrupt interaction between the N-terminal and C-
terminal domains. Interestingly, peptide microarray showed that Chk1 stimulated 
by activating peptide is able to phosphorylate novel peptide substrates which are 
not observed with unstimulated Chk1. The data suggest that the last C-terminal 70 
amino acids of Chk1 play an important role in auto-inhibition through interaction 
with the F region of the core catalytic domain. Binding to p21 is able to activate 





sites. Furthermore, activating peptide is able to modulate 
Chk1 specificity towards other substrates. 
     
CHAPTER 1: INTRODUCTION             
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1.1 Introduction 
The survival of a human being is dependent on the homeostatic control between 
cellular proliferation, differentiation and death; this is tightly regulated in normal 
tissue yet is aberrant in disease processes such as cancer. Central to this 
homeostatic control is the coupled regulation of cell division and maintenance of 
genomic integrity. DNA damage, due to exogenous and endogenous elements such 
as ultraviolet irradiation and reactive oxygen species, is ubiquitous throughout the 
cell cycle and can create potentially lethal genetic lesions that will disrupt this 
homeostasis (Sancar et al., 2004). To guard against propagation of deleterious 
genetic material, damaged cells activate a global response known as the DNA 
damage response that includes DNA repair mechanisms, cell cycle checkpoints 
and apoptosis (Norbury and Hickson, 2001). Cell cycle or DNA damage 
checkpoints function to arrest the cell cycle to facilitate DNA repair and might be 
involved in the induction of transcriptional programs that determine damaged cell 
fate (Lowndes and Murguia, 2000). Checkpoint kinases Chk1 and Chk2 play an 
important role in transducing checkpoint signals emanating from ATR and ATM 
to the downstream cell cycle effector molecules (Bartek and Lukas, 2003). The 
introduction chapter will cover an overview of cell cycle mechanisms and the 
DNA damage response before focusing on the checkpoint kinase Chk1. The 
results chapters will discuss findings on the mechanistic regulation of Chk1 
through a chemical genetics approach using small peptide-mimetic ligands based 
on the growth regulator p21
waf1 
before concluding with a discussion on future 
work.  
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1.2 Overview of Cell Cycle 
The eukaryotic cell cycle is an ordered set of events and is divided into four phases: 
S-phase is the period when chromosomes are replicated and it is preceded by a 
gap-phase termed G1 and followed by another gap-phase called G2. Collectively, 
G1, S and G2 are known as interphase where the cell grows by synthesizing new 
cellular proteins and starts deoxyribonucleic acid (DNA) replication. M-phase 
refers to mitosis when the cell undergoes division into two daughter cells. 
However not all cells in the human body are dividing. Indeed the majority of cells 
exist in a terminally differentiated state. Furthermore, stem cells or cells deprived 
of external growth stimuli reside in G0-phase known as the quiescent state. 
Quiescent cells can re-enter the cell cycle at G1-phase upon appropriate growth 
stimuli. This is in contrast to senescent cells which are arrested permanently and 
cannot be stimulated to re-enter the cell cycle by known growth stimuli. The 
normal progression of the cell cycle is critical for faithful segregation of parental 
genetic material to its progeny as misregulation often causes diseases such as 
cancer (Murray and Hunt, 1993).   
A close understanding of cell cycle mechanisms is needed to devise strategies to 
combat the uncontrolled divisions of cells that can lead to cancer. Much of our 
knowledge comes from studies on Saccharomyces cerevisiae and Saccharomyces 
pombe, Caenorhabditis elegans and Xenopus lavis. Interestingly, many of their 
cell cycle mechanisms are conserved across species and indeed are observed in the 
mammalian cell cycle (Murray and Hunt, 1993). A brief overview of cell cycle 
regulation is introduced in the following section. 
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1.2.1 G1/S-phase 
G1 refers to the gap period before S-phase and after M-phase. This is when cells 
start to synthesize new proteins required in S-phase for DNA replication. Tight 
regulation is necessary to maintain the cell in G1 before it is ready to engage in 
DNA replication and central to this are the cyclin-dependent kinases (CDKs) and 
the retinoblastoma protein (pRb) (Alberts et al., 2002).   
Hypophosphorylated pRb interacts with a family of activating transcription factors,  
termed E2F, which prevents their transcriptional activation of cell cycle genes 
necessary for G1/S progression and DNA synthesis. In addition, pRb also functions 
as a transcriptional repressor module with histone deacetylases (HDACs) at the 
promoter of S-phase genes. Phosphorylation and inactivation of pRb is mediated 
by CDKs (Stevaux and Dyson, 2002).   
CDKs have been described as engines that drive the events of the eukaryotic cell 
cycle. They are serine/threonine kinases that phosphorylate a number of substrates 
such as pRb, p53 and other CDKs. Activation of CDKs depends on the presence of 
a positive regulatory subunit (cyclin), the concentration of which oscillates during 
the cell cycle; its appropriate phosphorylation status; and sequestering of their 
inhibitors, cyclin-dependent kinase inhibitors (CKIs) (Morgan, 1997, Ekholm and 
Reed, 2000).   
Levels of cyclin D peak at late G1-phase and this is dependent on growth factor 
stimulation. Cyclin D then forms a complex with CDK4/6. As aforementioned, 
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CDKs also need to be appropriately phosphorylated to form active complexes. 
Phosphorylation on threonine residue 161 (Thr
161
), by CDK-activating kinase 





), by the Cdc25A phosphatase, activates CDK4/6 activity. 
CDK4/6-cyclin D complexes then phosphorylate pRb, which block pRb s 
transcriptional repression function and releases E2F transcriptional activating 
factors. This initiates the cell cycle to progress through the restriction point in G1-
phase, which signifies an irreversible commitment to undergo cell division even in 
the absence of mitogenic signals (Donjerkovic and Scott, 2000). Levels of cyclin 
A and cyclin E are up-regulated by the activation of E2F and they form complexes 
with CDK2 to maintain the inactivation of pRb, which is necessary for entry into 
S-phase. Once the cell progresses to S-phase, cyclin E becomes degraded while 
the levels of cyclin A persist into mitosis (Donjerkovic and Scott, 2000, Ho and 
Dowdy, 2002).  
The activity of CDKs is also dependent on regulation by cyclin-dependent kinase 
inhibitors (CKIs) which are largely grouped into two families: namely, inhibitor of 
CDK4 (Ink4) and CDK-interacting protein/ Kinase inhibitory protein (Cip/Kip). 
Due to their anti-proliferative function, they are also known as tumour suppressors 
(Vidal and Koff, 2000).  









which inhibit the D-type cyclin-dependent kinases (CDK4/6) by binding 
in competition with cyclin D. All four members are characterised by the presence 
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of four ankyrin repeats of which the third repeat is essential for CDK4/6 







share a conserved N-terminal domain and inhibit Cdk4- and Cdk2-binding 
complexes stoichiometrically by interacting with both CDKs and cyclins to 
prevent a functional CDK-cyclin complex. In addition, p21
cip1/waf1 
inhibits DNA 
synthesis by binding with proliferating cell nuclear antigen (PCNA), a processivity 
factor of DNA polymerase delta (pol ) (Vidal and Koff, 2000). More functions of 
p21
waf1 
will be described in the introduction to Chapter 3.   
1.2.2 S-phase 
The control of S-phase is a very complex process that is independent of external 
growth factors as compared to the G1 phase. It is intrinsically controlled by the 
E2F transcription factor family which up-regulates the genes required for 
deoxynucleotide triphosphate (dNTP) and DNA synthesis, including thymidylate 
synthase (TS) and DNA polymerase pol . The level of E2F is negatively 
regulated via feedback from the increased dNTPs. As DNA synthesis is completed 
at the end of S-phase, dNTPs would accumulate and thereby mediate E2F 
inactivation (Pardee et al., 2004).   
CDK2-cyclin A/E complexes also regulate S-phase progression. As 
aforementioned, they phosphorylate pRb and facilitate the release of E2F which 
then forms active transcriptional dimers with the DP proteins. In addition, CDK2-
cyclin E also phosphorylates the components of a pre-replication complex which 
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then associates with Cdc45 to activate the replication origin and initiate DNA 
replication. CDK2-cyclin A has also been implicated in the control of DNA 
replication by activating existing pre-replication complexes and elongation and 
also preventing re-replication (Woo and Poon, 2003). In the late S-phase, E2F is 
phosphorylated by CDK2-cyclin A and targeted for degradation to ensure the 
unidirectional progression of S-phase and prevent the initiation of a new S-phase 
prior to mitosis (Pardee et al., 2004).   
1.2.3 G2/M-phase 
After DNA replication is completed, the cell enters G2 phase which is a gap period 
before mitosis. In this phase, synthesis of proteins required for mitosis occurs. 
Transition through G2/M-phase was first found to be mediated by a protein called 
M-phase promoting factor (MPF). Later it was elucidated that MPF is made up of 
a catalytic subunit, CDK1 and a regulatory subunit, cyclin B (Murray and Hunt, 
1993). CDK1 is activated by phosphorylation on Thr
161 
mediated by a Cdk-





protein phosphatase Cdc25C (Nigg, 2001). Active CDK1 then phosphorylates 
numerous substrates such as nuclear lamins, condensins and other microtubule-
binding proteins necessary for the onset of mitosis.  
In addition, once the cell progresses into late G2-phase, cyclin A begins to 
associate with CDK1, where it could potentially be involved in the reorganization 
of the cytoskeleton for mitosis (Hutchison and Glover, 1995). Furthermore, 
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increasing evidence has shown that CDK2-cyclin A has a critical role in the timing 
of mitosis through regulation of CDK1-cyclin B activation (Mitra and Enders, 
2004, Gong et al., 2007, De Boer et al., 2008).    
1.2.4 M-phase 
The mitotic phase can be broken down into different stages: namely prophase, 
prometaphase, metaphase, anaphase, telophase and cytokinesis.  
Prophase is characterised by chromatid condensation and the self-assembly of the 
mitotic spindle, a structure required for the separation of chromosomes into two 
daughter cells. During this period, the nuclear envelope also begins to breakdown. 
It disappears completely in prometaphase and the kinetochores on the 
chromosomes are attached to the mitotic spindle via the microtubules extending 
from the centrosomes. In metaphase, the chromosomes are aligned along the 
metaphase plate in the middle of the cell. They are kept in this position by the 
balance of microtubule forces emanating from the opposite spindle poles, until the 
separation of sister chromatids in anaphase (Nigg, 2001, Alberts et al., 2002).  
The transition from metaphase to anaphase is triggered by the activation of the 
Anaphase Promoting Complex (APC). APC functions to mediate the degradation 
of CDK1-cyclin B and an inhibitory protein called securin. Following the 
inactivation of securin, separase then mediates the cleavage of cohesin, a subunit 
responsible for the binding of the sister chromatids and therefore facilitating the 
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separation of chromatids (Alberts et al., 2002). APC, also known as the cyclosome, 
is a multi-subunit 20S E3-ubiquitin ligase that couples ubiquitin molecules onto its 
substrates in a concerted effort with E2 ubiquitin-conjugating enzymes. Activation 
of APC is dependent on Polo-like kinase 1 (Plk1)-mediated phosphorylation. This 
modification primes APC for binding to its regulatory factors, namely cell division 
cycle 20 (Cdc20) and Cdc20 homology 1 (Cdh1) which are characterised by seven 
WD40 motif repeats (Fang et al., 1999, Baker et al., 2007). It has been suggested 
that APC exhibits differential substrate selectivity depending on the activator it 
binds to, Cdc20 or Cdh1 (Peters, 2006). Mitotic exit is also regulated by APC 
where it mediates the destruction of Plk1 and Aurora B (Baker et al., 2007).  
Anaphase is characterised by the movement of each set of chromosomes towards 
opposite poles. The nuclear envelope then begins to reform around the daughter 
chromosomes as they start to decondense in telophase. Cytokinesis is marked by 
the formation of an actomyosin-based contractile ring that splits the cell into two 
daughter cells. Following cytokinesis completion, the cell cycle progresses into G1 
phase (Nigg, 2001).   
1.3 DNA damage response 
DNA is the blueprint of life as it contains the genetic code which is central to the 
development and function of living organisms. DNA is constantly damaged by 
omnipresent endogenous cellular metabolites such as reactive oxygen species that 
arise during respiration or environmental genotoxic agents such as ultraviolet (UV) 
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radiation and other chemical agents. These DNA-damaging agents cause chemical 
modifications to the DNA bases, DNA backbone breakages, including single- and 
double-stranded breaks, and DNA-DNA or DNA-protein cross-linkages that 
encumber transcription and/or replication (Sancar et al., 2004).  For example, UV 
radiation generates 6-4 photoproduct and cyclobutane-pyrimidine dimers which 
distort the DNA helix and cause DNA replication arrest (Ward et al., 2004). 
Damaged genetic material can form transcripts for the synthesis of aberrant protein 
molecules that may function in the development and progression of diseases.  
To ensure genomic stability and maintain the fidelity of DNA replication so as to 
minimize the occurrence of heritable mutations, nature has built in a set of evolved 
surveillance and response mechanisms to monitor cell cycle progression and cope 
with DNA damage. When a cell encounters damage, the appropriate DNA repair 
mechanism is promptly activated to repair the lesions. At the same time, cell cycle 
progression is arrested by checkpoint activation to facilitate DNA repair. If the 
damage is too extensive to be repaired, these potentially deleterious mutations are 
removed from the proliferating pool by either inducing a permanent proliferative 
arrest, known as senescence, or programmed cellular death, termed apoptosis. This 
convoluted cellular response is known as the DNA damage response (DDR) 
(Sancar et al., 2004, Bartek et al., 2007). The following section will briefly outline 
the various elements involved.     
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1.3.1 DNA damage checkpoint 
DNA damage checkpoints or cell cycle checkpoints are activated to halt cell cycle 
progression in response to DNA damage. Perhaps it is not well-appreciated that 
key elements of the checkpoint pathways also operate in the unperturbed cell cycle 
to ensure the fidelity of normal cell cycle progression (Sancar et al., 2004). As 
aforementioned, cell division is an ordered set of events. These checkpoints ensure 
that certain events are completed before progression onto the next phase; for 
example, if the chromosomes are not aligned properly along the metaphase plate, 
transition into anaphase is blocked to prevent aneuploidy (Hutchison and Glover, 
1995). Similarly, these checkpoints function to sequester damaged cells in the 
affected cell cycle phase until DNA damage is repaired to avert improper 
segregation of damaged chromosomes and ensure genomic stability. However, 
checkpoint function is not limited to cell cycle arrest and its action also percolates 
throughout the entire DDR network, resulting in coordinated spatial and temporal 
activation of DNA repair and induction of transcriptional programmes (Zhou and 
Elledge, 2000). Due to their pivotal role in DDR and cell cycle progression, it is 
not surprising to note that checkpoint pathways are well conserved across species 
ranging from Saccharomyces cerevisiae to Xenopus lavis and mammals, though its 
specificities may differ.  
Checkpoint signalling pathways are generally made up of three important groups 
of proteins (Figure 1.1) (Sancar et al., 2004):  
1. Sensor proteins these recognise aberrant DNA structure and initiate the 
biochemical pathway,  
  
- 11 -  
2. Transducer proteins these serve to amplify the signals from the sensors by 
phosphorylating other target proteins,  
3. Effector proteins these aim to arrest cell cycle progression.   
1.3.1.1 Sensor proteins 
Sensor proteins are found at the top of the checkpoint signalling pathway where 
they scan the DNA structure for strand breakage, incomplete DNA replication, 
undesirable DNA adducts or other abnormalities and then initiate biochemical 
signals that modulate the function of their downstream target proteins. Two major 
players in DNA damage checkpoints are the phospho-inositide 3-kinase-like-
kinase (PIKK)-related proteins: Ataxia telangiectesia mutated protein (ATM) and 
ATM-Rad3-related protein (ATR). They are serine/threonine kinases with 
conserved kinase domains at the C-termini (Abraham, 2001) and serve 
overlapping yet distinct branches of the checkpoint network depending on the type 
of DNA damage. Primarily, ATM responds to double-stranded DNA breaks 
(DSBs) induced by ionising radiation (IR), while ATR is activated upon single-
stranded DNA breaks (SSBs) generated by UV irradiation or stalled DNA 
replication (Sancar et al., 2004).  
ATR has been found to be an essential protein in embryonic development where 
ATR-null mouse embryos fail to develop beyond the blastocyst stage (Brown and 
Baltimore, 2000). In Xenopus, ATR is found to associate with chromatin that is 
dependent on RNA primer synthesis by DNA polymerase pol  in the absence and 
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presence of stalled replication forks (Hekmat-Nejad et al., 2000). Following 
activation of the ATR-dependent checkpoint, nucleotide and base excision repair 
is stabilised by binding to a heterotrimeric protein complex called replication 
protein A (RPA) (Michael et al., 2000). This facilitates the loading of ATR onto 
the RPA-coated ssDNA which is dependent on ATR-interacting protein (ATRIP) 
(Zou and Elledge, 2003). Rad17, part of the replication factor C homolog also 
binds to the RPA coated-ssDNA and loads the Rad9-Rad1-Hus1 (9-1-1) complex 
onto the chromatin (Zou et al., 2003). The 9-1-1 complex is structurally related to 
PCNA, a protein that functions as a clamp to hold the chromatin together during 
replication (Shiomi et al., 2002). Rad17 association with the chromatin is ATR-
independent but it is phosphorylated by ATR after stress and this phosphorylation 
is dependent on the 9-1-1 complex. Ablation of the Rad9 subunit of the 9-1-1 
complex diminished ATR function, leading to gross chromosomal aberration. 
Hence, it has been postulated that sensor proteins localise onto the chromatin 
independently but interact to initiate the checkpoint signalling pathway (Zou et al., 
2002, Dang et al., 2005). It should also be noted that ATR can also be activated by 
RPA-independent mechanism (Dodson et al., 2004) as it was found that TopBP1 
can increase the activity of ATR even in the absence of RPA. This suggests that 
two different initiating signals may exist for activating ATR-dependent checkpoint 
responses (Kumagai et al., 2006). Activated ATR phosphorylates numerous 
checkpoint substrates including Chk1, RPA and BRCA1 which contain a 
consensus motif serine (Ser)/Thr followed by a glutamine (Gln) residue (SQ/TQ) 
(Kim et al., 1999).  
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ATM is a 370 kDa protein kinase primarily activated in response to ionising 
radiation where double stranded breaks are induced. Its function is defective in 
ataxia-telangiectasia (A-T) patients who display radiation hypersensitivity, 
aberrant checkpoint function and increased chromosomal breakage (Kastan and 
Lim, 2000). Upon initiation of DNA lesions, ATM undergoes intermolecular 
autophosphorylation at Ser
1981 
which causes the inactive ATM dimers to dissociate 
and form active monomers that initiate an ATM-dependent checkpoint signalling 
cascade. ATM activation appears to be independent of DNA DSB binding, but 
may be triggered from changes in chromatin structure (Bakkenist and Kastan, 
2003). However, ATM activation does seem to depend on a functional Mre11-
Rad50-Nbs1 (MRN) complex. MRN may help to tether ATM to the double-
stranded breaks through ATM-dependent phosphorylation of histone H2AX (Uziel 
et al., 2003) which also serves to localise the assembly of the DNA repair complex 
(Bartek and Lukas, 2007). Further evidence for MRN-dependent activation of 
ATM has shown that purified inactive dimeric ATM displays an 80-200 fold 
increase in activity in the presence of the MRN complex and linear DNA (Lee and 
Paull, 2005). Furthermore, it was also suggested that ATM-dependent 
phosphorylation of Nbs1, part of the MRN complex, may contribute to the 
recruitment of ATM substrates (Lee and Paull, 2007). Based on studies hitherto, it 
was proposed that damaged DNA is bound directly and processed by the MRN 
complex, which facilitates the recruitment and activation of ATM. Active 
monomeric ATM then serves to phosphorylate substrates localised or recruited to 
the lesions. In addition, ATM also phosphorylates histone H2AX surrounding the 
site of DSB which facilitates the recruitment of yet more substrates, thereby 
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reinforcing the signal (Kurz and Lees-Miller, 2004). Like ATR, activated ATM 
preferentially phosphorylates substrates on a general consensus motif a Ser/Thr 
residue which is followed by a Gln (SQ/TQ). Among its putative substrates are 
Chk2 which is phosphorylated on Thr
68 
and p53 which is phosphorylated on Ser
15 
(Kim et al., 1999, Matsuoka et al., 2000).  
The above summary of the ATM/ATR-signalling machinery depicts it as a multi-
protein complex, however it is important to note that this is also a dynamic 
collection of protein complexes whose members change with the type of DNA 
damage, location relative to the site of damage and time after damage initiation 
(Abraham, 2001).    
1.3.1.2  Transducers 
Checkpoint kinase 1 and 2 (Chk1 and Chk2) are the downstream targets of the 
checkpoint pathway that relay and amplify the ATR and ATM initiating signals. 
Until recently, it was thought that Chk1 is primarily activated by ATR in response 
to replication blocks and UV treatment, while Chk2 is modified by ATM upon IR-
induced double stranded breaks (Abraham, 2001). In fact, studies have shown that 
ATR-Chk1 and ATM-Chk2 are not exclusive branches of the DNA damage 
response pathway, but demonstrate a high degree of cross-talk where ATM is 
capable of activating Chk1 in response to IR (Gatei et al., 2003). This has been 
demonstrated in a study where ATM and Chk1 cooperate in response to IR to 
down-regulate the activity of mammalian Tousled-like kinase 1 (Tlk1), a kinase 
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that is potentially involved in the regulation of chromatin assembly and DNA 
replication in S-phase (Groth et al., 2003). Similarly, ATR has also been 
demonstrated to phosphorylate Chk2 in vitro (Matsuoka et al., 2000).  
Chk2 is a nuclear Ser/Thr protein kinase which can be activated in response to 
DNA damage throughout the cell cycle, even in quiescent cells (Lukas et al., 
2001). Chk2 contains three functional domains an N-terminal SQ/TQ cluster 
domain (SCD), a forkhead-associated domain (FHA) and a C-terminal kinase 
domain. The SCD contains 7 SQ/TQ motifs of which Thr
68 
is the principal 
phosphorylation site, whereas the FHA domain is involved in protein-protein and 
intramolecular interactions (Figure 1.2) (Ahn et al., 2004). Phosphorylation of 
Thr
68 
induces Chk2 dimerisation where the FHA domain of the first molecule 
interacts with the phospho-Thr
68 
region of the second molecule (Ahn et al., 2002). 




within the activation loop of the kinase domain, resulting in active Chk2 molecules 
(Lee and Chung, 2001). Aside from a role in dimerisation, phospho-Thr
68 
may also 
facilitate association with other FHA domain-containing proteins such as the 
mediator of DNA damage checkpoint protein 1 (MDC1) FHA domain which binds 
selectively to phospho-Thr
68 
of Chk2 (Lou et al., 2003). An important scaffold 
molecule in Chk2 activation is BRCA1, which is required for Thr
68 
phosphorylation by ATM (Foray et al., 2003). Following ATM-dependent 
activation, Chk2 is released from the damaged DNA-associated complex to target 
its downstream substrates, thus amplifying the checkpoint signal (Lukas et al., 
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2003) and this may involve Chk2-dependent phosphorylation of BRCA1 (Ahn et 
al., 2004).   
A detailed overview of Chk1 protein kinase will be discussed in the later sections.    
1.3.1.3  Effectors 
Chk1 and Chk2 transduce checkpoint activation signals to numerous effectors of 
which the best characterised are the dual-specificity phosphatases Cdc25A and 
Cdc25C. Phosphorylation on Ser
124 
by both checkpoint kinases mediates the 





of Cdk2, thus halting G1/S-phase progression (Falck et al., 
2001, Sorensen et al., 2003). Similarly, Chk1 and Chk2 phosphorylation of 
Cdc25C on Ser
216 
promotes 14-3-3 binding and initiates Cdc25C cytoplasmic 
relocalisation (Peng et al., 1997, Matsuoka et al., 1998, Lopez-Girona et al., 1999). 
As a result, Cdk1-cyclin B remains inactivated and G2/M transition is prevented.  
In addition, Chk2 phosphorylates E2F1 at Ser
364 
which results in increased protein 
stabilisation and transcriptional activation leading to apoptosis (Stevens et al., 









been reported in vitro (Shieh et al., 2000, Hirao et al., 2000, Craig et al., 2003). 
Modification of these residue is thought to disrupt interaction with its inhibitory 
protein, murine double minute 2 protein (MDM2), leading to increased 
transcriptional activation of its target genes including p21
waf1 
(Chehab et al., 1999, 
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Bean and Stark, 2001). This illustrates how Chk1 and Chk2 integrate the 
checkpoint activation signal from ATR/ATM to phosphorylate numerous 
substrates and effect a cell cycle arrest.    
1.3.2 DNA repair 
Multiple DNA repair mechanisms have evolved to cope with the myriad of DNA 
damage which occurs within the cell. This includes base excision repair which 
deals with damaged DNA bases, nucleotide excision repair, which removes UV-
induced DNA lesions such as thymine dimers and mismatch repair, which corrects 
replication errors (Houtgraaf et al., 2006).  
Double-stranded DNA break induced by ionising radiation and reactive oxygen 
species are lethal forms of DNA damage and if left unchecked, can initiate 
carcinogenesis and apoptosis. Two distinct repair mechanisms have developed to 
manage DSBs, namely homologous recombination (HR) and non-homologous end 
joining (NHEJ). HR utilises the extensive DNA homology region on the 
undamaged sister chromatid to generate a relatively error-free repair, whereas 
NHEJ facilitates the ligation of free ends without the presence of a homologous 
template in a more error-prone manner. Due to its requirement for a sister 
chromatid, HR is only activated in S or G2-phase whereas G1 and G0 or terminally 
differentiated cells rely on NHEJ (Wyman and Kanaar, 2006).  It has been 
recognised that DNA damage is often associated with phosphorylation of histone 
H2AX which is believed to facilitate recruitment of DNA damage response 
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proteins (Fernandez-Capetillo et al., 2004). Indeed, it has been shown that in 
response to DSBs, ATM/ATR-mediated H2AX phosphorylation is necessary for 
the recruitment of cohesin during the HR reaction (Unal et al., 2004, Strom et al., 
2004). In addition, the fact that the MRN complex may process the DSB ends in 
HR demonstrates how the checkpoint signals and DNA repair pathway are 
integrated (Khanna and Jackson, 2001).           
1.3.3 Apoptosis 
Programmed cell death or apoptosis is activated in response to irreparable DNA 
damage as it is deleterious for the excessively damaged chromosomes to be 
replicated. Furthermore, some cells such as lymphocytes and epithelial cells in gut 
are highly sensitive to low level of DNA damage and will activate the apoptotic 
program instead. However it is not clear what causes the cell to trigger its 
apoptotic program after it is overwhelmed by excessive DNA damage. One of the 
key players could be the p53 protein. After genotoxic stress, p53 is phosphorylated 
by ATM and the checkpoint kinases which promotes dissociation from its inhibitor, 
MDM2 (Colman et al., 2000). This results in increased p53-dependent 
transcriptional activation of genes which include DNA repair proteins and cell 
cycle inhibitors. It is believed that post-translational modifications and increased 
levels of p53 protein in response to high levels of DSBs can lead to up-regulation 
of pro-apoptotic genes such as BCL2-associated X protein (Bax), p53-upregulated 
modulator of apoptosis (PUMA), FAS (apoptosis stimulating factor) receptor and 
Noxa (Yu and Zhang, 2003, Roos and Kaina, 2006). Puma and Noxa facilitate 
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cytochrome C release from the mitochondria by activating Bax or Bak 
mitochondrial translocation and also by inhibiting anti-apoptotic Bcl2-family 
proteins. Cytochrome C activates Apaf-1 which leads to apoptosome assembly and 
caspase activation (Borges et al., 2008). Similarly, in the presence of DNA 
damage, c-Jun NH(2)-terminal kinase (JNK) promotes Bax translocation into the 
mitochondria through phosphorylation of 14-3-3 complex, a cytoplasmic anchor of 
Bax (Tsuruta et al., 2004). In addition to cytochrome C, Smac/Diablo (second 
mitochondria-derived activator of caspases) is also released into the cytoplasm to 
induce apoptosis via the apoptosome-dependent pathway and cleavage of 
inhibitors of apoptosis (IAPs) (Kim, 2005). Activated p53 is also known to trigger 
the death-receptor pathway that involves the Fas receptor and its ligand, both of  
which are upregulated in response to UV irradiation (Roos and Kaina, 2006, 
Timares et al., 2008). Activated Fas ligand-receptor mediates the formation of a 
death-inducing signalling complex (DISC), which contains the Fas-associated 
death domain (FADD) and caspase 8. In type I cell death, processed caspase 8 
directly activates the executioner molecule, caspase 3 whilst in type II cell death, 
caspase 8 functions to release pro-apoptotic proteins such as cytochrome C from 
the mitochondria which then amplifies the apoptotic signal (Kim, 2005).  
Given the fact that over 50 % of tumour cells are defective in p53, a p53-
independent apoptotic mechanism appears necessary (Roos and Kaina, 2006). One 
such pathway involves E2F1 and the p53 homolog, p73 protein. Upon DNA 
damage, Chk1 and Chk2 mediate E2F1 stabilisation through phosphorylation. This 
results in the transactivation of the p73 gene and increased DNA-damage induced 
  
- 20 -  
cell death in a p53-independent manner (Urist et al., 2004). p73 has been shown to 
mediate the transactivation of PUMA which leads to Bax mitochondria 
translocation and cytochrome C release (Melino et al., 2004). A caspase-
independent pathway also exists via the apoptosis-inducing factor (AIF). Upon 
pro-apoptotic signals, flavoprotein AIF translocates from the permeable 
mitochondria to the nucleus, where it binds to DNA and induces chromatin 
condensation and DNA fragmentation through unknown mechanism (Cande et al., 
2002).   
1.3.4 Senescence or Adaptation 
Damaged cells do not always undergo apoptosis; they can also initiate another 
response by undertaking an irreversible growth arrest, termed cellular senescence, 
so that deleterious effects are not propagated to its progeny (Bartek and Lukas, 
2007). DNA damage-initiated senescent cells are often characterised by 
senescence-associated DNA damage foci (SDFs) which contain DDR proteins 
such as ATM, 53BP1 (p53-binding protein 1) and phosphorylated histone ( -
H2AX) (Campisi and d'Adda di Fagagna, 2007). However, it is not clear if SDFs 
play a key role in the induction of senescence or whether it is just an artefact 
created as a result of an earlier response to facilitate DNA repair. Increasing 
evidence points to p53 as an important link in senescence. Tumour cells with wild-
type p53 are more likely to senesce in response to chemotherapy as compared to 
cells with mutant p53 (Ling et al., 2000, Roberson et al., 2005). This is often 
accompanied by increased expression of p21
waf1 
which is involved in G1 arrest (Di 
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Leonardo et al., 1994, Herbig et al., 2004). Senescence growth arrest can also be 
mediated through the p16 pathway. Telomere damage induces the delayed 
expression of p16 which mediates G1/S arrest through pRb pathway, especially in 
a defective p53 setting (Jacobs and de Lange, 2005). However, the mechanism by 
which the p53 or p16 pathway in controlling senescence is not clear. It is also not 
clear what governs the cell in its choice between apoptosis or senescence. It was 
speculated that the nature and intensity of damage may be important as well as the 
cell type as damaged fibroblasts and epithelial cells are likely to senesce while 
damaged lymphocytes tend to undergo apoptosis (Campisi and d'Adda di Fagagna, 
2007).  
Adaptation, a process whereby the cells resume cell cycle progression in the 
presence of persistent DNA damage, was first described in yeast S.cerevisiae 
(Toczyski et al., 1997). It was later reported that checkpoint adaptation also exists 
in Xenopus in response to DNA replication blocks and in human cells after IR 
(Yoo et al., 2004, Syljuasen et al., 2006). The molecular mechanisms of 
checkpoint adaptation are relatively unknown, however evidence points to polo-
like kinase 1 (Plk1) as the dominant player in this network. Plk1 deletion or 
depletion in S.cerevisiae and human cells respectively prevent mitotic entry in 
later stages after DNA damage (Toczyski et al., 1997, Syljuasen et al., 2006). One 
possible mechanism might involve the link between Plk1 and Chk1. Plk1 has been 
shown to phosphorylate Claspin at Ser
934 
resulting in its dissociation from 
chromatin in Xenopus and this prevents Claspin-mediated activation of Chk1 (Yoo 
et al., 2004). In human cells, Claspin undergoes -TrCP-SCF ubiquitin ligase-
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dependent degradation after phosphorylation by Plk1 in checkpoint recovery 
(Mailand et al., 2006, Peschiaroli et al., 2006). Checkpoint recovery allows the 
cells to re-enter the cell cycle after DNA damage is repaired through attenuation of 
checkpoint signals. Checkpoint recovery and adaptation pathways often involve 
the same components (Bartek and Lukas, 2007) however, Claspin might be 
dispensable for checkpoint adaptation as depletion of Claspin in human cells did 
not accelerate mitotic entry after IR (Syljuasen, 2007). It is possible that Plk1 may 
activate phosphatases such as PPM1D (Protein phosphatase magnesium-dependent 
1 delta) that dephosphorylates Chk1 (Lu et al., 2005). It is also suggested that 
CDK1-cyclin B may be targeted by Plk1 during G2 checkpoint adaptation as the 
level of inhibitory phosphorylations on CDK1-cyclin B is decreased by Plk1-
mediated degradation of Wee1 kinase (van Vugt et al., 2004). At the same time, 
cyclin B levels increase during prolonged G2 arrest and this triggers the 
termination of IR-induced checkpoint in HeLa cells (Syljuasen, 2007). It is not 
clear what the physiological significance of checkpoint adaptation is. One possible 
reason could be to allow the damaged cells to move into a phase where apoptosis 
is initiated. Another interesting theory is that adaptation may exist to allow natural 
evolution at the expense of genomic instability (Syljuasen, 2007).     
1.4 Checkpoint kinase 1 
Checkpoint kinase 1 or Chk1 was first discovered in fission yeast and operates in 
DNA damage checkpoints (Walworth et al., 1993, al-Khodairy et al., 1994). Its 
checkpoint function is largely conserved among S.cerevisiae, S.pombe, Drosophila, 
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X.laevis and mammals, though the checkpoint signal specificity that regulates 
Chk1 has diverged. Sequence analysis also revealed a high degree of similarity 
among Chk1 homologs (Fogarty et al., 1997, Sanchez et al., 1997, Nakajo et al., 
1999, Chen and Sanchez, 2004). Although both fission and budding yeast Chk1 
are dispensable for viability, Chk1 has been shown to be an essential kinase in the 
development of mammalian embryonic stem cells and Chk1-null murine embryos 
fail to develop beyond the blastocyst stage and exhibit grossly abnormal 
morphology (Takai et al., 2000, Liu et al., 2000). Similarly, abrogation of Chk1 in 
Xenopus embryos triggers apoptosis after the midblastula transition (Carter and 
Sible, 2003). Chk1-deficient somatic cells also display aberrant checkpoint 
function, indicating that Chk1 is required for the normal proliferation of adult 
somatic cells (Zachos et al., 2003, Lam et al., 2004). Cytogenetic analysis 
discovered that the CHK1 gene is localised to chromosome 11q24, which is 
adjacent to the ATM gene at 11q23 (Sanchez et al., 1997). Northern blot analysis 
showed that the CHK1 gene is detected in all human tissues examined and in large 
amounts in human thymus, testis, small intestine and colon (Sanchez et al., 1997). 
Chk1 mutations are rare in human tumours, however loss of heterozygosity (LOH) 
at chromosome 11q21-24, a region containing several tumour suppressors 
including Chk1 is observed in a variety of human malignancies (Kramer et al., 
2004a).      
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1.4.1 Chk1 Structure 
Chk1 is made up of 476 amino acids which comprise an N-terminal catalytic 
domain (residues 1-265), for which the crystal structure has been elucidated, a 
flexible linker region and a less well-conserved C-terminal regulatory domain that 
is thought to contain a pseudosubstrate sequence which can auto-inhibit the 
catalytic domain (Figure 1.3) (Chen et al., 2000). A detailed outline of Chk1 
structure is given in the introduction to Chapter 4.    
1.4.2 Regulation of Chk1 
1.4.2.1 Post-translational modification 
The Chk1 protein kinase contains several conserved SQ/TQ phosphorylation 
motifs in the regulatory domain which are recognised by ATR/ATM. Of these 
SQ/TQ sites, Ser
345 
was the first residue found to be phosphorylated by ATR in 
response to UV, IR and hydroxyurea (HU) treatment (Liu et al., 2000). Subsequent 
studies have shown that Ser
317 
is also phosphorylated by ATR and site-directed 




contributes to the 
activation of Chk1 and its increased kinase activity (Zhao and Piwnica-Worms, 





, further demonstrating a high degree of crosstalk and connectivity 
between the ATM and ATR pathways (Gatei et al., 2003, Kurz et al., 2004). It has 




phosphorylation induce a conformational 
change within Chk1 leading to the release of the regulatory domain autoinhibition 
which activates the kinase (Zhao and Piwnica-Worms, 2001). 
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In addition, phosphorylation of Ser
317/345 
has been shown to promote dissociation 
of Chk1 from chromatin, leading to phosphorylation of Chk1 s soluble substrates 
(Smits et al., 2006). Indeed, the spatial effect of phosphorylated Chk1 is observed 
after laser microirradiation where it spreads rapidly throughout the nucleus 
(Bekker-Jensen et al., 2006). The localisation effect of Ser
317/345 
phosphorylation 
was further elucidated in an elegant study where phosphorylation at Ser
317 
was 
found to be important for Chk1 release from the chromatin and for subsequent 
effective modification on Ser
345 
which promotes its cytoplasmic localisation and 
association with the centrosomes (Niida et al., 2007). It was observed that 
centrosomal localisation of Chk1 is important for checkpoint function as forced 
immobilisation of Ser
317/345 
mutants at the centrosome prevents mitotic catastrophe, 





association (Niida et al., 2007). However, in another study, Ser
345 
phosphorylation 
was seen to produce different results. It was determined that sequences around 
Ser
345 
form a putative 14-3-3 binding motif and that phosphorylation at this site 
mediates 14-3-3 association which blocks Crm1-dependent nuclear export of Chk1 
(Jiang et al., 2003).   
Other studies have shown that ATR-dependent phosphorylation on Ser
345 
not only 
leads to Chk1 activation but also mediates delayed degradation by the cullin 
family E3-ligase members, Cul1 and Cul4A (Zhang et al., 2005). It was speculated 
that coupling of the activation and subsequent degradation of Chk1 prevents its 
constitutive activation and allows cellular recovery from checkpoint activation, 
thus permitting DNA replication to resume (Zhang et al., 2005). Oncogenic 
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PPM1D has been identified as the serine/threonine phosphatase which binds Chk1 





leading to decreased Chk1 kinase activity and checkpoint recovery (Lu et al., 
2005).   
   
Further inhibitory mechanisms for Chk1 have been identified, for example, protein 
kinase B/Akt (PKB/Akt) phosphorylates a conserved site at Ser
280 
(Shtivelman et 
al., 2002). Analysis has pointed out that Ser
280 
modification prevents complex 
formation, presumably with Claspin, as well as ATR-activating phosphorylation at 
Ser
345
, leading to defective checkpoint function (King et al., 2004). Phosphatase 
and tensin homologue (PTEN) is an inhibitor of PKB/Akt. Chk1 kinase activity is 
significantly lower in PTEN
-/- 
cells as compared to wild-type cells and this is due 
to activated PKB/Akt-dependent phosphorylation of Chk1 on Ser
280 
(Puc et al., 
2005). In addition, it was shown that Ser
280 
phosphorylation triggers 
monoubiquitination of Chk1 on Lys
274 
and mediates enhanced cytoplasmic 
localisation, leading to defective checkpoint function (Puc and Parsons, 2005).   




, were also reported 
(Shiromizu et al., 2006). These modifications were mediated by CDK1 during 
early mitosis. The physiological significance of this phosphorylation is not clear as 





appeared to block Ser
317/345 
phosphorylation in 
nocodazole-arrested mitotic cells, suggesting that CDK1-targeted mitotic 
phosphorylation of Chk1 might prevent Chk1 activation during early mitosis 
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(Shiromizu et al., 2006). This mode of mechanism was seen in Cdc25C where 
phosphorylation at Ser
214 
by CDK1 prevents Chk1-inactivating phosphorylation 
on Ser
216 
during mitosis (Bulavin et al., 2003).  
A large-scale proteomic analysis of ATM/ATR phosphorylated substrates in 
response to DNA damage has identified Chk1 Ser
308 
as a novel phosphorylation 
site, though its biological significance is unknown (Matsuoka et al., 2007). It is 
however possible that Ser
308 
is an autophosphorylation site, just as Ser
296 
is 
suggested to be (Clarke and Clarke, 2005). Autophosphorylation of Chk1 was first 
observed in S.pombe studies but has been suggested to have minimal effect on 
Chk1 kinase activity (Walworth and Bernards, 1996, Chen et al., 2000). Chk1 
autophosphorylation sites have not been mapped out but deletion analysis 
suggested that they are found in the C-terminal domain and possibly the linker 
region (Chen et al., 2000, Ng et al., 2004).   
1.4.2.2 Adaptor proteins 
In addition to post-translational modifications, adaptor proteins are also involved 
in the regulation of Chk1. A well-characterized example is Claspin. It was first 
identified as a novel essential upstream regulator of Xenopus Chk1 (xChk1), 
where immunodepletion of Xenopus Claspin (xClaspin) resulted in the abrogation 
of xChk1 activation and therefore DNA replication checkpoint (Kumagai and 
Dunphy, 2000). In addition, xATR/ATRIP phosphorylated xChk1 only weakly in 
the absence of xClaspin (Kumagai et al., 2004). Claspin has also been found to 
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associate with ATR and Rad9, a subunit of the 9-1-1 complex (Chini and Chen, 
2003) and it is thought that a transient interaction between xClaspin and chromatin 
is sufficient for the activation of xChk1 (Lee et al., 2005).  
Phosphorylation of Claspin is required for its interaction with Chk1 since 
dephosphorylation of xClaspin abolishes binding with xChk1 (Kumagai and 
Dunphy, 2000) and in the mammalian system, this is dependent on ATR and 
phosphorylated Rad17 (Wang et al., 2006). Using deletion analysis, it was found 
that binding involves a 57 amino acid region in the C-terminal domain of xClaspin 
which contains two highly conserved repeated phospho-peptide motifs 




in each repeat is 
essential for xChk1 interaction with Claspin as mutation at either serine residue 
reduced xChk1 binding by more than 50 % and the double-mutant was unable to 
associate with xChk1 (Kumagai and Dunphy, 2003). On the other hand, human 







are necessary for Chk1 recognition and its subsequent 
activation (Clarke and Clarke, 2005). It also seems that differential 
phosphorylation requirements exist in response to distinct types of DNA damage. 




in the SQ/TQ motifs recognized by 




are phosphorylated in 
response to stalled replication forks. This may suggest that the specificity of 
Claspin in response to different DNA damage could be determined by site-specific 
phosphorylation, which would potentially expand the functional diversity of the 
protein (Yoo et al., 2006). 
  
- 29 -  





, as xATR depletion abrogated xClaspin phosphorylation and thus 
binding to xChk1 (Kumagai and Dunphy, 2003). However, the serine residues 
phosphorylated do not resemble the preferred ATR substrate consensus motif 
(SQ/TQ) and furthermore, direct phosphorylation of Claspin by ATR has not been 
observed. Thus it seems that an intermediate kinase might be responsible for the 
modification (Kumagai and Dunphy, 2003). Interestingly, in mammalian systems, 
Chk1 was found to phosphorylate Claspin at Thr
916 
and it was therefore suggested 
that Claspin and Chk1 could interact in a phosphorylation-independent manner to 
initiate ATR-mediated activation of Chk1 and that this association is maintained 
through Chk1 phosphorylation of Claspin (Chini and Chen, 2006).  Indeed, 
Claspin stabilization has been shown to require active Chk1 kinase. This 
highlighted the existence of a positive autoregulatory feedback loop, in which 
Chk1 stabilizes Claspin, while Claspin facilitates the activation of Chk1 (Chini et 
al., 2006).  
The Claspin docking site has also been mapped to a region surrounded by 









the kinase domain of xChk1 (Jeong et al., 2003). Interestingly, these four residues 
form a putative phosphate-binding site that is involved in Chk1 catalytic activity 
(Chen et al., 2000). This could explain the phosphorylation requirement of Claspin 
to associate with Chk1. Furthermore, it was also suggested that given the spacing 
between the two Chk1-binding motifs in xClaspin, two Chk1 monomers could 
interact with a single molecule of Claspin to facilitate Chk1 intermolecular 
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autophosphorylation. However this remains to be seen (Jeong et al., 2003). 
Although no stable interaction between Claspin and the C-terminal domain of 
Chk1 has been observed, it appears that this regulatory domain also has a role in 
mediating Claspin-Chk1 interaction as deletion of all or part of the xChk1 
regulatory domain significantly diminished binding of xChk1 to xClaspin (Jeong 
et al., 2003).   
The significance of Claspin in the checkpoint pathway has been highlighted by the 
observation that it is targeted for inactivation during the adaptation process in 
Xenopus studies. This involves the docking of xPolo-like kinase (xPlk) onto 
xClaspin primed by phosphorylation at Thr
906 
which then allowes xPlk-dependent 
phosphorylation of xClaspin at Ser
934
. This leads to the dissociation of xClaspin 
from chromatin, xClaspin inactivation and therefore attenuation of the checkpoint 
response (Yoo et al., 2004). Interestingly, the temporal regulation of Claspin and 
Chk1 are similar; both protein levels peak at unperturbed late S-phase and their 
levels declined in mitosis (Chini and Chen, 2003). Increasing evidence has shown 
that Claspin can function in the cell cycle progression of unperturbed cells when 
its localization to the replication fork is dependent on replication initiation proteins, 
MCM 2-7 and Cdc45, but independent of ATR, RPA and Rad17 in Xenopus (Lee 
et al., 2003). Electron microscopy studies have also revealed that Claspin is a ring-
shaped molecule that can encircle the DNA, specifically at the single-stranded 
branch points, with high affinity, and this suggests that Claspin may monitor 
unperturbed DNA replication and function as a direct sensor protein at the stalled 
replication fork (Sar et al., 2004). In unperturbed cycling cells, Claspin is also 
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targeted for degradation at the onset of mitosis. This is dependent on Plk1-




) located in the 
N-terminal domain of Claspin, which is then recognized by SCF
TrCP 
ubiquitin 
ligase. Mutant Claspin which cannot be degraded stabilizes Chk1 activation, thus 
abrogating cell cycle progression into mitosis (Mailand et al., 2006, Peschiaroli et 
al., 2006, Mamely et al., 2006). Claspin is also targeted for cleavage by caspase-7 
at Asp
1072 
during apoptosis, illustrating a key regulation in the balance between 
cell cycle arrest and apoptosis in response to DNA damage. This cleavage 
separates the two functional domains of Claspin, a Chk1-binding N-terminal 
domain and a DNA-binding C-terminal domain (Clarke et al., 2005).  
In mammalian cells, other proteins have also been implicated in the activation of 
Chk1 as siRNA-mediated depletion of Claspin did not fully block Chk1 activation 
following DNA damage (Chini and Chen, 2003). Claspin has been shown to 
associate with BRCA1 where it mediates BRCA1 phosphorylation on Ser
1524
. This 
modification is significantly reduced upon Claspin-depletion. Claspin could also 
cooperate with BRCA1 to regulate Chk1 activation after UV or IR as siRNA-
mediated ablation of either Claspin or BRCA1 greatly diminished Chk1 
phosphorylation on Ser
345
. However, combination of both siRNAs did not result in 
greater inhibition of Chk1 activation  (Lin et al., 2004). In Xenopus, xClaspin and 
xBRCA1 have been shown to act synergistically to potentiate the activation of 
xChk1 as addition of both exogenous xClaspin and xBRCA1 to cells depleted of 
endogenous xClaspin and xBRCA1 resulted in stronger phosphorylation of xChk1 
than addition of either protein alone (Yoo et al., 2006). TopBP1 has also been 
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implicated in the activation of Chk1 as it is required for ATR-mediated 
phosphorylation of Chk1 and its various substrates; phosphorylation of Chk1 is 
greatly diminished in TopBP1-deficient cells as compared to Claspin-deficient 
cells (Liu et al., 2006). Diminshed Chk1 phosphorylation may however be 
explained by the xTopBP1-dependent activation of xATR which places TopBP1 
upstream of Claspin in the signalling cascade (Kumagai et al., 2006). In another 
study, Mediator of DNA Damage Checkpoint Protein 1 (MDC1) was implicated in 
ATR-dependent Chk1 activation as its depletion resulted in defective 
phosphorylation of Chk1 (Stewart et al., 2003). It also appears that ATM 
phosphorylation of Chk1 is dependent on a functional Nijmegen breakage 
syndrome protein 1 (Nbs1) which may facilitate Chk1 access to ATM (Gatei et al., 
2003).   
1.4.3 Functions of Chk1  
Even though the role of Chk1 in the checkpoint response has been conserved 
among organisms ranging from yeasts to mammals, it has evolved to take on a 
broader responsibility in the mammalian DNA damage response. Indeed, while 
S.cerevisiae Chk1 is only activated in the late S and G2 phase, mammalian Chk1 
also functions in the intra-S phase and the mitotic/spindle checkpoint. Although, 
Chk1 is largely expressed in the S and G2-phase (Lukas et al., 2001), it has been 
implicated in the G1/S phase checkpoint where UV-induced degradation of 
Cdc25A is dependent on Chk1 but not p53 (Mailand et al., 2000). The following 
sections summarise the role of Chk1 in the mammalian checkpoints. 
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1.4.3.1 G2/M Checkpoint 
The G2/M checkpoint serves as a control for cell cycle transition from G2-phase to 
mitotic-phase of which the centrosome acts as a command centre (Doxsey, 2001). 
Increasing evidence has highlighted the importance of its role and a rapidly 
growing list of cell cycle regulatory proteins such as Chk1, Chk2, p53, Aurora A, 
Plk1, Cdc25, CDK1 and cyclin B are found to associate with the centrosome 
(Kramer et al., 2004a).  
It recently became clear that CDK1-cyclin B is first activated at the centrosome in 
prophase for mitotic initiation (Jackman et al., 2003). As aforementioned, Cdc25C 
is a positive regulator of CDK1-cyclin B but in the event of unreplicated or 
damaged DNA, it becomes phosphorylated by Chk1 on Ser
216 
which creates a 14-
3-3 binding site (Sanchez et al., 1997). This forces the cytoplasmic sequestration 
of Cdc25C and/or masks the residues required for interaction with CDK1-cyclin B 
(Dalal et al., 1999, Morris et al., 2000, Sancar et al., 2004). However it has been 
reported that ionising radiation treatment did not lead to increased Cdc25C Ser
216 
phosphorylation and inactivation of Cdc25C did not correlate with increased 14-3-
3 association. It has been suggested that inactivation of Cdc25C results from novel 
Chk1-mediated phosphorylation sites, though this has yet to be demonstrated 





inhibits Cdk1 association via 14-3-3 binding (Chen 
et al., 2003a). On the other hand, Chk1 further enforces the inactivation of CDK1-
cyclin B through its phosphorylation of Wee1 kinase on Ser
549 
which creates a 14-
3-3 binding site and enhances its kinase activity (O'Connell et al., 1997, Lee et al., 
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2001, Rothblum-Oviatt et al., 2001). Similarly, the tyrosine kinase Mik1 is 
stabilised by Chk1 upon DNA damage checkpoint activation in fission yeast 
(Baber-Furnari et al., 2000). Wee1 and Mik1 catalyse the inactivation of CDK1 
through inhibitory phosphorylation on Tyr
15
.  
Chk1 s role in mediating the inactivation of CDK1-cyclin B at the centrosome is 
emphasised by reports that Cdk1 activation is correlated with Chk1 disappearance 
from the centrosome (Kramer et al., 2004b), and depletion of Chk1 resulted in 
activation of CDK1-cyclin B (Hu et al., 2001). Furthermore, forced 
immobilisation of kinase-dead Chk1 at the centrosome prompted premature 
activation of CDK1 while wild-type Chk1 prevented the timely activation of 
CDK1 (Kramer et al., 2004b).  
Chk1 also negatively controls the level of CDK1-cyclin B by regulating 
transcriptional repression. In unperturbed cells, Chk1 actively phosphorylates 
histone H3 at Thr
11 
and this is dependent on Chk1 s association with chromatin. 
This modification allows the histone acetyltransferase, GCN5, to bind and mediate 
the recruitment of transcription factors and elevate the transcriptional level of 
CDK1 and cyclin B. In the event of DNA damage, phosphorylated Chk1 
undergoes chromatin dissociation, resulting in hypophosphorylated histone H3-
Thr
11
, reduced GCN5 binding and thus transcriptional repression of CDK1 and 
cyclin B (Shimada et al., 2008).    
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It is also interesting to note that viral infection can activate the Chk1 response as 
demonstrated by human immunodeficiency virus type 1 (HIV-1) viral protein R 
(Vpr). This protein induced a G2 arrest that was dependent on ATR and Chk1-
mediated inactivation of Cdk1-Cyclin B, although it was not clear whether Vpr 
actually inflicts DNA damage or it elicits a signal that mimics DNA damage 
(Roshal et al., 2003). Similarly, accumulation of reactive oxygen species (ROS) 
induced G2/M arrest that is also dependent on Chk1 (Zhang et al., 2001).   
1.4.3.2 Intra-S Checkpoint 
During DNA replication in S-phase, genotoxic stress can cause stalled replication 
forks, preventing cell cycle progression. If left unchecked, stalled replication forks 
will become unstable and are prone to collapse, resulting in genomic instability 
and chromosomal aberrations. Therefore checkpoints are activated to arrest the 
cell cycle, block late origin firing, stabilise stalled replication forks and then re-
initiate DNA replication (Paulsen and Cimprich, 2007). Increasing evidence has 
also shown that Chk1 is an essential kinase involved in the regulation of S-phase 
progression in unperturbed cells (Syljuasen et al., 2005, Petermann et al., 2006).  
Replication blocks can cause the uncoupling of DNA polymerase and helicase 
activities and lead to excessively long stretches of ssDNA that are coated with 
RPA (replication protein A) as evident in Xenopus studies (Walter and Newport, 
2000). This provides an initiating signal for ATR activation in cells following UV 
irradiation (Ward et al., 2004). Activated Chk1 then phosphorylates Cdc25A 
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phosphatase at Ser
124 
which prompts proteolytic degradation. Hyper-
phosphorylated Cdc25A fails to remove phosphate groups at CDK2-Cyclin E, thus 
mediating S-phase arrest (Xiao et al., 2003, Zhao et al., 2002). In addition, Chk1 
also functions to inhibit late replicon initiation via the same Cdc25A pathway 
where loss of Chk1 stimulates the initiation of DNA replication, even in the 
absence of DNA damage (Feijoo et al., 2001, Heffernan et al., 2002, Miao et al., 
2003).  
It has been suggested that Chk1 functions to stabilise stalled replication forks 
and/or restart replication blocks. This follows the discovery that Chk1-deficient 
DT40 cells failed to maintain viable replication structures and were unable to 
restart DNA replication after release from replication block (Zachos et al., 2003, 
Zachos et al., 2005). Using a DNA fibre-labelling technique, it was further 
reported that ablating Chk1 resulted in reduced global rates of replication fork 
progression. This suggested that Chk1 is involved in maintaining the stability of 
replication forks (Petermann et al., 2006).   
Proliferating cell nuclear antigen (PCNA) is a homotrimeric ring protein that acts 
as a processivity factor for DNA polymerase Pol  in both DNA replication and 
DNA repair (Moldovan et al., 2007). A link between PCNA and Chk1 was first 
described in S.pombe where PCNA together with p21
waf1 
functions to inhibit cell 
cycle progression through Chk1 protein kinase upon DNA damage (Tournier et al., 
1996). Since then, Chk1 and Claspin have been shown to interact with PCNA and 
this interaction is reduced in the event of DNA damage (Brondello et al., 2007, 
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Yang et al., 2008, Scorah et al., 2008). Chk1 association with PCNA is dependent 





identified in the Chk1 C-terminal domain. Furthermore, mutation of the PIP box 
leads to defective G2/M and S-phase checkpoint due to reduced ATR-dependent 
phosphorylation of Chk1 and hence defective dissociation of Chk1 from chromatin 
(Scorah et al., 2008). It was also demonstrated that Chk1, together with Claspin 
and Timeless, regulates DNA damage-induced PCNA ubiquitination in an ATR-
independent manner (Yang et al., 2008). However, in another study, ATR was 
implicated in ubiquitination of PCNA. It was shown that monoubiquitination of 
PCNA is ATR/Chk1-dependent and is required for interaction with the translesion 
synthesis DNA polymerase Pol . This allows replication forks to continuously 
advance along damaged DNA, thereby attenuating the S-phase checkpoint (Bi et 
al., 2006).  
These observations supported the concept that the ATR-Chk1 pathway operates in 
S-phase to regulate DNA replication and that this checkpoint signal is amplified in 
the presence of genotoxic stress, though the mechanism of amplification remains 
unclear.   
1.4.3.3 Mitotic Spindle Checkpoint 
The mitotic spindle checkpoint is activated to prevent unattached or poorly 
attached kinetochore-microtubules and chromosome mis-segregation. Defects in 
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the spindle checkpoint are associated with chromosomal instability and aneuploidy 
(Kops et al., 2005).   
Chk1 has been implicated in the mitotic spindle checkpoint. Studies in budding 
yeast revealed that in the presence of DNA damage, Securin, an anaphase inhibitor, 
is stabilised by Chk1-mediated phosphorylation which blocks its ubiquitination 
mediated by the Anaphase Promoting Complex (APC). Hence the cell cycle is 
blocked before anaphase, presumably to allow DNA repair before sister 
chromosome segregation (Sanchez et al., 1999) (Wang et al., 2001). In 
mammalian cells, Chk1 positively regulates the spindle checkpoint through the 
activation of Aurora B. Optimal Aurora B activity is required for the 
phosphorylation and localisation of the spindle checkpoint protein BubR1 to the 
kinetochores which sustains mitotic arrest (Zachos et al., 2007). These data 
suggest that Chk1 is a positive regulator of the mitotic spindle checkpoint.   
Alternatively, Chk1 has been proposed to negatively regulate the spindle 
checkpoint. Chk1-depleted cells displayed metaphase arrest which was dependent 
on hyper-activated polo-like kinase 1 (Plk1) (Tang et al., 2006a). Plk1 has been 
shown to be a positive regulator of the spindle checkpoint (Tang et al., 2006b). 
Co-depletion of spindle checkpoint proteins BubR1 or Mad2 with Chk1 is able to 
reverse the effects of Chk1 depletion-induced metaphase block, suggesting that 
Chk1 could function to inactivate the spindle checkpoint via negative regulation of 
Plk1 (Tang et al., 2006a). It has been suggested that the differences in these 
observations may be due to different degrees of Chk1 depletion (Zachos et al., 
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2007), as seen in the case of kinetochore proteins (Nuf2R, Ndc80
Hec1 
and Nnf1R), 
where 80 % depletion of the proteins activates the spindle checkpoint while 99 % 
depletion inactivates it (Meraldi et al., 2004, McAinsh et al., 2006).   
1.4.4 Cellular Responses of Chk1 to anticancer treatment 
Most of the therapeutic agents applied in clinical cancer therapy cause DNA 
damage and thus induce cell cycle checkpoint activation. Given that over half of 
tumour cells have defects in the p53 and pRb pathway, they rely heavily on the 
checkpoint kinases to maintain cell cycle arrest. Cancerous cells are able to exploit 
this double-edged checkpoint mechanism to keep DNA-damaged cells in check 
and repair the damage necessary to maintain cancer cell propagation, giving rise to 
chemotherapeutic resistance. Indeed, gene expression profiling has shown that 
Chk1 is often over-expressed in tumour tissues as compared to normal adjacent 
cells, demonstrating the over-reliance on this checkpoint kinase for cell cycle 
progression in tumour tissues (Cho et al., 2005). Furthermore, a genetic alteration 
analysis of 25 human tumour cell lines revealed no mutation for CHK1 gene, 
indicating that integrity of this protein is important to the viability of the tumour 
cells (Ejima and Yang, 1999). However, in another study, a shorter isoform of 
CHK1 gene is preferentially expressed in small cell lung cancer as compared to 
non-small cell lung cancer and normal lung tissues. It was revealed that this 
shorter CHK1 isoform lacked 32 amino acids within the carboxyl portion of the 
kinase domain that could affect substrate recognition (Haruki et al., 2000). It has 
nevertheless been postulated that targeting Chk1 could be an attractive approach to 
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circumvent chemotherapeutic resistance. Normal healthy cells with an active p53 
pathway are less sensitive to the loss of Chk1 due to the presence of intact and 
redundant checkpoint pathways. This was clearly shown with WS-1 fibroblasts 
which exhibited significantly less, and tolerable, cellular apoptosis as compared to 
U2OS tumour cells in response to antimetabolites (Cho et al., 2005). Moreover 
normal cells are arrested in G1 phase in a p53-dependent manner, whereas over 
half of tumour tissues which are p53-deficient depend more on the S and G2/M 
checkpoints. Thus Chk1 represents an Achilles heel in cancer cells that can be 
targeted to augment conventional therapies. The therapeutic potential of Chk1 
inhibitor as a component of cancer therapy is briefly reviewed here.  
As aforementioned, inhibiting Chk1 function does not significantly affect normal 
cells due to compensation from other checkpoint pathway mechanisms. Another 
point to note is that Chk1 inhibition has very little effect on apoptosis in the 
absence of DNA-damaging drugs, thus underpinning it as a valid drug target 
without manifesting cytotoxicity on its own (Chen et al., 2003b).  
Many studies have been published investigating the potential of Chk1 abrogation 
as a chemo-sensitizer in cancer cells treated with anti-cancer agents eliciting 
various phases of cell cycle arrest. Antimetabolites, such as 5-Fluorouracil (5-FU) 
and HU which are used widely in cancer treatment, activate Chk1 and elicit S-
phase cell cycle arrest through Chk1-mediated Cdc25A degradation and 
subsequent inhibition of Cdk2. Downregulation of Chk1 potentiates the toxicity of 
antimetabolites through abrogation of S-phase checkpoint which results in mitotic 
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catastrophe and eventual apoptosis (Xiao et al., 2005b, Cho et al., 2005). It has 
also been shown that ablation of Chk1 function also results in increased cellular 
apoptosis in the presence of DNA-damaging agents such as 6-thioguanine (6-TG), 
doxorubicin (Dox) and camptothecin (CPT), mediating G2/M cell cycle arrest 
(Jackson et al., 2000, Yan et al., 2004, Chen et al., 2006). Similarly, Chk1 
inhibition also sensitises cells to anti-mitotic agents such as Taxol and augments 
mitotic catastrophe and apoptosis (Xiao et al., 2005a). Conversely, it has been 
shown that Chk1 is required for optimal spindle poison-induced cell death (Zachos 
et al., 2007).  
The importance of Chk1 downregulation in chemotherapy was highlighted in an 
elegant test which studied the relevancy of three checkpoint kinases, namely Chk1, 
Chk2 and mitogen-activated protein kinase-activated protein kinase 2 (MK2) in 
cancer therapy. It showed that only downregulation of Chk1, but not Chk2 or MK2, 
abrogated chemotherapeutics-induced cell cycle arrest, leading to cell death. Thus 
this places Chk1 inhibition as the only viable checkpoint target of these three 
kinases for anticancer treatment (Xiao et al., 2006).    
There are conflicting reports on whether targeted Chk1-mediated sensitisation of 
tumour cells to the cytotoxicity of anti-cancer agents is p53-dependent (Cho et al., 
2005, Chen et al., 2006, Vitale et al., 2007). It is noted that topoisomerase 
inhibitors which impinge upon G2/M arrest exhibit selective p53 status and DNA 
replication inhibitors affecting S-phase progression showed no dependence on p53. 
It was suggested that Chk1 and p53 cooperate to maintain G2 arrest, whereas p53 
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is not required for S-phase checkpoint, though the mechanisms remain elusive 
(Tse and Schwartz, 2004). In a recent study, human fibroblast cells starved for 
pyrimidine nucleotides by treatment with N-(phosphonacetyl)-L-aspartate (PALA) 
exhibited G1, G2 and S-phase checkpoint arrest by activating the ATR-Chk1-p53 
pathway. This was dependent on functional p53 and its target proteins, p21 and 
macrophage inhibitory cytokine 1 (MIC1) (Hastak et al., 2008). In cells lacking 
p53 or with a defective p53 pathway, failure to arrest DNA synthesis during 
depletion of pyrimidine nucleotides caused irreversible DNA damage that led to 
apoptosis (Agarwal et al., 1998, Agarwal et al., 2006). It is therefore important to 
determine which class of therapeutic drugs should be given in conjunction with 
Chk1 inhibitors, depending on p53 status of the cancer patient, in order to enhance 
the efficacy of the chemotherapeutic agents.  
On a separate note, although methyl methanesulfonate (MMS), HU and 
aphidicolin (Aph) lead to stalled replication forks, the mechanisms by which 
replication forks are blocked in response to these agents may vary. Indeed, lesions 
induced by MMS may be repaired or even bypassed, however this is not observed 
with HU- or APH-induced replication blocks (Paulsen and Cimprich, 2007). 
Therefore, it is important to exercise caution when interpreting results even though 
they affect the same checkpoint.  
On an interesting note, activation of cellular senescence programs lead to the 
suppression of Chk1, as evidenced by the loss of phosphorylation on Ser
345 
and S-
phase arrest in response to UV irradiation and CPT treatment. This was 
  
- 43 -  
accompanied by chromosomal instability. Thus it was hypothesized that the 
stimulation of senescence signalling could provide a novel and promising 
approach for sensitising cells towards cytotoxic drugs (Gabai et al., 2008).    
Although it has been shown that Chk1 is a highly promising and viable drug target, 
caution needs to be exercised as to how it will perform in clinical trials; conflicting 
/various conclusions may be drawn from the same cell line depending on the drug 
type, dosage, incubation time, variant cell line, analytical method and different 
conclusions may be obtained with distinct cell lines due to various defects in the 
pathway. A prime example of this is the p53-dependence at different phases of cell 
cycle arrest. Hence, dissecting the interaction of cell cycle checkpoints is an 
important step to developing effective therapeutic strategies.   
1.4.5 Chk1 inhibitors 
7-hydroxystaurosporine (UCN-01), initially developed as a novel protein kinase C 
(PKC) inhibitor, was identified as a viable drug targeting Chk1 that sensitises 
tumour cells to a wide variety of genotoxic agents (Tse et al., 2007). This inhibitor 
is 100,000 times more potent than caffeine at abrogating checkpoint arrest (Bunch 
and Eastman, 1996). Unfortunately, its Phase I/II clinical development has been 
limited by unfavourable pharmacokinetics and toxicity. UCN-01 exhibited 
cytotoxicity when administered on its own and importantly it binds avidly to 
plasma proteins, leading to excess UCN-01 concentration in blood plasma and 
thus compromising patient safety (Sausville et al., 2001). Furthermore, UCN-01 
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inhibits a plethora of kinases including Chk2 and Cdk1. Thus identification of 
alternative highly selective Chk1 inhibitors represents a high priority.   
An indolocarbazole named isogranulatimide is structurally related to UCN-01 and 
was recently shown to inhibit Chk1 selectively (40-fold over Chk2) with an IC50 of 
100 nM. Its mechanism of action was elucidated where it served as an ATP-
competitive Chk1 inhibitor with an additional hydrogen bonding to the ATP-
binding pocket compared to UCN-01. This caused a conformational change in the 
kinase s  glycine-rich loop which may contribute to Chk1 inhibition (Jiang et al., 
2004).  A bis-imide granulatimide analogue was also discovered to inhibit Chk1 
with an IC50 of 2 nM (Henon et al., 2007).   
In addition to developing small-molecule inhibitors to Chk1, alternative ways to 
down-regulate Chk1 function have been examined. It was shown that using 
17AAG, an Hsp90 inhibitor, resulted in the depletion of Chk1 protein and 
sensitization to gemcitabine (Arlander et al., 2003). In a later study, Chk1 was 
found to be a chaperone Heat Shock Protein 90 (Hsp90) client and poorly 
chaperoned Chk1 displayed a very low level of catalytic activity (Arlander et al., 
2006). Similarly, using Hsp90 inhibitor, geldanamycin abrogates G2-phase arrest 
in p53-negative leukaemia cells through the depletion of Chk1 (Sugimoto et al., 
2008). Geldanamycin is known to induce proteosomal degradation of Chk1 
(Nomura et al., 2005).  
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It is likely that more Chk1 inhibitors with increasing potency and selectivity will 
be discovered in the future. However, an inhibitor exhibiting high enzyme 
selectivity in a biochemical assay may not be replicated once the compounds enter 
the cells (Collins and Garrett, 2005). Thus it is important to develop a reliable cell-
based assay for measuring inhibitor potency in vivo.    
1.5 Project Objectives 
Chk1 plays an integral role in mediating cell cycle checkpoint pathways and is a 
promising target for anticancer therapy. The mode of Chk1 activation whereby it 




has been well 
characterised and this affects Chk1 association with chromatin. Intrinsic kinase 
activity is kept at basal level through Chk1 C-terminal domain inhibitory action on 
the N-terminal catalytic domain. Deletion or truncation of this C-terminal domain 
relieves autoinhibition (Katsuragi and Sagata, 2004), resulting in increased kinase 
activity. However it was not clear what mechanisms counteract the autoinhibition. 
The aims of the project were firstly to validate and characterise Chk1 as a potential 
regulator of the tumour modifier p21
waf1 
and to dissect the intermolecular 
interaction between these two proteins in order to better understand the basis of 
Chk1 substrate recognition. Having discovered that p21 could function as an 
allosteric activator Chk1 catalytic activator, I then went on to delineate the 
mechanism by which substrate docking modulate Chk1 function using 
peptidomimetic ligands.   
A
F igu re 1.1 A simplified illustr ation of the A T M and A T R signalling pathway.
(A) Ionising radiation induces double-stranded breaks that leads to activation of ATM in
conjunction with the MRN complex. Activated ATM then catalyses the phosphorylation of
Chk2 on Thr68 that is dependent on BRCA1. On the other hand, UV radiation and/or
replication blocks elicit single-stranded break which is coated with RPA. This initiates the
ATR signalling cascade that leads to the activation of Chk1 in the presence of adaptor protein
Claspin. Both transducer molecules Chk1 and Chk2 go on to phosphorylate effector molecules
such as Cdc25A and Cdc25C to regulate S-phase and G2/M arrest respectively. Furthermore,
ATM and Chk2 is able to activate p53 to initiate G1/S arrest, apoptosis or senescence
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F igu re 1.2 A schematic functional domain a rchitectu re of C hk2 and its mode of
activation.
(A) Chk2 contains three functional domains: a SQ/TQ cluster domain (amino acids 19-69)
where Thr68 is the main ATM phosphorylation site; a forkhead-associated domain (FHA)
(amino acids 115-175) involved in phosphoprotein interaction; kinase domain (amino acids
226-486). (B) In the event of IR irradiation, activated ATM phosphorylates Chk2 on Thr68
which induces its dimerisation of another Thr68-phosphorylated Chk2 via the FHA domain.
This event initiates inter-molecular autophosphorylation on Thr383 and Thr387 within the












F igu re 1.3 A schematic functional domain a rchitectu re of C h k1.
(A) Chk1 contains a N-terminal kinase domain, a flexible linker region and C-terminal
regulatory domain thought to autoinhibit the catalytic activity of Chk1. Like Chk2, Chk1 also
has a SQ/TQ cluster region of which Ser317 and Ser345 are phosphorylated by ATR. Ser280
phosphorylation by PKB/Akt is thought to inactivate Chk1. Cdk1 is thought to phosphorylate










     
CHAPTER 2: MATERIALS AND METHODS             
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2.1 General Reagents 
Chemicals and reagents were supplied by Sigma unless otherwise stated. Tissue 
culture reagents including Dulbecco s modified eagle s medium (DMEM), 
McCoy s 5A medium, penicillin/streptomycin solution, trypsin-EDTA solution 
and Lipofectamine 2000 were supplied by Invitrogen unless otherwise stated, 
while fetal bovine serum (FBS) was supplied by Autogen Bioclear.   
2.2 Cell Culture 
2.2.1 Mammalian cell culture 
2.2.1.1 Cell lines 
All cells were kept in a humidified incubator at 37
o
C. Media were supplemented 
with 10 % (v/v) fetal bovine serum (FBS). D-MEM was further supplemented with 
1 % (v/v) penicillin/streptomycin. 
Table 2.1 List of cell lines used in this study.      
Cell Line Source Medium % CO2 
HeLa Adenocarcinoma D-MEM 5 
HCT116 WT Colorectal carcinoma McCoy s 5A 10 
HCT116 p21-/- Colorectal carcinoma McCoy s 5A 10 
  
- 47 -  
2.2.1.2 Culturing and cryopreservation of cells 
Adherent cell culture were grown to confluency in 10 cm
2 
culture dishes 
containing 10 ml tissue culture medium in optimal conditions before passaging 
with 1/10 dilution. Cell passaging was performed in a laminar flow hood using 
aseptic techniques: The medium was discarded before the cells were rinsed with 
sterile 1x phosphate buffered saline (PBS). Two ml of warmed 1x Trypsin-EDTA 
solution was added to cover the adhering cell layer and the culture dish was 
incubated at 37
o
C until the cells started to detach from the culture dish. Eight ml of 
appropriate warmed tissue culture medium was added to inhibit further trypsin 
activity before 1ml of cells culture were transferred to a 9 ml of fresh warmed 
tissue culture medium in new tissue culture dish.  
To cryopreserve cell lines, cells were grown to 90 % confluency in 10 cm
2 
tissue 
culture dish before trypsinised as above. The cells were transferred to a sterile 15 
ml Vulcan tube and centrifuged at 1000 revolutions per minute (rpm) for 5 
minutes at room temperature. Cell pellet were resuspended gently with 3 ml of 
freezing medium (50 % (v/v) FBS, 10 % (v/v) dimethyl sulfoxide (DMSO), 40 % 
(v/v) Tissue culture medium (according to cell line)) and transferred to cryovial 





storage box at -70
o
C overnight before transferred to a liquid nitrogen freezer for 
long-term storage.  
To recover cells from liquid nitrogen storage, the cryovial was thawed quickly at 
37
o
C by swirling. Thawed cells were transferred to a sterile 15 ml Vulcan tube. 
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Nine ml of warmed appropriate tissue culture medium was added drop by drop 
with swirling before the cells were centrifuged at 1000 rpm for 5 minutes at room 
temperature. The medium was discarded and the cells were resuspended with 2 ml 
of tissue culture medium before transferred to a new 10 cm
2 
tissue culture dish 
containing 8 ml of fresh tissue culture medium.   
2.2.1.3 Transient transfections  
Cells were seeded onto new 10 cm
2 
plate in growth medium without antibiotics 
and grown to 90 % confluency. The cells were transfected with plasmid DNA (in a 
pcDNA
TM 
3.2/V5-DEST gateway vector) (Invitrogen) using Lipofectmine
TM 
2000 
(Invitrogen) according to manufacturer s handbook. Eight g of plasmid DNA was 
transfected using 8 l of Lipofectamine
TM 
2000 in a 1:1 ratio. Cells were then 
incubated at 37
o
C overnight before they were harvested or subjected to chemical 
treatment.   
2.2.1.4 Aphidicolin treatment 
Aphidicolin (Calbiochem) was dissolved in ethanol at a stock concentration of 
2.95 mM and addeded directly to the cell culture to give a final concentration of 
20 M. Treated cells were incubated at 37
o
C for 4 hours before cells were 
harvested.   
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2.2.1.5 Cycloheximide treatment 
Cycloheximide was dissolved in DMSO at a stock concentration of 100 mg/ml and 
added directly to the cell culture to give a final concentration of 30 g/ml. Cells 
were harvested at the appropriate time point after treatment.    
2.2.2 Bacterial Cell Culture 
2.2.2.1 Bacterial Media 
Both Lucia-Bertani (LB) medium (1 % (w/v) Tryptone, 0.5 % (w/v) Yeast Extract, 
1 % (w/v) NaCl) and LB agar (1 % (w/v) Tryptone, 0.5 % (w/v) Yeast Extract, 
1 % (w/v) NaCl, 1.5 % (w/v) Agar, granulated) were sterilised by autoclaving at 
121
o
C for 20 minutes. LB agar was liquefied by heating in a microwave oven. 
Warmed LB agar was added with selective antibiotic(s) before poured into 90 mm 
diameter Petri dishes (Sterilin) and left to cool. The culture dishes were stored at 
4
o
C for no longer than one month. Prior to use, the plates were dried at 37
o
C for 1 
hour.   
2.2.2.2 Preparation of competent cells 
A starter culture was prepared by inoculating 5 l of DH5 in 2 ml of LB medium 
and incubated overnight at 37
o
C at 225 rpm. The starter culture was diluted 1:100 
in 200 ml of LB medium and incubated at 37
o
C at 225 rpm until an OD600nm of 
between 0.3 and 0.5 was reached. The cells were centrifuged at 4000 x g for 20 
minutes at 4
o
C and resuspended in 80 ml of ice-cold transforming buffer I (30 mM 
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Potassium acetate, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 15 % (v/v) 
glycerol; adjusted to pH 5.8 with acetic acid and sterilised by filtration),. After 10 
minutes incubation at 4
o
C, the cells were centrifuged at 4000 x g for 5 minutes at 
4
o
C and gently resuspended in 8 ml of transforming buffer II (10 mM MOPS, 75 
mM CaCl2, 10 mM RbCl, 15 % (v/v) glycerol; adjusted to pH 6.5 with postassium 
hydroxide and sterilised by filtration). After incubation at 4
o
C, the cells were 
aliquoted (100 l) into sterile microcentrifuge tubes and snap-frozen in liquid 
nitrogen and stored at -70
o
C.   
2.2.2.3 Transformation of E.coli competent cells 
Competent E.coli cells were transformed with plasmid DNA. Fifty l of DH5 
competent cells were thawed on ice and mixed with 100 ng of plasmid DNA. The 
cells were incubated on ice for 30 minutes before heat-shocked at 42
o
C for 45 
seconds. Following 2 minutes of incubation on ice, 500 l of LB medium was 
added and the cell suspension was incubated at 37
o
C at 225 rpm for 1 hour. One 
hundred l of the cell suspension was then plated onto the warmed LB agar plate 
containing the selective antibiotics required for the plasmid of interest and 
incubated overnight at 37
o
C.      
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2.2.3 Sf9 insect cells 
2.2.3.1 Culturing of Sf9 insect cells 
Sf9 insect cells were cultured with Sf-900 II serum-free medium supplemented 
with 1 % (v/v) penicillin/streptomycin in suspension in a spinner flask at 27
o
C. 
Cells were subcultured to 1 x 10
6 
viable cells/ml when the viable cell density 
reached 3 x 10
6 
viable cells/ml.   
2.2.3.2 Transformation of DH10BacTM E.coli with plasmid DNA 
For the purpose of converting plasmid containing human CHK1 gene into Bacmid 
for infection of Sf9 insect cells, DH10Bac
TM 
competent cells were used. Two 
hundred l of DH10Bac
TM 
competent cells were thawed on ice and mixed gently 
with 1 ng of Gateway pDEST
TM 
10 plasmid DNA containing gene of interest. The 
cells were incubated on ice for 30 minutes before they were heat-shocked for 45 
seconds at 42
o
C. Following 2 minutes incubation on ice, 800 l of Luria-Bertani 
(LB) medium was added and the cell culture was incubated at 37
o
C at 225 rpm for 






) of the cells with LB medium were 
prepared and 100 l of each dilution was plated on LB agar plate containing 50 
g/ml kanamycin, 7 g/ml gentamicin, 10 g/ml tetracycline, 100 g/ml Bluo-gal 
and 40 g/ml isopropyl- -D-1-thiogalactopyranoside (IPTG) and incubated for 48 
hours at 37
o
C. White colonies were picked and restreaked on fresh LB agar 
containing the above-mentioned antibiotics, Bluo-gal and IPTG and incubated 
overnight at 37
o
C to confirm that successful recombination had occurred.  
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2.2.3.3 Isolating Recombinant Bacmid DNA 
A single white colony of DH10 containing recombinant Bacmid was picked to 
inoculate 2 ml of LB medium containing 50 g/ml kanamycin, 7 g/ml gentamicin 
and 10 g/ml tetracycline and incubated at overnight at 37
o
C. One and a half ml of 
bacterial culture was transferred to a 1.5 ml microcentrifuge tube and centrifuged 
at 14,000 x g for 1 minute. The supernatant was removed and the cell pellet was 
resuspended in 0.3 ml of Solution I (15 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 
g/ml RNase A) before mixed with 0.3 ml of Solution II (0.2 N NaOH, 1 %  (w/v) 
SDS). The cell suspension was incubated at room temperature for 5 minutes or till 
the suspension turned from turbid to almost translucent. After incubation, 0.3 ml 
of 3 M potassium acetate, pH 5.5 was added and the solution was mixed gently. 
The suspension was then incubated on ice for 10 minutes before centrifuged at 
14,000 x g for 10 minutes. The supernatant was transferred to a microcentrifuge 
tube containing 0.8 ml of isopropanol and inverted a few times before incubated 
on ice for 10 minutes. The sample was centrifuged for 15 minutes at 14,000 x g at 
room temperature and the supernatant was removed. Five hundred l of 70 % 
ethanol was added to the DNA-pellet and the tube was inverted several times to 
wash the pellet before it was centrifuged for 5 minutes at 14,000 x g at room 
temperature. The supernatant was removed and the DNA-pellet was air-dry for 10 
minutes at room temperature before plasmid DNA was dissolved in 40 l of 
nuclease-free dH2O.     
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2.2.3.4 Transfecting insect cells and isolating P1 viral stock 
In order to generate recombinant baculovirus, insect cells were transfected with 
Bacmid DNA. Insect cells were seeded in 6-well dish at a density of 1 x 10
6 
in 2 
ml of growth medium containing antibiotics in each well and incubated for 1 hour 
at 27
o
C to allow cell attachment. The bacmid DNA: Cellfectin
® 
reagent 
(Invitrogen) complexes were prepared according to manufacturer s handbook and 
added to each wells containing cells. Cells were then incubated at 27
o
C for 4 hours 
before the DNA:lipid complexes were removed. Two ml of growth medium 
containing antibiotics was then added to each wells and cells were incubated at 
27
o
C for 72 hours or till signs of viral infection were visible. After transfected 
cells displayed signs of late stage infection (e.g. cell detachment and granular 
appearance), the medium containing virus were collected from each well and 
centrifuged at 1000 rpm for 5 minutes. The clarified supernatant was recovered as 
P1 viral stock and stored at 4
o
C and protected from light.   
2.2.3.5 Amplification of Baculoviral stock 
P1 viral stock was used to infect insect cells to generate a high titre P2 viral stock. 
Insect cells were seeded in 50 ml suspension culture at 2 x 10
6 
cells/ml and 
infected at a multiplicity of infection (MOI) of 0.1 according to the manufacturer s 
handbook. Infected cells were incubated for 48 hours at 27
o
C. After 48 hours, the 
culture was collected and centrifuged at 1000 rpm for 5 minutes. The clarified 
supernatant was recovered and stored at 4
o
C and protected from light. P3 viral 
stock was also generated in the same way. 
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2.2.3.6 Recombinant protein expression from Sf9 insect cells 
Cells were grown at a density of 2 x 10
6 
cells/ml before they were infected with P3 
viral stock at a MOI of 10. Infected cells were incubated for 48 hours at 27
o
C 
before they were centrifuged at 4000 rpm at 4
o
C for 20 minutes.   
2.3 Molecular Biology Methods 
2.3.1 Amplification of plasmid DNA 
A single colony of transformed bacteria was picked and used to inoculate 5 ml of 
LB medium containing selective antibiotics to generate a starter culture. The 
culture was incubated at 37
o
C at 225 rpm for 6-8 hours.    
2.3.2 Purification of plasmid DNA 
Plasmid DNA was isolated using Qiagen® plasmid DNA Mini or Maxi Kits. For 
Miniprep, the starter culture was used directly according to the manufacturer s 
instructions. For Maxiprep, The starter culture was diluted 1:500 in 250 ml of 
selective LB medium. The culture was incubated overnight at 37
o
C at 225 rpm. 
Cells were centrifuged at 6000 rpm for 20 minutes at 4
o
C and plasmid DNA was 
isolated according to the manufacturer s instruction. Plasmid DNA was 
resuspended in nuclease-free dH2O and stored at -20
o
C.    
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2.3.3 Quantification of plasmid DNA 
The concentration of plasmid DNA was determined by spectrophotometry at 260 
nm using the PowerwaveXS
TM 
Microplate Spectrophotometer (Bio-Tek). Plasmid 
DNA was diluted 1:100 in 100 l of nuclease-free dH2O and added to wells of a 
96-well UV-Star
TM 
Plate (Greiner). 100 l of nuclease-free dH2O was used as a 
blank control. DNA concentrations were calculated based on the basis that 50 
g/ml of DNA gives an OD260nm of 1.0.   
2.3.4 Agarose gel electrophoresis 
One percent (w/v) Agarose gel was prepared by adding agarose to 1x Tris-Borate-
EDTA (TBE) buffer (90 mM Tris-HCl, pH 8.0, 90 mM Boric acid, 2 mM EDTA, 
pH 8.0; adjusted to pH 8.0) and heated in a microwave oven until dissolved. The 
agarose solution was cooled till handwarmed before ethidium bromide was added 
to a final concentration of 0.5 g/ml. The agarose solution was left to set in a 
horizontal agarose gel tray with a comb inserted. The agarose gel was placed in a 
horizontal electrophoresis gel tank (Jencons) filled with 1x TBE buffer. DNA 
samples were diluted 1:6 in 6x Agarose loading buffer (0.25 % (w/v) 
Bromophenol Blue, 0.25 % (w/v) Xylene cyanol FF, 15 % (w/v) Ficoll) and 
loaded onto the gel. The DNA samples were electrophoresed at 100 V for 50 
minutes before bands were visualised under a UV transilluminator.     
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2.3.5 Site-directed mutagenesis 
Primers containing the desired mutations were designed according to the 
quidelines in the QuikChange
TM 
Site-Directed Mutagenesis Kit Manual 
(Stratagene). Oligonucleotides were purchased from Sigma-Aldrich in PAGE-
purified form before reconstituted in nuclease-free dH2O. Site-directed 
mutagenesis was carried using the QuikChange
TM 
Site-Directed Mutagenesis Kit 
(Stratagene) according to manufacturer s instructions. After mutant strand 
synthesis reaction, 1 l of DpnI restriction enzyme (10U/ l) was added to the 
amplification reaction and mixed. The reaction mixture was microcentrifuged for 1 
minutes and incubated at 37
o
C for 1 hour to digest the parental (nonmutated) 
dsDNA. After incubation, 2 l of DpnI-treated DNA was used to transform 25 l 
of DH5 competent cells using heat-shock method (Materials and Methods 
2.2.2.3).   
2.3.6 Sequence analysis of plasmid DNA 
All sequence analysis was performed by the Sequencing Unit at the MRC Human 
Genetics Unit, Edinburgh. Ten l of sequencing reaction containing 2 l of 
BigDye® Terminator 3.1 (Applied Biosystems), 3.2 pmol of primer, 1x BigDye 
Sequencing buffer (Applied Biosystems), 250 ng of DNA template and nuclease-
free dH2O was assembled. The sequencing reaction was thermal-cycled using 
cycling parameters according to the manufacturer s instructions.   
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The sequenced DNA was then precipitated by mixing the reaction with 2.5 l of 
125 mM EDTA and 30 l of 100 % (v/v) ethanol. After vortexing, the reaction 
was incubated at room temperature for 15 minutes. After centrifuging at 13000 
rpm for 20 minutes, the solution was removed and precipitated DNA was 
microcentrifuged for 20 seconds. Residual ethanol was removed before 30 l of 
70 % (v/v) ethanol was added to the precipitated DNA and centrifuged at 13000 
rpm for 5 minutes. The ethanol was removed before the precipitated DNA was 
microcentrifuged for 20 seconds. Residual ethanol was removed and the 
precipitated DNA was left to air-dry before sequence-analysed.   
2.4 Protein Detection 
2.4.1 Cell lysis 
2.4.1.1 Mammalian cells 
Cells were washed with cold PBS and scraped into 200 l of lysis buffer (50 mM 
Hepes, pH 7.4, 0.5 % (v/v) Triton X-100, 150 mM NaCl, 10 mM NaF, 1mM DTT, 
1mM EDTA, 1mM EGTA, 10 mM sodium -glycerophosphate, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 0.27 M sucrose, 1x Protease 
Inhibitors (1 g/ml Leupeptin, 0.4 g/ml Aprotinin, 0.2 g/ml Pepstatin, 0.12 mM 
Benzamidine, 1 g/ml Soya bean trypsin inhibitor, 40 g/ml Pefabloc, 0.1 mM 
EDTA)). The cell lysate were transferred into a 1.5 ml microcentrifuge tube and 
resuspended by pipetting up and down. The cell lysates were then incubated on ice 
for 15 minutes before centrifuged at 13000 rpm for 15 minutes. The supernatant 
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was recovered as cleared cell lysate and snap-frozen in liquid nitrogen and stored 
at -70
o
C.   
2.4.1.2 Sf9 insect cells 
Infected insect cells were centrifuged at 4000 rpm at 4
o
C for 20 minutes. 
Supernatant was removed and the pellet was resuspended with twice the cell pellet 
volume of lysis buffer (25 mM Hepes, pH 7.4, 20 mM NaF, 10 mM NaCl, 1x 
Protease Inhibitors (1 g/ml Leupeptin, 0.4 g/ml Aprotinin, 0.2 g/ml Pepstatin, 
0.12 mM Benzamidine, 1 g/ml Soya bean trypsin inhibitor, 40 g/ml Pefabloc, 
0.1 mM EDTA)). After incubation on ice for 15 minutes, cell lysates were 
centrifuged at 13000 rpm for 15 minutes. The supernatant was recovered as 
cleared cell lysates and snap-frozen in liquid nitrogen and stored at -70
o
C.   
2.4.2 Protein Quantification 
Protein concentrations were determined using BCA
TM 
Assay Kit (Pierce) in a 96-
well plate. Bovine serum albumin (BSA) protein standards of known concentration 
were prepared in dH2O. Cell lysate (1.25 l) was diluted in 23.75 l of the 
appropriate lysis buffer. 25 l of lysis buffer was used as a blank control. After 
200 l of working reagent was added to each sample and incubated at 37
o
C for 30 
minutes, the protein concentration was determined at 562 nm using the 
PowerwaveXS
TM 
Microplate Spectrophotometer (Bio-tek), Read-outs were 
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converted to concentrations using the standard curve generated from the known 
BSA standards and were adjusted by the dilution factor.   
2.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved on the basis of their molecular weight by discontinuous 
SDS-PAGE. SDS-PAGE at appropriate polyacrylamide concentrations was 
prepared using a Mini-PROTEAN3
TM 
(Bio-Rad) blot. Higher concentration of 
polyacrylamide was used to resolve lower molecular weight protein and vice versa. 
For example, Chk1 protein was usually resolved by 10 % resolving gel, p21 
protein was resolved using 12 % gel and peptides were resolved by 15 % gel. The 
resolving gel (6 - 15 % Acrylamide, 390 mM Tris-HCl pH 8.8, 0.1 % SDS, 0.1 % 
Ammonium peroxidisulphate, polymerisation was initiated by adding 0.08 % 
TEMED) was overlaid with dH2O to remove air bubbles and flatten the top surface 
before left to polymerise at room temperature. After the resolving gel was set, the 
dH2O was removed and the stacking gel (5 % Acrylamide, 123 mM Tris-HCl pH 
6.8, 0.1 % SDS, 0.1 % Ammonium peroxidisulphate, 0.1 % TEMED) was added 
with either a 10-well or 15-well comb and left to polymerise. After the stacking 
gel was set, the comb was removed and the gel cassette was assembled with the 
Mini-PROTEAN3
TM 
electrophoresis module and immersed in running buffer (192 
mM Glycine, 25 mM Tris, 0.1 % (w/v) SDS).  
SDS sample buffer (45 mM Tris-HCl, pH 6.8, 10 % glycerol, 1 % (w/v) SDS, 
0.01 % (w/v) Bromophenol Blue, 50 mM DTT) was added to 50 g of cell lysates 
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protein in a ratio of 1:4 (v/v) and the samples were heated at 95
o
C for 5 minutes 
prior to loading. Two l of PageRuler
TM 
Prestained Protein Ladder (Fermentas) 
was loaded as protein standards. Protein samples were separated by 
electrophoresis in running buffer at 80-150 V until the Bromophenol blue dye 
front reached the bottom of the gel.   
2.4.4 Native PAGE 
Proteins were resolved on the basis of their charge and molecular weight by native 
PAGE. The key parameters in native PAGE system are the pI of the protein of 
interest and the pH of the running buffer. If the pH of the running buffer is greater 
than the pI of the protein of interest, the protein will acquire a negative charge and 
migrate towards the positive electrode (anode). In contrast, if the pH of the 
running buffer is lower than the pI of the protein of interest, the protein will 
acquire a negative charge and migrate towards the negative electrode (cathode). 
Chk1 protein has a pI of 8.2. Polyacrylamide gel at 10 % or 15 % was prepared 
without SDS and using 390 mM Tris buffer, pH 8.8 and a Mini-PROTEAN3
TM 
(Bio-Rad) blot. The resolving gel was overlaid with dH2O to remove air bubbles 
and flatten the top surface before left to polymerise at room temperature. After the 
resolving gel was set, the dH2O was removed and the stacking gel with a 
polyacrylamide concentration of 5 % (123 mM Tris buffer, pH 8.8 was used and 
SDS was not added) was added with either a 10-well or 15-well comb and left to 
polymerise. After the stacking gel was set, the comb was removed and the gel 
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cassette was assembled with the Mini-PROTEAN3
TM 
electrophoresis module and 
immersed in running buffer (without SDS).  
Samples were prepared with 5 l of the sample buffer (without SDS and DTT) abd 
resolved as in Materials and Methods 2.4.3.     
2.4.5 Coomassie Brilliant Blue Staining 
Resolving gels were submerged in Destain I (50 % (v/v) Methanol, 10 % (v/v) 
Acetic Acid) for more than 5 minutes in a tray with rocking. After that, Destain I 
was replaced with Coomassie Brilliant Blue stain (50 % (v/v) Methanol, 10 % (v/v) 
Acetic Acid, 0.2 % (w/v) Coomassie Blue R-250) and the gel was stained 
overnight with rocking. Stained gels were then destained with Destain II (7.5 % 
(v/v) Methanol, 10 % (v/v) Acetic Acid) to remove excess stain. Destaining was 
performed until the protein bands became visible and the gel background was clear. 
Gels were dried onto a 3 mm Whatman paper using a gel-dryer.   
2.4.6 Immunoblotting 
For the purpose of western blotting, resolved proteins were transferred 
electrophoretically to PROTRAN
TM 
nitrocellulose transfer membrane (Schleicher 
& Schuell Biosciences). Gel were equilibrated in tanks with transfer buffer (192 
mM Glycine, 25 mM Tris, 20 % (v/v) Methanol) and assembled with an ice block. 
Electroblotting was performed at 100 V for 1 hour or at 20 mA overnight. After 
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transfer, the membrane was rinsed in PBS/T (0.1 % (v/v) Tween-20, 1x PBS (137 
mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4; adjusted to pH 7.4 
with HCl) for 5 minutes before the protein were stained with black ink (Pelikan) 
diluted in PBS/T (1/250) for 10 minutes. The membrane was washed twice with 
PBS/T for 5 minutes to remove excess stain. Non-specific antibody binding was 
blocked with 5 % (w/v) dried skimmed milk diluted in PBS/T for 1 hour. The 
membrane was then incubated with the primary antibodies diluted in 5 % (w/v) 
milk-PBS/T for 1 hour at room temperature or overnight at 4
o
C. Any unbound 
antibody were removed with three 10 minutes washes in PBS/T at room 
temperature. The membrane was then incubated with the appropriate secondary 
antibody diluted 1/1000 in 5 % (w/v) milk-PBS/T for 1 hour at room temperature. 
Any unbound antibodies were removed with three 10 minutes washes in PBS/T. 
The membrane was then overlaid with enhanced chemiluminescence solution 
(ECL) (1 part of ECL solution I (100 mM Tris, pH 8.5, 2.5 mM Luminol stock, 
0.4 mM p-Coumaric acid) mixed with 1 part of ECL solution II(100 mM Tris, pH 
8.5, 0.02 % (v/v) H2O2)) for 1 minute. Excess ECL solution was drained before 
membranes were exposed to Hyperfilm
TM 
ECL (Amersham Biosciences).  
      
2.4.7 Stripping nitrocellulose membrane 
Membranes were stripped to remove primary and secondary antibodies from the 
membrane before they were reprobed with additional antibodies. The membrane 
was incubated with two changes of stripping buffer (1.5 % (w/v) glycine, 0.1 % 
(w/v) SDS, 1 % (v/v) Tween-20; adjusted to pH 2.2 with HCl) for 10 minutes at 
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room temperature. The membrane was rinsed twice with PBS for 10 minutes and 
twice with PBS/T for 5 minutes before it was ready for the blocking stage as 
described in Materials and Methods 2.4.6.   
2.4.8 Antibodies 
2.4.8.1 Primary antibodies 
Table 2.2 List of primary antibodies used in this study.   
2.4.8.2 Secondary antibodies 
Secondary antibodies were sourced from Dako and HRP-conjugated forms of 
Rabbit -Mouse IgG; Swine -Rabbit IgG; Rabbit -goat IgG; Rabbit -sheep IgG 
were used.  
Target kDa Type Supplier Dilution 
Chk1 (G-4) 56 Mouse monoclonal Santa Cruz 1:1000 
Chk1 56 Sheep polyclonal Millipore 1:1000 
Chk1 phospho-Ser317 56 Rabbit polyclonal Cell Signalling Technology 1:1000 
Chk1 phospho-Ser345 56 Rabbit polyclonal Cell Signalling Technology 1:1000 
His tag - Mouse monoclonal Novagen 1:1000 
p21 (Ab-1) 21 Mouse monoclonal Calbiochem 1:500 
p21 phospho-Thr145 21 Rabbit polyclonal Santa Cruz 1:1000 
p21 phospho-Ser146 21 Goat polyclonal Santa Cruz 1:1000 
V5 tag - Mouse monoclonal Abcam 1:1000 
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2.5 In vitro Kinase assay 
Kinase reactions containing 100 ng of protein kinase, 0.5-1 g of substrate were 
assembled in kinase buffer (50 mM Hepes, pH 7.4, 0.1 mM EGTA, 0.1 % (v/v) -
mercaptoethanol, 20 mM Magnesium Acetate) in a final volume of 9 l. The 
reactions were initiated by adding 1 l of either 1 mM ATP or 1 mM ATP 
containing a 1/50 dilution of radiolabelled [
32
P]-ATP (Perkin Elmer) (3000 
Ci/mol) and incubated for 30 minutes at 30
o
C. The reactions were stopped with 5 
l of 5x SDS sample buffer and reaction products were resolved by SDS-PAGE. 
Gels were dried onto 3 mm Whatman paper and exposed to a storage phosphor 
screen (Amersham Biosciences) overnight before [
32
P] incorporation was 
visualised and quantified via a phosphorimager (Storm 840, Amersham 
Biosciences). Actual counts of [
32
P] incorporation into reaction products was 
determined from a [
32
P]-ATP standard curve.   
2.6 Immunoprecipitation-kinase assay (IP-kinase) 
To immunoprecipitate protein complexes from cell lysates, 2 mg of mammalian 
cell lysate was first pre-cleared with 40 l of 50 % (w/v) Protein G Sepharose
TM 
4 
Fast Flow suspension (GE Life Sciences) (diluted in mammalian lysis buffer) for 1 
hour at 4
o
C with rotation. After incubation, the sample was microcentrifuged for 
10 seconds and the cleared supernatant was recovered. The supernatant was then 
incubated with 2 g of appropriate primary antibody and incubated for 2 hours at 
4
o
C. After incubation, 40 l of 50 % (w/v) Protein G Sepharose
TM 
4 Fast Flow 
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protein G/antibody complexes were collected by microcentrifuging for 30 seconds. 
The supernatant was removed and the beads were washed twice with 500 l of 
lysis buffer. The beads was then split equally into two 0.6 ml microcentrifuge 
tubes. One of the samples was further washed with 200 l of lysis buffer before 20 
l of 5x SDS sample buffer was added and it was subjected to SDS-PAGE. The 
other sample was washed twice with 200 l of 2x kinase buffer before the beads 
were resuspended in 9 l of kinase reaction buffer containing substrate and kinase 
buffer was added. The kinase reaction was initiated as described in Materials and 
Methods 2.5.     
2.7 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
2.7.1 Indirect ELISA 
Antigens were diluted to a final concentration of 1 g/ml in 100 l of 0.1 M 
NaHCO3, pH 9.6 before added to each well of PVC 96-well microtitre plate. The 
microtitre plate was covered with parafilm and incubated overnight at 4
o
C. Excess 
antigens were removed by washing with four changes of 200 l of PBS/T before 
non-specific antibody binding was blocked with 200 l of 3 % (w/v) BSA in 
PBS/T for 1 hour at room temperature.  Appropriate primary antibodies (diluted in 
50 l of 3 % (w/v) BSA-PBS/T) were added and incubated for 1 hour. Any 
unbound antibodies were washed off with six changes of 200 l of PBS/T. 
Appropriate secondary antibodies (diluted in 50 l of 3 % (w/v) BSA-PBS/T) were 
then added and incubated for 1 hour. Any unbound antibodies were washed off 
with six changes of 200 l of PBS/T. Binding was detected by adding 50 l of 
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ECL solution (1:1 ratio of ECL I and ECL II solution) and relative light units 
(R.L.U) were quantified using a luminometer (Fluoroskan Ascent FL).        
2.7.2 Streptavidin capture of peptide antigens 
Protein complexes were also captured in an ELISA format using streptavidin 
capture of biotinylated peptides. Biotinylated peptides were immobilised in PVC 
96-well microtitre plate. First, each well was coated with 1 g of streptavidin 
(diluted in 50 l of dH2O) and incubated overnight at 37
o
C. After incubation, the 
wells were washed with four changes of 200 l of PBS/T. Appropriate amounts of 
peptides were diluted in 50 l of dH2O and added to each well and incubated at 
room temperature for 1 hour. Excess peptides were washed off with six changes of 
200 l of PBS/T before non-specific antibody binding was blocked with 3 % (w/v) 
BSA (diluted in 200 l of PBS/T) for 1 hour. Appropriate primary antibodies 
(diluted in 50 l of 3 % (w/v) BSA-PBS/T) were added and incubated for 1 hour. 
Any unbound antibodies were washed off with six changes of 200 l of PBS/T. 
Appropriate secondary antibodies (diluted in 50 l of 3 % (w/v) BSA-PBS/T) were 
then added and incubated for 1 hour. Any unbound antibodies were washed off 
with six changes of 200 l of PBS/T. Binding was detected by adding 50 l of 
ECL solution (1:1 ratio of ECL I and ECL II solutions) and R.L.U were quantified 
using a luminometer (Fluoroskan Ascent FL).    
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2.8 Isolation of p21 protein from inclusion bodies 
Plasmids containing TrcHisA p21 wild-type or TrcHisA p21 NT mutant were 
transformed into BL21 E.coli cells and streaked onto selective LB agar. Following 
overnight incubation at 37
o
C, a single colony was picked to inoculate a 10 ml of 
selective LB medium and incubated at 37
o
C at 225 rpm overnight. The overnight 
culture was then added to 500 ml of selective LB medium and incubated at 37
o
C at 
225 rpm until an OD600nm of 0.4 was reached. A final concentration of 1mM IPTG 
was then added and the culture was incubated for a further 2 hours at 37
o
C. Cells 
were collected by centrifuging at 8000 rpm at 4
o
C for 10 minutes. The cell pellet 
was resuspended in ice-cold 50 mM Tris-HCl, pH 8.0. The cell suspension was 
then centrifuged as before and the pellet was resuspended in 25 ml of ice-cold 50 
mM Tris-HCl, pH 8.0. The cell suspension was centrifuged again as before and the 
final pellet was resuspended at 0.66 ml/g in 10 % (w/v) sucrose, 50 mM Tris-HCl, 
pH 8.0 lysis buffer. A final concentration of 150 g/ml of lysozyme and 0.1 M of 
NaCl was added and the mixture was mixed gently and incubated at 0
o
C for 45 
minutes. The cell lysate was then warmed to 37
o
C for 1 minute and returned to 
0
o
C till the cell lysate turned viscous. The sample was then sonicated with three 10 
seconds pulses before it was centrifuged at 10000 rpm at 4
o
C for 10 minutes. The 
inclusion bodies was resuspended in 25 ml of lysis buffer (50 mM Tris-HCl, pH 
8.0, 2 mM EDTA, 100 mM NaCl, 1 mM PMSF, 0.5 % (v/v) Triton X-100, 1.2 
mM Benzamidine, 10 g/ml Leupeptin) and recentrifuged at 10000 rpm at 4
o
C for 
10 minutes. This was repeated twice. The inclusion bodies was then resuspended 
in 5 ml of the solubilisation buffer (5 M guanidine hydrochloride, 50 mM Tris-
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suspension was then centrifuged at 10000 rpm at 4
o
C for 10 minutes. Five ml of 
the supernatant was then diluted into 20 ml of refolding buffer (50 mM Tris-HCl, 
pH 8.0, 0.005 % (v/v) Tween-80, 2 mM reduced glutathione, 0.02 mM oxidised 
glutathione) and mixed for 12-18 hours at 4
o
C. The diluted supernatant was then 
dialysed against dialysis buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 0.005 % 
(v/v) Tween-80) for 1-2 hours at 4
o
C. The dialysis procedure was repeated 3 more 
times with decreased concentration of NaCl (250, 200, 150 mM). The dialysed 
supernatant was then centrifuged at 10000 rpm at 4
o
C for 10 minutes to remove 
any insoluble or precipitated proteins.   
2.9 Purification of His-tagged proteins 
Histidine tagged proteins were purified via nickel agarose affinity chromatography. 
Sf9 insect cells were infected and Chk1 baculovirus for 48 hours at 27
o
C. After 
infection, the cells were collected by centrifuging at 4000 rpm for 20 minutes at 
4
o
C. The cell pellet were then resuspended with twice the cell pellet volume of 
lysis buffer as described in Materials and Methods 2.4.1.2. Twenty ml of IMAC5 
buffer (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 5 mM imidazole) was then added to 
25 ml of cell lysate before filtered through a 0.45 m button filter. Two ml of Ni-
NTA agarose slurry (Qiagen) was prepared with 3 ml of IMAC5 buffer and added 
to the filtered lysate. After incubation at 4
o
C for 1 hour, the lysate-Ni-NTA 
mixture was loaded onto a 10 ml polypropylene column and the flow-through was 
collected. The column was washed with 10 ml of IMAC5 buffer and then washed 
with 40 ml of IMAC25 buffer I (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 25 mM 
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imidazole, 0.5 % (v/v) Triton X-100, 0.5 % (v/v) Tween-20) before a final wash of 
10 ml of IMAC25 buffer II (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 25 mM 
imidazole). All the wash fractions were collected for analysis. The protein was 
eluted with 20 ml of IMAC150 buffer (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 5 
mM imidazole). The eluted proteins/fraction was then concentrated with 35 000 
PEG (Poly(ethylene glycol) (Fluka) using dialysis tubing of molecular weight cut-
off of 6000-8000. PEG binds to H2O. Concentrated proteins/fractions were then 
dialysed overnight with dialysis buffer (20 mM Hepes, pH 8.0, 10 % (v/v) glycerol, 
1 mM DTT, 1 mM Benzamidine, 150 mM NaCl) at 4
o
C. The eluted protein was 
further dialysed with fresh dialysis buffer for 2 hours at 4
o
C. The flow-through, 
wash fractions and the dialysed eluted proteins were then analysed by SDS-PAGE 
and immunoblotting.    
2.10 Gel Filtration/Size exclusion chromatography 
Gel filtration chromatography is a method in which molecules are separated based 
on their sizes. Larger molecules are eluted first whilst smaller molecules require 
longer time to elute as they are retarded within the column. A gel filtration column 
Superdex 200 (Amersham Biosciences) was used with an AKTA FPLC 
(Amersham Biosciences). The column was equilibrated with two column volume 
(C.V) of buffer (20 mM Hepes, pH 8.0, 10 % (v/v) glycerol, 1 mM DTT, 1 mM 
Benzamidine, 150 mM NaCl) with a flow rate of 0.5 ml/minute. Purified 
recombinant insect cell-expressed Chk1 (Trp Ala
192/208
) was concentrated to 
about 500 l using Centricon Centrifugal Filter Device, Ultracel YM-10 
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membrane (Millipore) according to manufacturer s instructions prior to loading 
onto the column. Sample was eluted with 1.5x C.V of buffer with a flow rate of 
0.3 ml/minute and 0.5 ml fractions were collected. Elution fractions were then 
analysed by SDS-PAGE and immunoblotting.   
2.11 PepChip Kinase assay 
Trial/Evaluation PepChip kinase slides were purchased from Mimotopes. Each 
slide contains 2 duplicate sets of 192 peptides and each set contains 2 x 4 
subarrays of 6 x 4 peptide spots. Fifty l of kinase reaction containing 50 g/ml of 
purified recombinant protein kinase in kinase buffer (50 mM Hepes, pH 7.4, 0.1 
mM EGTA, 0.1 % (v/v) -mercaptoethanol, 20 mM Magnesium Acetate), 0.01 % 
(v/v) Brij-35, 10 M ATP and 300 Ci/ml [
33
P]-ATP was assembled and overlaid 
onto the PepChip slide and incubated for 3 hours at 30
o
C in a humidified chamber. 
After incubation, the slide was washed once with PBS/Tx (1x PBS, 1 % (v/v) 
Triton X-100), twice with NaCl/Tx (2 M NaCl, 1 % (v/v) Triton X-100) and twice 
with dH2O and then air-dried. Slides were exposed to storage phosphorscreen and 
[
33
P] incorporation into the peptide substrates on the PepChip slide were 
visualised by phosphorimager. The spot signals were correlated with the peptide 
sequences using the grid provided by the manufacturer and the coordinates were 
used to identify the peptide protein sequence from an excel spreadsheet also 
provided by the manufacturer.  
      
     
CHAPTER 3: DOCKING-DEPENDENT REGULATION OF 
CHK1 BY p21
WAF1             
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3.1 Introduction 
This chapter identifies p21
waf1 
as potential novel substrate for checkpoint kinase 
Chk1. Furthermore, an N-terminal region of p21
waf1 
has been characterised to 
function as a docking-dependent modulator of Chk1 catalytic activity. Therefore, I 
will start with a brief introduction into p21
waf1
, a growth regulator.    
3.1.1 Cyclin-dependent kinase inhibitor, p21waf1/cip1 
p21
waf1/cip1
, or p21 as known hereinafter, is the first identified cyclin-dependent 
kinase (Cdk) inhibitor (CKI) which binds to Cdk2 and its associated cyclins, 
leading to the disruption of Cdk/cyclin-dependent phosphorylation of pRb (Harper 





(Harper, 1997). In addition to cdk inhibition, p21 also 
regulates the cell cycle in multiple ways which will be briefly discussed here. 
Despite playing a major role in cell cycle regulation, p21 mutations are very rare 
(Shiohara et al., 1997). However, p21-deficient mice do develop spontaneous 
tumours by the age of 16 months, indicating the importance of p21 for tumour 
suppression (Martin-Caballero et al., 2001). Therefore a variety of mechanisms for 
p21 regulation exists at the transcriptional and post-translational level which will 
also be described here.      
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3.1.2 p21waf1 structure 
Proteolysis, circular dichroism (CD) and nuclear magnetic resonance (NMR) 
experiments have shown that p21 has a highly disordered structure (Kriwacki et al., 
1996), which explains the lack of p21 crystal structure. However, p21 does adopt 
an ordered conformation upon association with Cdks (Kriwacki et al., 1996, Sung 
et al., 2001). It was discussed that this disorder-order transition for p21 could 
increase specificity for Cdk at the expense of binding affinity. Secondly, this 
highly disordered feature allows p21 to adopt multiple conformations in relation to 
different substrates and facilitate diverse binding events (Kriwacki et al., 1996). 
p21 shares a significant homology with p27 and p57 in the N-terminal region and 
targets a broad range of CDK-cyclin complexes, whereas the C-terminal region is 
less conserved (Figure 3.1) (Dotto, 2000).   
The N-terminal region of p21 is necessary and sufficient to inhibit CDK-cyclin 




(Cy1 motif) is important for the binding interface between p21 




, is required for Cdk2 association, suggesting that these two regions 
independently allow p21 association with Cdk2-cyclin A/E (Chen et al., 1996b). 
However, cyclin D1 only binds to p21 via the Cy1 motif when complexed with 
Cdk4 as either cyclin D1 or Cdk4 alone does not associate with p21 (Chen et al., 
1996b). This cyclin-binding motif (RxL) is conserved among the p27, p57, 
regulators and substrates of Cdk-cyclin complexes (Dotto, 2000). It has been 
shown that both the N-terminal cyclin-binding motif and the Cdk-binding motif 
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are needed to inhibit Cdk2 kinase activity (Fotedar et al., 1996). Using data 
extrapolated from the crystal structure of the p21 relative, p27, with Cdk2, 
inhibition of Cdk kinase activity is mediated by p21 binding and subsequent Cdk2 
structural changes. This results in a p21 N-terminal region buried inside the Cdk2 
catalytic cleft, with Tyr
77 
sterically blocking the ATP-binding site of Cdk2 (Russo 
et al., 1996). It was also reported that amino acids 26-45 are potentially involved 
in p21 dimerisation (Chen et al., 1996a).     
In contrast to the N-termini, the C-terminal regions of the CKI Cip/Kip family are 
poorly conserved. It was discovered that amino acids 139-164 of p21 are essential 
for binding to proliferating cell nuclear antigen (PCNA), a processivity factor  for 
DNA polymerase , and inhibits DNA synthesis (Chen et al., 1995, Luo et al., 
1995, Chen et al., 1996a). Association with PCNA is dependent on the removal of 
an inhibitory phosphate group at Ser
146 
of p21 (Scott et al., 2000). A second but 




(Cy2 motif) that resides 
within the PCNA-binding domain has also been identified, suggesting that PCNA 
may regulate p21 activity on Cdk-cyclins (Chen et al., 1996b). A peptidomimetic 
ligand containing the lower affinity cyclin-binding motif has been shown to be a 
potent inhibitor of Cdk4-cyclin D, but not Cdk2 (Ball et al., 1997). A basic nuclear 





(Rodriguez-Vilarrupla et al., 2002).    
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3.1.3 Functions of p21waf1 
p21 s role in mediating cell cycle arrest through the inhibition of Cdk-cyclin 
activity is well established. However it appears that cytoplasmic p21 also 
functions to facilitate the association of Cdk4/6 with cyclin D and promote their 
nuclear localisation, resulting in G1 phase progression. It was also shown that low 
concentrations of p21 promote assembly of Cdk-cyclin complexes while high 
concentrations of p21 inhibit the activity of Cdk (LaBaer et al., 1997).  
In addition, it has been shown that E2F-dependent transcription can also be 
repressed by a p21-dependent mechanism that is independent of Cdk activity 
(Delavaine and La Thangue, 1999). Similar to the reported direct association of 
p21 with E2F subunits (Delavaine and La Thangue, 1999), p21 was shown to bind 
to the N-terminus of c-Myc, disrupting the interaction between c-Myc and Max. 
This is thought to suppress c-Myc-dependent transcription and also activate DNA 
replication as c-Myc competes with PCNA for the same binding site on p21 
(Kitaura et al., 2000).   
On the other hand, p21 can function to inhibit DNA synthesis via negative 
regulation of PCNA. It has been suggested that p21 regulates PCNA function by 
preventing PCNA interaction with DNA-(cytosine-5) methyltransferase (MCMT), 
leading to unmethylated replicated DNA (Chuang et al., 1997). Similarly, p21 
disrupts PCNA interaction with Fen 1 (a 5 -3 exonuclease involved in DNA 
replication) and concomitantly inhibits DNA synthesis (Warbrick et al., 1997). 
Apart from inhibiting DNA synthesis, numerous conflicting observations are 
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reported as to whether p21 can prevent PCNA-dependent DNA repair (Fotedar et 
al., 2004).   
p21 also associates with poly (ADP-ribose) polymerase family, member 1 (PARP1) 
through the C-terminal PCNA-binding domain. Although the significance of the 
interaction is not clear, this is thought to cooperatively regulate PCNA functions 
during DNA synthesis/repair (Frouin et al., 2003). Similarly, human 
papillomavirus (HPV)-16 E7 oncoprotein can abrogate inhibition of CDK activity 
and PCNA-dependent DNA synthesis by competing for the same PCNA/cyclin-
binding motif in the C-terminal domain of p21 (Funk et al., 1997).  
The C-terminal domain of p21 has been shown to de-repress the transcriptional 
repression activity of a p300 sumoylation-dependent transcriptional repression 
domain, CRD1, independently of cyclin or PCNA binding (Garcia-Wilson and 
Perkins, 2005). Although direct interaction between CRD1 and p21 was not 
observed, it was believed that p21 could target other parts of the transcriptional 
repression machinery.  
p21 is thought to protect against apoptosis as it was found to bind to procaspase-3 
and block its cleavage into the active form. The binding module is located in the 
N-terminus of p21 but is independent of the Cdk- and cyclin-binding motifs. In 
contrast, interaction between p21 and the activated form of caspase-3 was not 
observed (Suzuki et al., 1998, Suzuki et al., 1999). Interestingly, activated 
caspase-3 is also able to cleave p21, resulting in a truncated form of p21 that failed 
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to localise in the nucleus and loss of p21 function (Gervais et al., 1998, Zhang et 
al., 1999b). Besides inhibition of caspase-3 activation, p21 also binds to the pro-
apoptotic stress-activated protein kinase (SAPK) and inhibits its catalytic activity, 
possibly via blocking activating phosphorylation by its upstream MKK4 kinase 
(Shim et al., 1996). Interestingly, this anti-apoptotic function is mediated by 
cytoplasmic localisation of p21 which is dependent on phosphorylation by 
PKB/Akt (Blagosklonny, 2002). Futhermore, poor prognosis of many breast 
tumours is often associated with high expression of cytoplasmic p21, leading to 
the suggestion that p21 may be a cytoplasmic oncoprotein with anti-apoptotic 
activity (Winters et al., 2001, Blagosklonny, 2002). This showed that p21 may 
exhibit different functions depending on its subcellular localisation; regulation of 
cell cycle and transcription in the nucleus and modulation of apoptosis in the 
cytoplasm.  
Besides modulating cell cycle control and apoptosis, p21 is also an important 
determinant in cell differentiation. Keratinocyte cell differentiation is induced by a 
proteosome-dependent decrease in p21 with overexpression of p21 inhibiting 
differentiation (Di Cunto et al., 1998).  In contrast, p21 is reported to have a 
positive effect in retinoic acid-induced differentiation of acute promyelocytic 
leukaemia cells, as ablation of p21 prevents differentiation. This positive 
regulation is uncoupled from the cell cycle effects of p21 (Casini and Pelicci, 
1999). Thus p21 is implicated as an important regulator of differentiation which 
can be either positive or negative depending on the cell type and specific stages of 
differentiation (Dotto, 2000). 
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3.1.4 Regulation of p21waf1 
Induction of the p21 gene was first discovered to be transcriptionally regulated by 
the p53 protein (el-Deiry et al., 1993). Two conserved p53-binding sites were 
found in the p21 promoter sequence of which at least one is required for p53-
dependent transcriptional activation of p21 (el-Deiry et al., 1995). Basal 
expression of p21 has been shown to be regulated by p53 in the absence of 
genotoxic stress (Tang et al., 1998). In response to DNA damage or ribonucleotide 
starvation, p21 transcript levels are upregulated by activated p53 (Di Leonardo et 
al., 1994, Linke et al., 1996). Apart from p53, breast cancer type 1 susceptibility 
protein (BRCA1) and the transcription factor Sp1 also mediate the induction of 
p21 gene expression through the Sp1-binding sites (Biggs et al., 1996, 
Somasundaram et al., 1997). It was also demonstrated that p300/CBP could 
cooperate with Sp1 to positively regulate p21 expression (Billon et al., 1999). In 
addition, a number of proteins such as interferon regulatory factor 1 (IRF1) and 
transcription factor AP2 also function in p53-independent regulation of p21 
expression as reviewed in (Gartel and Tyner, 1999).    
Although p53-dependent transcriptional activation of p21 has been well-
characterised, mechanisms of transcriptional repression of p21 are still under-
appreciated. However it is clear that the c-Myc proto-oncogene functions to 
repress p21 transcription (Gartel and Radhakrishnan, 2005). c-Myc is a 
transcription factor that functions to activate or repress transcription of target 
genes through recruitment of distinct co-factors (Adhikary and Eilers, 2005, 
Cowling and Cole, 2006). In cell line studies, overexpression of c-Myc leads to 
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p21 repression and switches DNA damage-induced cell cycle arrest to an apoptotic 
response (Seoane et al., 2002, Arango et al., 2003). Conversely, down-regulation 
of c-Myc leads to an increased level of p21, implicating c-Myc as a bona fide 
transcriptional repressor of p21 (McConnell et al., 2003, Gui et al., 2004). 
Although it was shown that repression of p21 transcription by c-Myc occurred at a 
proximal promoter region, the mechanistic basis of the repression is not well-
understood (Claassen and Hann, 2000). It was suggested that c-Myc-dependent 
inhibition of transcription factors Sp1/Sp3 or Miz-1 activity is needed for 
repression. In addition, active recruitment of the DNA methyltransferase 3a 
(Dnmt3a) co-repressor by c-Myc to the promoter region is also required for p21 
repression (Brenner et al., 2005). Apart from c-Myc, other proteins such as polo-
like kinase 1, histone deacetylase 1 and zinc-finger protein 76 (ZNF76) are able to 
functionally interfere with the transcriptional activators (p53 and Sp1/Sp3) and 
basal transcriptional machinery (TATA-binding protein) to repress p21 
transcription (Lagger et al., 2003, Ando et al., 2004, Zheng and Yang, 2004). p21 
repression through direct binding to the proximal promoter by transcription factors 
such as T-box protein 2 (Tbx2), Runt-related transcription factor 2 (RUNX2) and 
zinc finger and BTB domain-containing protein 4 (ZBTB4) has also been 
described (Westendorf et al., 2002, Prince et al., 2004, Weber et al., 2008). 
Increasing evidence also points towards epigenetic silencing as another system to 
regulate p21 transcription (Gartel and Radhakrishnan, 2005).              
p21 has been reported to be phosphorylated at various sites catalysed by a diverse 
range of distinct kinases. The best characterised site is Thr
145 
which lies within the 
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PKB/Akt consensus phosphorylation site (Liang and Slingerland, 2003). 
Phosphorylation on Thr
145 





of p21 and PCNA, thereby destabilising the complex 
(Rossig et al., 2001, Child and Mann, 2006). In addition, PKB/Akt-catalysed 
Thr
145 
modification can induce relocalisation of p21 from the nucleus to the 
cytoplasm in endothelial cells (Zhou et al., 2001). However, it was also reported 
that increased PKB/Akt activity did not induce p21 cytoplasmic localisation in 
keratinocytes (Segrelles et al., 2006). Nevertheless, it is thought that cytoplasmic 
localisation limits p21 access to Cdk2 complexes, leading to defective cell cycle 
arrest (Asada et al., 1999).  
PKC , a downstream target of 3-phosphoinositide dependent protein kinase 1 
(PDK1), phosphorylates p21 on Ser
146 
which mediates degradation of p21 (Scott et 
al., 2002). Another study has also implicated PKC in the phosphorylation of p21 
on Ser
153
, and is thought to affect its subcellular localisation. Calmodulin is able to 
bind to the C-terminal domain of p21 at amino acids 145 to 164 and this binding 
blocks Ser
153 
modification and prevents nuclear export (Rodriguez-Vilarrupla et 




, PKC is also capable of phosphorylating p21 
at Ser
160
. This is thought to decrease p21 binding to PCNA as phosphorylation is 
likely to disrupt Ser
146 
hydrogen bonding with PCNA (Gulbis et al., 1996, Scott et 
al., 2000).   
In addition, Thr
57 
has been described as a phosphorylation target of which GSK3 , 
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stabilises p21, leading to elevated binding with cyclin B1 at the G2/M transition 
(Rossig et al., 2002, Kim et al., 2002, Dash and El-Deiry, 2005). Furthermore, 
p38 and JNK are found to phosphorylate p21 on Ser
130
, which is also thought to 
stabilise p21 (Kim et al., 2002). However a recent report showed that CDK2 
targets p21 at Ser
130 
for proteosome-dependent degradation (Zhu et al., 2005). It is 
likely that a combination of post-translational modifications is needed to 
determine the type of regulation.  
p21 stability is also reported to be regulated by WISp39 which contains a 
tetratricopeptide repeat (TPR) domain that allows recruitment of heat shock 
response protein Hsp90. p21, WISp39 and Hsp90 then form a heterotrimeric 
complex responsible for accurate p21 folding and stability (Jascur et al., 2005).  
There is controversy regarding whether degradation of p21 is ubiquitin-dependent 
or independent. A study has showed that p21 mutant, which cannot be 
ubiquitinated in vivo, still undergoes degradation and remains sensitive to 
proteasomal inhibition (Sheaff et al., 2000). This could be due to the direct 
interaction between the C-terminus of p21 and the C8 subunit of 20S proteosome 
in an ubiquitin-independent manner as deletion of the C8 binding region in p21 
attenuates C8 binding and increases p21 stability (Touitou et al., 2001). However 
it has been suggested that there is no strong evidence of the existence of an active 
stand-alone 20S proteosome (Bloom and Pagano, 2004).  
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In contrast, p21 degradation has been shown to be mediated by a unique 
ubiquitination mechanism. In this system, degradation is dependent on an 
ubiquitin chain conjugated to the N-terminal methionine residue, instead of the 
conventional lysine residues. In addition, a functional NEDD8 conjugation system 
is required for p21 degradation in vivo (Bloom et al., 2003).   
In response to low doses of UV irradiation, p21 is degraded via the Skp2-
dependent proteosome pathway (Bendjennat et al., 2003). The initiating signal for 
UV-induced p21 degradation was shown to involve GSK3 -dependent 
phosphorylation of p21 at Ser
114 
(Lee et al., 2007).   
3.1.5 Relationship between p21 and Chk1 
The first link between p21 and Chk1 was uncovered in a fission yeast study where 
the association of p21 and PCNA is thought to lead to ATR-dependent activation 
of Chk1 (Tournier et al., 1996). Overexpression of PCNA led to G2-phase arrest, 
while deletion of the Chk1
+ 
gene abolished this inhibition. The authors thought 
that the association of p21 and PCNA could be modulated by Chk1, though the 
mechanism is not clear.    
In another study, Chk1 has been reported to be downregulated at the 
transcriptional level in a p53-dependent manner. This repression requires p21 and 
cells lacking p21 cannot downregulate Chk1. It was suggested that p53 and Chk1 
are involved in a feedback loop mechanism where Chk1 stabilised p53 through 
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phosphorylation and p53 in turn downregulated Chk1. In the damaged cell context, 
Chk1 downregulation by p53 would prevent an excessively prolonged G2-phase 
arrest that could trigger apoptosis (Gottifredi et al., 2001).     
3.1.6 Objectives 
In this chapter, I aim to validate and characterise Chk1 protein kinase as a 
potential regulator of p21 and dissect the intermolecular interaction between Chk1 
and p21 to investigate the basis of Chk1 substrate recognition.                
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3.2 Results 
3.2.1 Identification of Checkpoint kinase 1 (Chk1) as a p21waf1 kinase 
p21 is an important component of the DNA damage response which functions to 
arrest the cell cycle by inhibiting cyclin-dependent kinase activity (Harper et al., 
1993). Previous research from the Ball lab aiming to identify novel protein kinases 
for p21 has developed a screen for endogenous activity from whole cell lysates 
(Scott et al., 2002). Whole cell lysate from HeLa cells was subjected to three 
rounds of chromatographic fractionation using Q-Sepharose, SP-Sepharose and 
HS-Poros columns to obtain an active p21 kinase fraction. The active p21 kinase 
fraction was then analysed by gel filtration using a Superose 12 column. Each gel 
filtration column fraction was collected and the kinase activities were 
characterised. Four possible waves of kinase activities were noted. One of the 
kinases was found to be PKC (Scott et al., 2002) which correspond to the first 
activity from fraction 1 to 4 with the activity strongest in fraction 1 (PKC 
immunoblot not shown). A possible second wave of activity was observed in 
fraction 5 with the appearance of a slow mobility shift in the p21 blot (Figure 3.2; 
fraction 5; top and middle panel). The third possible activity was seen in fraction 6 
to 7 where the slower mobilised p21 form is more dominant in the [
32
P] blot 
(Figure 3.2; fraction 6 to 7; top panel). Lastly, the fourth activity was putatively 
identified as Chk1 (Figure 3.2; fraction 7 to 8; Scott and Ball, unpublished data).  
The experiments described herein were repeated twice and the results are 
consistent unless stated otherwise. Figures displayed herein are best representation 
of the results.  
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Using this data as a starting point, I decided to validate p21 as a potential substrate 
for Chk1. The Chk1 substrate consensus sequence was delineated to a Rxx(S/T) 
motif (O'Neill et al., 2002) and Chk1 has also been demonstrated to phosphorylate 
Cdc25C at Ser
216 
which contains the RxxS motif. In contrast, Chk1 was also 




which do not resemble 
the Cdc25C phosphorylation motif targeted by Chk1 (Shieh et al., 2000). 
Therefore it is possible that Chk1 could display flexible substrate specificity 
modulated by allosteric action. To identify a possible Chk1 substrate consensus 
sequence within p21, full-length p21 amino acid sequence was aligned with 
Cdc25C phosphorylation motif (amino acids 211 to 221) and p53 phosphorylation 
motif (amino acids 13 to 23). Analysis of the sequence revealed that a C-terminal 





shared a suggestive homology with the Cdc25C and p53 phosphorylation motifs 




phospho-acceptor sites fit within 
the Chk1 substrate consensus motif, Rxx(S/T). Like p53 phosphorylation motif, 





. In addition, p21 also shares negatively-charged aspartic acid 





. This suggested that p21 could be a novel substrate for protein 
kinase Chk1.  
Chk1, Chk2 and death-associated protein kinase (DAPK) belong to the same 
superfamily of calcium/calmodulin-dependent protein kinase and are also involved 
in stress response pathways (Figure 3.4). Both Chk2 and DAPK1 have been 
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in vitro respectively (Craig 
et al., 2003, Fraser and Hupp, 2007). To test whether p21 is indeed a substrate of 
Chk1, a kinase assay was set up to compare the activity of Chk1, Chk2 and DAPK 
towards p21. Recombinant human p21 was expressed and purified from BL21 
E.coli. Chk1 baculovirus was generated using methods outlined in Chapter 2 and 
titrated before studies were carried out to determine optimal expression conditions 
for parameters such as viral dilution (multiplicity of infection) and incubation time 
(data not shown). Using these optimal conditions, recombinant human N-
terminally tagged His-Chk1 proteins were expressed in Sf9 insect cell system by 
infecting with Chk1 baculovirus. The expressed proteins were purified using the 
Ni-NTA column. Recombinant human N-terminally tagged His-Chk2 and GST-
DAPK1 core (kinase domain of DAPK1) were also expressed and purified from 
Sf9 insect cells (both Chk2 and DAPK1 were kindly provided by Hupp lab). 
Protein concentrations of Chk1, Chk2 and DAPK1 were determined by BCA assay 
and normalised to 100 ng.   
Kinase assay conditions such as kinase buffer, incubation time and temperature 
were also tested and optimised (data not shown). All kinase assays described 
hereinafter were incubated at 30
o
C for 30 minutes and then stopped by addition of 
SDS-sample buffer unless stated otherwise. In Figure 3.5A, [
32
P] incorporation 
into p21 by Chk1 is comparable to that of DAPK1. Negative controls with either 
no kinase or substrate showed no [
32
P] incorporation, indicating the absence of a 
contaminating kinase or substrate in the sample preparation. In addition, Chk1 was 
shown to phosphorylate p21 in a dose-dependent manner, demonstrating a linear 
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relationship (Figure 3.6B and C). In comparison to Chk1, Chk2 activity towards 
p21 was very weak (Figure 3.5A), suggesting that phosphorylation of p21 by 
calcium calmodulin family members is specific for some member and not others. 
Interestingly, previous studies have indicated that Chk1 and Chk2 have very 
similar substrate specificity (O'Neill et al., 2002). Thus the preferential 
phosphorylation of p21 by Chk1 suggested that there may be additional 
determinants outwith the phosphorylation motif. The above data suggested that 
Chk1 was an effective kinase towards p21 in vitro.   
3.2.2 Chk1 phosphorylates p21 Ser146   
To further characterise Chk1 activity towards p21, a library of biotinylated 
overlapping 20-mer peptides based on the sequence of p21 were synthesized 
(Figure 3.6A). Peptides were dissolved in DMSO. Each p21 peptide was 
assembled with recombinant human Chk1 in a kinase reaction to identify the 
possible p21 phosphorylation region catalysed by protein kinase Chk1. DMSO 
was used as a negative control. In Figure 3.6B, there was a 16-fold increase of 
[
32
P] incorporation into p21 peptide 10 and a 9-fold increase of [
32
P] 
incorporation into p21 peptide 11 as compared to DMSO control. This indicated 
that the C-terminal domain of p21 contains phospho-acceptor sites targeted by 













. Interestingly, peptide 10 exhibited an 
approximately 2-fold increase of [
32
P] incorporation as compared to peptide 11 
suggesting that residues before Thr
145 
might be important for Chk1 substrate motif 
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recognition. Indeed, as revealed in Figure 3.3, a conserved arginine residue is 




phospho-acceptor site that 
fits Chk1 consensus substrate motif, Rxx(S/T). In addition, a conserved glutamine 
residue was found at P-1 position relative to Thr
145 
phospho-acceptor site. Perhaps 
this explained why peptide 11 which lacks the conserved arginine and glutamine 
residues showed lower [
32
P]-ATP incorporation than peptide 10.   




were used to determine 
whether these sites were phosphorylated by Chk1. The specificity of the p21 
phospho-antibodies were first confirmed using an ELISA format (Figure 3.7A and 





(KRRQTpSMTDFYHSKRRLIFS) peptides together with a non-
phosphorylated p21 peptide control (KRRQTSMTDFYHSKRRLIFS) were 





antibodies. Any unbound primary 
antibodies were washed off before incubating with HRP-conjugated -rabbit or -
goat secondary antibodies. Any unbound secondary antibodies were washed off 
before the bound antibodies were detected by enhanced chemiluminescence. The 
data showed that the phospho-Thr
145 





antibodies were specific towards 
phospho-Ser
146 
peptides with little or no reactivity towards non-specific peptides. 
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Recombinant human p21 was then assembled with recombinant human Chk1, 
Chk2 or DAPK in kinase assay using unlabelled ATP before reaction products 
were resolved by SDS-PAGE. p21 phosphorylation was then analysed by 





(Figure 3.7C). It showed that p21 Ser
146 
is predominately phosphorylated by Chk1 
while Thr
145 
is mildly phosphorylated above background as compared to that by 
DAPK. It has been published that DAPK targeted p21 at Thr
145 
(Fraser and Hupp, 
2007). Consistent with the [
32
P]-ATP kinase assay, very weak phosphorylation of 
p21 Ser
146 
by Chk2 was detected, indicating that activation of Chk2 by allosteric 
mechanisms is required for efficient activity towards p21 as previously 
demonstrated (Craig et al., 2003). Total p21 protein level was detected to show 





were not available, Chk1-dependent 
phosphorylated p21 was subjected to tryptic cleavage followed by high 
performance liquid chromatography (HPLC) separation by reverse phase. The 
phospho-peptides were then analysed by mass spectrometry and Edman 
degradation confirming Ser
146 
to be the major phospho-acceptor site for Chk1 on 
p21 (data not shown).   
3.2.3 Activity of cellular Chk1 towards recombinant p21 
Recombinant human Chk1 has been shown to phosphorylate p21 at Ser
146
. To 
assess whether cellular Chk1 is active towards recombinant human p21, 
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and characterised in kinase assays. Before Chk1 immunoprecipitation-kinase (IP-
kinase) assays were carried out, the conditions of the assay were first optimised. 
To determine whether DNA damage-induced activation of Chk1 is required for 
activity towards p21, HeLa and isogenic HCT116 p21
-/- 
cells were treated with 
aphidicolin, a specific inhibitor of DNA polymerase  and  and blocks cell cycle 
at early S-phase via the activation of Chk1 (Feijoo et al., 2001). The optimal 
concentration of aphidicolin required for Chk1 activation was determined by 
titration of the cell cycle inhibitor agent into the cell medium over 4 hours before 
cells were harvested and analysed by SDS-PAGE and immunoblotting. Ethanol 
(the aphidicolin carrier) was used as a negative control. As reported, treatment 
with aphidicolin leads to the activation of Chk1 which is accompanied by a 
mobility shift of the enzyme by SDS-PAGE and immunoblot analysis (Feijoo et al., 
2001). Activation of Chk1 was visualised in three different cell lines (HeLa, 
HCT116 wild-type (p21
+/+
) and HCT116 p21
-/- 
cells) by immunoblotting using -
Chk1 antibodies. Following aphidicolin treatment, mobility shift of Chk1 was 
observed across all three cell lines (Figure 3.8A). Five M of aphidicolin treatment 
was sufficient to see an activation of Chk1. Mobility shift of Chk1 was not 
observed in the presence of ethanol treatment alone.   
To optimise the conditions for Chk1 activation, a time course of aphidicolin 
treatment was performed. Both HeLa and HCT116 wild-type cells were treated 
with 20 M of aphidicolin for a period of 10 to 240 minutes. Twenty M of 
aphidicolin treatment was chosen to ensure a robust activation of Chk1. Figure 
3.8B showed that Chk1 mobility shift was visible from 30 minutes of aphidicolin 
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treatment onwards with the greatest effect observed for 120 minutes and 240 
minutes of aphidicolin treatment. Therefore, 20 M of aphidicolin treatment for 4 
hours was set as the optimal condition to induce a DNA damage response in 
mammalian cells.     
Immunoprecipitation assays would be used to isolate Chk1 from mammalian cells, 
however it is not known where the Chk1 antibodies binds to the protein with 
regard to the catalytic site or substrate binding site. Therefore to test that the 
substrate utilisation of immunoprecipitated Chk1 is not affected by the presence of 
antibodies used in the IP-kinase assay, sheep -Chk1 antibodies were pre-
incubated with recombinant human Chk1 protein kinase prior to assembly with 
recombinant human p21 in [
32
P]-ATP kinase assay (Figure 3.9). This showed that 
in the presence of sheep -Chk1 antibodies, [
32
P] incorporation into p21 was 
slightly less than in the absence of sheep -Chk1 antibodies. This indicated that 
catalytic activity of recombinant human Chk1 was only slightly affected in the 
presence of sheep -Chk1 antibodies and thus it would be a suitable 
method/reagent to assay Chk1 catalytic activity in vitro.   
Next, sheep -Chk1 antibodies were used to immunoprecipitate Chk1 from cells 
and optimal buffer conditions were determined (data not shown). Cellular Chk1 
was then immunoprecipitated from HeLa and isogenic HCT116 p21
-/- 
cells and 
assayed for its activity towards recombinant human p21. As at this stage, it was 
not clear whether ATR-activation of Chk1 was required for its activity towards 
p21, therefore HeLa and HCT116 p21
-/- 
were incubated in the presence or absence 
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of aphidicolin prior to cell lysis and immunoprecipitation of the endogenous 
enzyme. Immunoblotting of whole cell lysates using -Chk1 antibodies showed 
that aphidicolin treatment led to activation of Chk1 as evidenced by the 
appearance of slower-migrated form of Chk1 (Figure 3.10; lower panel). 
Immunoblotting of Chk1 immunoprecipitates also suggested that similar amounts 
of Chk1 were immunoprecipitated from aphidicolin-treated and ethanol-treated 
cells (Figure 3.10; middle panel). Although it should be noted that the sheep -
Chk1 antibodies used does not immunoprecipitate the upper band (activating 
form). In fact, none of the commercial antibodies tested immunoprecipitated the 
upper band and the antibodies chosen for this assay was the best one for 
quantitative immunoprecipitation of total Chk1 protein. Analysis of the 
immunoprecipitated Chk1 showed that endogenous Chk1 from HeLa and HCT116 
p21
-/- 
cells were active towards recombinant human p21 (Figure 3.10; upper panel). 
[
32
P] incorporation into p21 was greater in the presence of Chk1 
immunoprecipitated from aphidicolin-treated HeLa as compared to Chk1 
immunoprecipitated from untreated HeLa cells, suggesting that aphidicolin-treated 
HeLa Chk1 was catalytically more active than untreated HeLa Chk1 despite the 
absence of the activated upper band. However no difference in [
32
P] 
incorporation into p21 was observed between Chk1 immunoprecipitated from 
untreated or aphidicolin-treated HCT116 p21
-/- 
cells.     
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3.2.4 Co-immunoprecipitation of Chk1 and p21 
We have shown that Chk1 co-eluted with a slower mobilised form of p21 in the 
gel filtration fraction and this form was suggestive of phosphorylation mediated by 
Chk1. I have also demonstrated that human recombinant and cellular Chk1 was 
active towards p21. Furthermore, the data suggests that p21 Ser
146 
is the major 
phospho-acceptor site catalysed by Chk1. To establish a physiological link, I 
attempted to look for evidence of physical interaction between Chk1 and p21 by 
co-immunoprecipitation. HCT116 wild-type cells were used as there is an 
abundant level of p21 and Chk1. Endogenous Chk1 was immunoprecipitated from 
HCT116 wild-type cells using sheep -Chk1 antibodies, however there was no 
visible evidence of p21 co-immunoprecipitation (data not shown). To circumvent 
the possibility that the antibodies used to immunoprecipitate Chk1 could affect 
interaction of p21 and Chk1, endogenous p21 was immunoprecipitated from 
HCT116 wild-type cells using rabbit -p21 antibodies. Again, there was no 
indication of Chk1 co-immunoprecipitation (data not shown), however non of the 
p21 antibodies available were able to quantitatively immunoprecipitated p21.   
As pointed out, I was unable to identify a commercial Chk1 antibody that was able 
to quantitatively recover all form of Chk1 from the cells. Thus in collaboration 
with Prof. David Gillespie s group, we tried to look for physical interaction of 
chick Chk1 and human p21. Chick Chk1 was used due to the availability of a 
better antibody reagent that recognises the C-terminal domain of chick Chk1 and 
has been shown by the Gillespie group to quantitatively immunoprecipitate both 
endogenous and exogenous chick Chk1. They have also demonstrated that the 
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immunoprecipitated protein retains catalytic activity (M.T. Scott, personal 
communication). No equivalent reagent is available for the human protein. Chick 
Chk1 shares 84 % homology with human Chk1 (Figure 3.11). Full-length chick 
Chk1 or a kinase-dead version of chick Chk1 was transfected into Cos1 cells alone 
or together with human p21. Chick Chk1 was immunoprecipitated from Cos1 cells 
using the -C-terminal Chk1 antibodies and immunoblotted for the presence of 
human p21. A low level of exogenous p21 was co-immunoprecipitated with full-
length chick Chk1 (Figure 3.12). Interestingly, when a kinase-dead version of 
chick Chk1 was transfected into Cos1 cells, a greater level of exogenous p21 co-
immunoprecipitated with it compared with wild-type Chk1 even though equal 
levels of wild-type and kinase-dead Chk1 was immunoprecipitated. The highly 
dynamic dissociation rates of enzyme-substrate complex may explain why a co-
immunoprecipitation complex between endogenous Chk1 and p21 protein was not 
detected. The data suggested that Chk1 could form a transient interaction with p21 
and this interaction was strengthened when a kinase-dead version of chick Chk1 
was introduced. This also suggests of a physiological link between Chk1 and p21.    
3.2.5 Chk1 catalytic activity can be allosterically regulated by a N-
terminal region of p21 
Protein kinases often achieve stringent substrate interaction through docking motif 
association (Remenyi et al., 2006, Goldsmith et al., 2007). Some members of the 
calcium-calmodulin dependent superfamily, for example DAPK1 and Chk2, have 
been shown to dock to their substrates enhancing specificity/activity (Craig et al., 
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2003, Fraser and Hupp, 2007). As suggested earlier, the discrepancy between the 
ability of Chk1 and Chk2 to phosphorylate p21 may indicate additional 
determinants such as substrate docking. These substrate docking motif interactions 
aim to tether the substrate to its enzyme and/or induce allosteric activation of the 
protein kinases. If the substrate docking motif is involved in tethering the substrate 
to the enzyme, then a ligand based on the docking motif should be able to 
competitively inhibit the protein-protein interaction, leading to inefficient 
phosphorylation of the substrate (Figure 3.13A). This is observed in the docking-
dependent regulation of pRb by CDK4 (Wallace and Ball, 2004). However if the 
substrate docking motif functions to activate the kinase allosterically, then the 
kinase activity will be stimulated by the ligand, leading to efficient 
phosphorylation of the substrate (Figure 3.13B). A prime example is the allosteric 
activation of Chk2 by two p53 DNA-binding domain peptides (Craig et al., 2003).   
A library of p21 peptides (Figure 3.6A) was added to a Chk1 kinase assay 
containing p21 to test whether a tethering or allosteric docking mechanism is 
required for Chk1 activity towards p21 (Figure 3.14). Interestingly, [
32
P] 
incorporation into p21 was significantly and consistently higher in the presence of 
peptide 4 as compared to the DMSO control or any other peptides. Peptide 2 also 
appeared to stimulate Chk1 catalytic activity towards p21 albeit to a lesser extent. 
In contrast, [
32
P] incorporation into p21 appeared to be inhibited in the presence 
of peptide 10 and 11; this is most likely explained by the fact that both peptide 10 
and 11 contain the Chk1 phospho-acceptor site at Ser
146
, resulting in competition 
between full-length p21 and peptide substrate utilisation by Chk1. This data was 
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reproducible with different batches of p21 peptides synthesised from different 
companies. To further characterise peptide 4 stimulation of Chk1 catalytic activity, 
kinetic analyses were undertaken. Addition of peptide 4 into the Chk1 kinase assay 
showed increased [
32
P] incorporation into Chk1 and p21 in a dose-dependent 
manner with increasing concentration of p21 peptide 4 (Figure 3.15A and B). This 
data suggested that p21 could function as a homotropic allosteric activator for 
Chk1, with peptide 4 functioning as a docking motif that allosterically stimulates 
Chk1 activity towards p21. It is possible that peptide 2 may also form the Chk1-
p21 binding interface.   
3.2.6 p21 peptide 4 forms a binding interface with Chk1 
To further characterise p21 peptide 4 stimulation of Chk1 catalytic activity, I 
wanted to establish that p21 peptide 4 binds to Chk1. To investigate further, I 
examined peptide 4 binding to Chk1 using non-denaturing gel electrophoresis in 
the absence of SDS. In non-denaturing gel electrophoresis, proteins retain their 
folded conformation and biological activity, thus any binding events should be 
preserved. Biotinylated p21 peptide 4 and recombinant human Chk1 were 
assembled in a kinase assay with or without unlabelled ATP. The kinase reactions 
were stopped using sample buffer without SDS/DTT and immediately resolved by 
non-denaturing gel electrophoresis. p21 peptide 4 was detected by HRP-
conjugated streptavidin. Interestingly, a band with a molecular weight of around 
50-54 kDa was detected in the reaction without ATP (Figure 3.16). Chk1 has a 
molecular weight of around 54 kDa and therefore the detected band was indicative 
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of peptide 4 binding to Chk1. However this band was not detected in the presence 
of ATP, suggesting that peptide 4 binding to Chk1 may be ATP-dependent and 
that presence of ATP may dissociate Chk1 and peptide 4 interaction. 
Immunoblotting for Chk1 protein showed that Chk1 migrated slower in the 
presence of ATP due to autophosphorylation and this was not seen in the absence 
of ATP. Unbound peptide was detected and migrated below the 20 kDa mark. The 
above data suggested that the stimulatory peptide 4 could form a docking interface 
with Chk1 protein kinase and that this may be sensitive to the presence of ATP. 
This was later supported by data (in chapter 4) showing that p21 peptide 4 can 
disrupt the intramolecular interaction between the C-terminal and N-terminal 
domain of chick Chk1 (Figure 4.20).   
3.2.7 p21 peptide 4 can allosterically regulate Chk1 catalytic activity 
towards other substrates 
p21 peptide 4 has been demonstrated to form a docking motif that is able to 
allosterically activate Chk1. DAPK1 activity towards weaker substrates such as 
p53
N1-66 
(an N-terminal domain of p53) has been shown to be allosterically 
enhanced in a docking-dependent manner, using potential docking motifs from 
high-affinity substrates such as p21 (Fraser and Hupp, 2007). However it is not 
clear if Chk1 activity towards other substrates can be modulated by p21-derived 
stimulatory peptide 4. To test this, peptide 4 was added to a Chk1 kinase assay 
containing either p53
N1-66 
or Cdc25C as the substrate. [
32
P] incorporation into 
p53
N1-66 
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incorporation into Cdc25C was also enhanced in the presence of peptide 4. This 
showed that p21-derived peptide 4 can modulate Chk1 activity towards other 
substrates, perhaps suggesting that p21 might function as a regulatory molecule 
that modulates the activity of Chk1 in vivo towards distinct substrates.  
To test whether the stimulatory effect of peptide 4 on Chk1 towards p21 is specific 
towards Chk1, peptide 4 was analysed for its ability to modulate Chk2 and 
DAPK1 activity towards p21. As DAPK1 and Chk2 are close relatives of Chk1, 
there is a possibility that they might be regulated by the same allosteric mechanism. 
Interestingly, Figure 3.18 showed that while p21 peptide 4 could stimulate Chk1 
activity, [
32
P] incorporation into p21 catalysed by DAPK1 core domain was 
slightly inhibited in the presence of peptide 4. Very little or no [
32
P] incorporation 
into p21 catalysed by Chk2 was detected with or without peptide 4. The data 
suggested that p21 peptide 4 allosteric activation was specific to Chk1, but not 
DAPK1 and Chk2.   
Allosteric regulation of Chk2 has been proposed to influence protein kinase 
substrate specificity (Craig et al., 2003). To address the concern that allosteric 
modulation of Chk1 activity might change its specificity in p21 phosphorylation 
and cause phosphorylation at additional/distinct sites on p21, we analysed Chk1 
phosphorylation of the p21 peptide library in the presence of the stimulatory 
peptide 4. However similar to the earlier experiment (Figure 3.6B), only peptide 
10 and 11 showed [
32
P] incorporation above background levels, indicating that 
Ser
146 
in the C-terminal domain could remained as the major phospho-acceptor site 
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. Kinase reactions were assembled with or without peptide 4 and were 
resolved by SDS-PAGE and transferred to nitrocellulose membrane before 




phospho-specific antibodies (Figure 
3.19B). The level of phospho-Ser
146 
detected was not affected by the presence of 
peptide 4 stimulation, suggesting that Ser
146 
remained as the major phospho-
acceptor site targeted by Chk1 but is not stimulated further. Interestingly, there 
was an increase of phosphate incorporation on phospho-acceptor site Thr
145 
in the 
presence of peptide 4. This could indicate that although Ser
146 
remained the 
predominant phospho-acceptor site, stimulation of Chk1 catalytic activity by 
peptide 4 could result in enhanced phosphate incorporation onto p21 Thr
145
. The 




is likely to explain the mobility shift 
observed on the phospho-Thr
145 
IgG immunoblot when the kinase reaction was 
incubated with p21 peptide 4 (Figure 3.19B; lane 1; upper panel), although it 
remains a possibility that the allosterically activated Chk1 could target other 
phosphorylatable serine and threonine residues in peptide 10 and 11.   
3.2.8 Threonine55, Proline58 and Tryptophan65 are critical amino acid 
residues for peptide 4 allosteric activation of p21 
It has now been accepted that protein-protein interactions often involve linear 
interaction or docking motifs. These linear motifs are normally between three to 
ten amino acids of which a few may be critical to form a docking interaction 
(Remenyi et al., 2006). In order to identify the amino acids critical for the docking 
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interface between Chk1 and p21 peptide 4, single alanine mutations were 
introduced across peptide 4 (Figure 3.20A). The mutated peptides were assembled 
with Chk1 and p21 in kinase assays and analysed for their effect on [
32
P] 
incorporation into p21 compared to unmutated peptide 4 (Figure 3.20B). Mutation 
of many residues showed little effect on peptide 4 stimulation of Chk1 towards 






strikingly attenuated the 







are the critical residues required for the allosteric docking 
interaction between p21 peptide 4 and Chk1 and are required for activation of 
Chk1 towards substrates such as p21.    
3.2.9 p21 peptide 4 functions as an allosteric docking motif required 
for efficient Chk1 phosphorylation of p21 
The data shown hitherto suggested that p21 peptide 4 could allosterically modulate 
Chk1 catalytic activity. However it was not clear whether the loss of the peptide 4 
region affects substrate utilisation. To test this, Chk1 kinetics of full-length p21 
and p21 peptide 10 utilisation was analysed. A titration of full-length p21 or 
peptide 10 was assembled with Chk1 in [
32
P]-ATP kinase assay. [
32
P] 
incorporation into full-length p21 or peptide 10 was quantified using a 
phosphorimager. The Michaelis-Menten kinetic constants were calculated via 
Hanes plot using hyperbolic regression software. Hanes plot is a common linear 
representation that determines the important kinetic parameters Km, Vmax and 
Vmax/Km rapidly, where [S]/v is plotted against [S]. The Michaelis-Menten kinetic 
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model states that Vmax is the enzyme s maximum reaction rate and Km is the 
concentration of substrate at which the enzyme s reaction rate is half Vmax. 
Although Figure 3.21 showed that the Km for p21 peptide 10 was higher than that 
of full-length p21. It should be noted that the outlying Km value in experiment set 
2 for p21 peptide 10 could spuriously increase the average Km. Hencefore a test of 
statistical significance is needed to determine whether there is a significant 
difference between the Km value of full-length p21 and p21 peptide 10.   
It was shown earlier that p21 peptide 4 was able to allosterically stimulate Chk1 
activity and bound Chk1 in an ATP-dependent manner. Thus it is possible that the 
N-terminal domain of p21 is involved in a docking interaction with Chk1 that 
enhanced substrate specificity and enzymatic activity. To further assess the 
requirement of docking motif for substrate recognition, I generated an N-terminal 
(amino acids 1-65) truncated p21 mutant (p21 NT) that was expressed in E.coli 
and purified using a two-step purification method (Figure 3.22A). N-terminally 
His-tagged p21 was first extracted from E.coli inclusion bodies and then further 
purified using Ni-NTA agarose before being analysed by coomassie blue stain and 
immunoblot (Figure 3.22B). The immunoblot showed that the His-tagged p21 NT 
mutant migrated at around 13-14 kDa which is consistent with the calculated 
molecular mass. To ensure that there were equal amounts of p21 in the kinase 
assays, the concentration of p21 NT mutant was normalised to that of full-length 
p21 using an ELISA assay (Figure 3.23). A titration of full-length p21 and the 
NT mutant was captured on a 96-well plate and overlaid with -p21 C-terminal 
antibody. Any unbound -p21 antibody was washed off before incubated with 
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HRP-conjugated secondary antibodies. Bound antibody was detected by enhanced 
chemiluminescence. The relative light unit values and concentration obtained for 
full-length p21 were computed to construct a XY-scatter plot from which a linear 
equation was derived. The concentration of p21 NT mutant was then calculated 
from the equation. After the concentration of the p21 proteins were normalised, a 
titrated amount of full-length p21 and NT mutant protein were assembled with 
Chk1 in [
32
P]-ATP kinase assays. Figure 3.24A showed that [
32
P] incorporation 
into p21 NT mutant was marginally lower than that of full-length p21 and this 
change is reproducible in duplicate sets of experiment. This suggested that the 
deleted N-terminal domain of p21 is required to ensure maximal Chk1 activity 
towards p21, augmenting the idea that the p21 N-terminal domain contains a Chk1 
docking site. To assess the possibility that p21 peptide 4 could function as docking 
motif in Chk1 substrate recognition, I tested if the addition of p21 peptide 4 could 
restore Chk1 optimal activity towards p21 NT mutant (Figure 3.24B). 
Interestingly, [
32
P] incorporation into p21 NT mutant in the presence of peptide 
4 was about 3-fold higher than in the absence of peptide 4. On the other hand, 
[
32
P] incorporation into full-length p21 was only about 2-fold higher in the 
presence of peptide 4. This indicated that peptide 4 could function as a docking 
peptide in place of a deleted p21 N-terminal region and reconstitute all the regions 
of p21 required for optimal targeting by Chk1.     
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3.3 Discussion 
3.3.1 Identification of Chk1 as a p21waf1 kinase  
p21 plays an important role in mediating cell cycle arrest. Upon appropriate 
signals, p21 functions to inhibit cyclin-dependent kinase (CDK) activity and DNA 
synthesis through negative regulation of PCNA (Harper et al., 1993, Chen et al., 
1995). p21 has already been reported to be phosphorylated by a diverse range of 
protein kinases such as GSK3 , PKB/Akt and p38 (Rossig et al., 2001, Kim et al., 
2002, Lee et al., 2007) and identification of novel protein kinase for p21 may 
contribute to a detailed understanding of the signalling pathways, in which p21 is 
involved. Gel filtration analysis showed that checkpoint kinase, Chk1 co-eluted 
with a kinase activity that generated a slower-migrated form of p21, suggesting 
that p21 could be a novel substrate of Chk1.   
The substrate specificity of Chk1 has been elucidated to contain the consensus 
motif Rxx(S/T) (Hutchins et al., 2000, O'Neill et al., 2002). Modelling of the Chk1 
kinase domain interaction with a peptide based on the phosphorylation site from 
Cdc25C revealed that the hydrophobic side chains at P-5 and P+1 positions of the 
substrate peptide, together with an arginine residue at P-3 position and small side 
chain at P+2 position are important for Chk1 substrate specificity (Chen et al., 
2000). Protein sequence analysis showed that p21 (amino acid 141 151) seems to 
fit in well with the Chk1 consensus substrate motif, displaying an arginine residue 
at P-3 position, a hydrophobic side chain at P+1 and a small side chain at P+2 
position relative to the Ser
146 
phospho-acceptor site (Figure 3.3). Furthermore, p21 
also shares upstream glutamine residue and downstream negatively-charged 
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phospho-acceptor site.  I have showed that recombinant human and 
cellular Chk1 phosphorylate recombinant p21 readily in vitro at the C-terminal end 
with Ser
146 
as the major phospho-acceptor site. Mass spectrometry and Edman 
degradation have further confirmed that Ser
146 
is the major phospho-acceptor site 
targeted by Chk1. As shown by immunoblotting, p21 Thr
145 
phospho-acceptor site 














do not contain an arginine residue at the P-3 position, allosteric 
regulation has been known to activate enzymes towards weak substrates (Craig et 
al., 2003, Fraser and Hupp, 2007).   
Ionising radiation-induced phosphorylation of Chk1 at Ser
345 
is found to co-
immunoprecipitate with p21, p53 and 14-3-3 (Tian et al., 2002). In addition, p21 
association with Chk1 is dependent on the presence of p53 (Tian et al., 2002). 
However, in this thesis, co-immunoprecipitation of endogenous Chk1 and p21 
from mammalian cells proved to be difficult, possibly due to epitopes masked by 
the Chk1-p21 or other interacting protein binding interface. It is also possible that 
Chk1 is activated differently in aphidicolin-induced S-phase arrest as opposed to 
irradiation-induced G2 arrest that could result in distinct protein partners. To 
circumvent this, collaboration was set up with Prof. David Gillespie s group to 
look at the physical interaction between chick Chk1 and human p21. Chick Chk1 
shares a 84 % homology with human Chk1. Using -C terminal Chk1 antibodies, 
transient co-immunoprecipitation of Chk1 and p21 was established and this 
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interaction was found to be more pronounced when a kinase-dead version of chick 
Chk1 was used. This is suggestive of a physiological link between Chk1 and p21.    
However given the promiscuity of the protein kinase can display for substrates in 
vitro, more studies will be needed to confirm that p21 is a novel substrate for 
Chk1:- 
1. Is p21 phosphorylated at the same site (Ser
146
) in mammalian cells in 
response to activated Chk1 under DNA damaging conditions? 
2. Do constitutively active mutants of Chk1 or kinases upstream of Chk1 lead 
to phosphorylation of p21 in cells? 
3. Does inhibition of the Chk1 protein kinase, through Chk1 inhibitors or 
siRNA attenuate phosphorylation of p21?   
3.3.2 Allosteric regulation of Chk1 by the N-terminal region of p21 
It has been reported for many protein kinases that a consensus substrate 
phosphorylation motif is not sufficient to confer stringent selective substrate 
recognition (Remenyi et al., 2006, Goldsmith et al., 2007). Indeed, Chk1 has been 






in vitro, however these p53 
sites do not share any similarity with the Chk1 substrate consensus motif (Shieh et 
al., 2000). Thus it has been postulated that Chk1 may be extremely flexible in its 
sequence requirements and substrate specificity. In the same study, Chk1 was 
shown to preferentially phosphorylate a tetrameric form of p53 as compared to 
monomeric p53 (Shieh et al., 2000). This could suggest that the tetramerisation 
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domain of p53 provides a docking platform for Chk1. Indeed, protein kinases 
often recognise their substrates through interactions in regions distinct to the active 
site (Figure 3.25). This involves modular protein-protein recognition domains such 
as SH2 and SH3 domains that are distinct to the catalytic domain. An example of 
this is the non-receptor tyrosine kinases (Miller, 2003). Another mode involves 
docking interactions in this case, a docking domain on the protein kinase binds 
to a linear interaction motif or docking motif present in its substrate. A well-
characterised example is MAPK with its docking requirement for D-site or DEF-
motif (Tanoue et al., 2000, Sheridan et al., 2008). Similarly, Chk2 activity towards 
p53 transactivation domain is allosterically regulated by high-affinity p53 Box II 
and Box V peptides (Craig et al., 2003).  
Using p21 substrate as a model substrate to investigate a docking-dependent 
regulation of Chk1 activity, it was shown that p21 peptide 4 was able to stimulate 
Chk1 activity towards p21 (Figure 3.14). Interestingly, peptide 4 binding to Chk1 
appeared to be ATP-dependent (Figure 3.16). In the absence of ATP, binding of 
peptide 4 to Chk1 was observed and there was no binding of peptide 4 to Chk1 in 
the presence of ATP. It is possible that transient allosteric activation of Chk1 by 
p21 peptide 4 leads to an ATP-dependent event and in turn induces a 
conformational change within Chk1 that blocks or disrupts the peptide 4 docking 
site. The ATP-dependent event could be autophosphorylation of Chk1. 
Autophosphorylation has been observed in the C-terminal domain of Chk1 (Ng et 
al., 2004) and mass spectrometry data has suggested that Chk1 Ser
407 
is the major 
phospho-acceptor site. 
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p21 peptide 4 modulation of Chk1 activity did not appear to be limited to p21 and  
p21 peptide 4 could also stimulate Chk1 catalytic activity towards p53
N1-66 
and 
Cdc25C. This suggests that Chk1 utilises a universal docking motif with 
characteristics of the p21 N-terminal domain for its allosteric activation. To test 
this possibility, I aligned the sequence of p21 peptide 4 with adaptor proteins 
Claspin and BRCA1, both of which have been reported to be involved in the 
activation of Chk1 (Figure 3.26A and B). Interestingly, sequence alignment 
identified homology between p21 peptide 4 and the C-terminal domain of Claspin 
and N-terminal of BRCA1. Although Chk1 has been reported to interact with the 
N-terminal domain of Claspin (Clarke and Clarke, 2005) whereas the C-terminal 
domain of Claspin is involved in DNA-binding (Clarke et al., 2005), it still 
remains to be seen whether the C-terminal region of Claspin can allosterically 
regulate Chk1 catalytic activity. Transfection of BRCA1 has been reported to 
induce an activation of Chk1 catalytic activity (Yarden et al., 2002). Therefore it 
raises the possibility that adaptor molecules such as BRCA1 and Claspin may 
share a similar docking motif that serve to activate Chk1 towards weak substrates 
that lack the docking motif. Indeed, it has been found that the cyclin subunit 
provides the docking groove for cyclin-dependent kinase which is necessary for 
substrate with RxL motif to dock to the cyclin/CDK complex (Loog and Morgan, 
2005). Adaptor or scaffold proteins could also function as allosteric modulators 
beyond bridging the kinase and substrate together. The yeast Ste5 scaffold protein 
is reported to allosterically activate autophosphorylation in the activation loop of 
the MAPK Fus3 (cell fusion-3) (Bhattacharyya et al., 2006). Such non-substrate 
regulatory molecules are called heterotropic allosteric modulators. However, more 
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biochemical experiments are needed to determine the possibility that BRCA1 and 
Claspin may share a similar docking motif (p21 peptide 4) that could stimulate 
Chk1 catalytic activity. In addition, it is not known if allosteric docking regulate 
the specificity of Chk1 interacting partners and if so, whether docking interactions 
may enhance pathway specificity under certain conditions? A novel double 
peptide synthesis technique developed by Espanel et al (2003) to identify more 
low-binding affinity allosteric docking motifs will perhaps help to answer the 
above question (Espanel et al., 2003).  
I have also shown that p21 peptide 4-dependent allosteric stimulation was specific 
to Chk1 but not DAPK1 and Chk2, two related calcium/calmodulin-dependent 
protein kinase superfamily members. In fact, DAPK1 catalytic activity was 
slightly inhibited in the presence of peptide 4. This suggested that although Chk1, 
Chk2 and DAPK are grouped under the same protein kinase superfamily, they do 
not share similar docking specificities.   
Although allosteric regulation is often thought to influence protein kinase 
specificity, it was shown that p21 peptide 4-dependent activation of Chk1 is still 




. Interestingly, phosphate incorporation onto Thr
145 
appeared to increase 
as a result of Chk1 activity enhanced by peptide 4 (Figure 3.19). Although, 




negatively regulates p21 




phosphorylation at the same time is not clear.       
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3.3.3 Threonine55, Proline58 and Tryptophan65 amino residues are 
critical for the function of allosteric docking motif  
p21 peptide 4 is a twenty amino acid long peptide. Linear docking motifs often 
contains a few amino acids that are important for docking interactions. Alanine 






are the critical 
amino acids for stimulation of Chk1 activity by p21 peptide 4. Mutations on these 
sites strikingly abolish the stimulatory effect of peptide 4 on Chk1 catalytic 
activity. It was discussed that weak interactions involving intrinsically 
unstructured proteins such as p21 only require a small binding interface with a 
small number of energy-bearing residues while tight interactions often involved 












3.27) (Lacy et al., 2004), suggesting that they might be important for allosteric 
binding interface. It would be interesting to see whether p21 mutated at these three 
residues would synergistically abolish Chk1 catalytic activity towards p21 
completely and also whether p27 and p57 can activate Chk1 in a similar 
mechanism too.   
3.3.4 A docking motif is required for efficient Chk1 activity towards 
p21 
Kinetics and deletion analysis suggested that a protein-protein interaction which is 
distinct from the active site is important for Chk1 substrate recognition. Chk1 
activity towards the C-terminal p21 peptide 10 required a very high substrate 
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concentration (Figure 3.21). Furthermore, Chk1 activity towards an N-terminal 
truncated p21 mutant protein is lower than the full-length p21 protein, suggesting 
that the first 66 amino acids of p21 may harbour a docking motif which is 
important for efficient Chk1 catalysis of substrates such as p21. By adding p21 
peptide 4 into the assay, Chk1 activity towards p21 NT recovered and 
interestingly is higher than that of stimulated Chk1 activity towards full-length p21 
(Figure 3.24). This suggested that p21 peptide 4 could function as docking motif 
that allosterically activates Chk1 for efficient utilisation of substrate.   
3.3.5 Possible Chk1-p21 signalling pathway 
p21 was shown to contain an allosteric signal in the N-terminal region required for 
stimulating Chk1 function. However it is not clear whether p21 play a role in 
regulating Chk1 function in vivo. I have showed in the next chapter (Figure 4.5) 
that p21 did not affect the stability of Chk1 protein or the steady state levels of the 
protein or aphidicolin activation of Chk1 protein in isogenic HCT116 wild-type 
(p21
+/+
) or HCT116 p21
-/- 
cells.   
Although we have yet to confirm Chk1-dependent phosphorylation of p21 Ser
146 
in vivo, an initial hypothesis was conceived from the available literature. PKC has 
been shown to mediate p21 degradation through phosphorylation on Ser
146 
(Scott 
et al., 2002), suggesting that Ser
146 
phosphorylation encodes for a degradation 
signal. Preliminary data from the Ball lab also showed that overexpression of 
exogenous Chk1 in HeLa cells led to decreased level of endogenous p21 (Figure 
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3.28) and that depletion of Chk1 using siRNA increased the half-life of p21. This 
could suggest that a Chk1-dependent pathway may regulate the stability of p21. It 
was reported that ubiquitin-dependent p21 degradation occurred in response to low 
(<40 J/m
2
) but not high doses of UV and this was independent of p53 and pRb 
(Bendjennat et al., 2003). Furthermore, UV-induced degradation of p21 required 
an ATR-dependent pathway and was necessary for effective DNA repair 
(Bendjennat et al., 2003). This UV-induced degradation signal was thought to be 
mediated by glycogen synthase kinase 3 (GSK3 )-dependent phosphorylation on 
p21 Ser
114 
(Lee et al., 2007), although it has also been shown that p21 
downregulation did not required GSK3 (Bendjennat et al., 2003). How the Lee et 
al, 2007 study relied heavily on overexpression of p21 mutants and previous 
studies have shown that overexpression of p21 dramatically alters the rate at which 
it is degraded (Cayrol and Ducommun, 1998). Therefore, it is possible that another 
checkpoint kinase might be responsible for the UV-induced degradation of p21. A 
likely candidate could be Chk1, as it is activated in response to UV in an ATR-
dependent manner.  
It was highlighted that p21 downregulation is required for monoubiquitination of 
DNA repair factor, PCNA, after replication stress as transient expression of stable 
p21 negatively regulated PCNA modification (Soria et al., 2006). 
Monoubiquitination of PCNA promotes DNA repair as monoubiquitin-modified 
PCNA preferentially interacts with DNA polymerase  (Pol ), which is capable 
of carrying out specialised translesion synthesis (TLS) past various DNA lesions 
(Kannouche et al., 2004). Although the signal for PCNA monoubiquitination is not 
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clear, it has been demonstrated that PCNA monoubiquitination required a stable 
Chk1-Claspin complex and a Claspin-associated protein, Timeless (Yang et al., 
2008). So it could be possible that Chk1 signals in parallel for p21 degradation via 
p21 Ser
146 
phosphorylation to ensure PCNA monoubiquitination and facilitate 
DNA repair after replication stress (Figure 3.29).  
Although this has not been experimentally determined, the biological functions of 
Chk1 might also be determined by its binding activity, rather than its catalytic 
activity. It was shown that docking of the enzyme to pRb was sufficient to inhibit 
caspase cleavage in the absence of CDK4 catalytic activity (Wallace and Ball, 
2004). Similarly, inhibition of MyoD-regulated transcription by CDK4 is 
dependent on CDK4 docking but does not require CDK4 catalytic activity (Zhang 
et al., 1999a). Therefore it is also possible that Chk1 regulate p21 function in a 
docking-dependent manner that does not require Chk1 catalytic activity.   
I have showed in the next chapter that [
32
P] incorporation into an unknown 
protein was observed in the immunoprecipitates from HCT116 wild-type (p21
+/+
) 
cells, but not HCT116 p21
-/- 
cells (Figure 4.8). It is possible that p21 could 
function as a regulatory molecule for Chk1 instead, where it regulates Chk1 
localisation or Chk1 interaction with other molecules.      
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3.3.6 Conclusions 
In this study, I have shown that Chk1 is an efficient kinase towards p21, 
phosphorylating the major phospho-acceptor site at Ser
146
. Using p21 as a model 
substrate, it was demonstrated that a p21 N-terminal region (amino acids 46 to 65) 
could function as an allosteric activator of Chk1. A peptidomimetic ligand 
(peptide 4) based on the p21 N-terminal region could also stimulate Chk1 activity 
towards substrate such as Cdc25 and p53
N1-66
, suggesting the existence of a 
general allosteric regulator of Chk1. This mechanism of allosteric activation is 







formed the critical binding interface 
required for allosteric stimulation of Chk1. Furthermore, this p21 N-terminal 
region could contain a docking motif that is required for efficient catalysis of p21 
by Chk1.        
A
F igu re 3.1 A schematic functional domain a rchitectu re of p21waf1.
(A) p21waf1 is a 164 amino acid protein which has a highly disordered structure. The functional
regions of p21 involved in protein-protein interactions have been determined and






































F igu re 3.2 Identification of C h k1 as a p21 kinase.
(A) HeLa cell extracts were subjected to chromatographic fractionation using Q-Sepharose and
SP-Sepharose columns. The active p21 kinase pool was then applied to a HS-Poros column
and fractionated. The active HS-pool was then subjected to gel filtration on a Superose-12
column and the fractions were analysed. (Top panel) Total p21 kinase activity was determined
as [!32P] incorporation into p21 protein by autoradiography. (Middle panel) Total p21 protein
was detected in the immunoblot using "-p21 IgG. (Lower panel) Presence of Chk1 protein was
detected in the immunoblot using "-Chk1 IgG. (Data provided by Mary Scott)
A
F igu re 3.3 Sequence alignment between C dc25 C , p21 and p53.
(A) Sequence alignment between Cdc25C, p21 and p53 known phosphorylation sites revealed
a suggestive homology with a line (|) representing conserved residues and colon (:) depicting
semi-conserved residues. Potential known phospho-acceptor residues are coloured red.
p53
p21waf1
. . . I . : . : I . :
P L S Q E T F S D L W
13 23
K R R Q T S M T D F Y141 151
Cdc25C
. . I : . I I . : . .
L Y R S P S M P E N L211
221
A
F igu re 3.4 A dendrogr am of the calcium/calmodulin-dependent p rotein kinase
super family.
(A) DAPK1, Chk1 and Chk2 (circled red) belong to the superfamily of calcium/cadmodulin-


















F igu re 3.5 Pu r ified recombinant human C h k1 phosphor ylates recombinant human p21 in
vitro.
(A) Kinase reactions containing 100 ng of either DAPK1 core/Chk1/Chk2 with or without p21
(0.6 #g) were assembled in the presence of [!32P]ATP. The reaction products were resolved by
SDS-PAGE and [!32P] incorporation into p21 was visualised by autoradiography. (B) Kinase
reactions containing 0.6 #g of p21 and titration of Chk1 (0 to 200 ng) were assembled in the
presence of [!32P]ATP. (C) Kinase reactions containing 100 ng of Chk1 and titration of p21 (0
to 0.9 #g) were assembled in the presence of [!32P]ATP. The reaction products were resolved





































F igu re 3.6 Recombinant human C h k1 phosphor ylates recombinant human p21 C -
ter minal domain.
(A) List of biotinylated overlapping p21 20-mer peptides with SGSG spacing. (B) Kinase
reaction containing 60 ng of Chk1, 1 #g of indicated p21 peptide (final peptide concentration ~
50 nM) and [!32P]ATP were assembled. DMSO was used as negative control. The reaction
products were resolved by 15% SDS-PAGE and [!32P] incorporation into p21 peptides were










































































































F igu re 3.7 Recombinant human C h k1 phosphor ylates recombinant human p21waf1 at
Ser146 in vitro.
(A and B) Specificity of "-p21 phospho-Thr145 IgG (A) or "-p21 phospho-Ser146 IgG (B) were
tested via ELISA using streptavidin capture of biotinylated p21 phospho-Thr145 peptide, p21
phospho-Ser146 peptide and p21 peptide 10 (titrated from 0-5 #g). (C) Kinase reactions
containing 100 ng of DAPK1 core/Chk1/Chk2 and 1 #g of p21 in the presence of unlabelled
ATP were assembled. The reaction products were resolved by 12% SDS-PAGE and
transferred to nitrocellulose membrane. Phosphorylation was detected using "-p21 phospho-











































































Eth 5 10 20 40 (#M of Aphidicolin)
F igu re 3.8 A ctivation of cellula r C h k1 in response to aphidicolin t reatment.
(A) Indicated cell lines were grown to >90% confluency before treated with a titration of
aphidicolin (5 #M to 20 #M) or ethanol as control. After 4 hours, the cells were harvested and
lysed. 50 #g of the whole cell lysates were resolved by 10% SDS-PAGE before transferred to
nitrocellulose membrane. Chk1 protein was detected using mouse "-Chk1 IgG. Red arrows are
indicative of activated forms of Chk1. (B) Indicated cell lines were grown to >90% confluency
before treated with 20 #M of aphidicolin for the indicated times. The cells were harvested and
lysed. 50 #g of the whole cell lysates were resolved by 10% SDS-PAGE before transferred to
nitrocellulose membrane. Chk1 protein was detected using mouse "-Chk1 IgG. Red arrows are



































F igu re 3.9 Recombinant human C h k1 kinase activity is not affected by
immunop r ecipitation antibodies.
(A) 100 ng of Chk1 was pre-incubated with 0.5 #g of sheep "-Chk1 IgG at 4oC for 1 hour
before 0.6 #g of p21 and [!32P-ATP] were added for kinase reaction. The reaction products
were resolved by 12% SDS-PAGE before [!32P] incorporation into p21 was visualised by
autoradiography and quantified by phosphoimager
A
F igu re 3.10 C ellula r C h k1 is active towa r ds recombinant human p21.
(A) Hela and HCT116 p21-/- cells were grown to >90% confluency and treated with 20 #M
aphidicolin for 4 hours before harvested. 1 mg of the cellular lysate was subjected to Chk1
immunoprecipitation by sheep "-Chk1 IgG before assembled with 0.6 #g of recombinant p21
for [!32P]-ATP kinase assay. The kinase reactions were resolved by 12% SDS-PAGE and
[!32P] incorporation into p21 was visualised by autoradiography (First panel). Chk1
immunoprecipitation was validated by immunoblotting with mouse "-Chk1 IgG (Second
panel). The cell lysates were resolved by 12% SDS-PAGE and immunoblotted with mouse "-









F igure 3.11 Sequence alignment of full-length human and chick C hk1.
(A) ClustalW2 sequence alignment reveals 84% homology between human and chick Chk1.$%$
means that residues in that column are identical; &:$ means that residues in that column are





p21 - + +-
F igu re 3.12 C o-immunop recipitation of human p21 and chick C h k1.
(A) Chick full-length Chk1 or kinase-dead Chk1 (KD-Chk1) was transfected into Cos1 cells
alone or together with human p21. Chick Chk1 was immunoprecipitated from Cos1 cells by "-
C-terminal Chk1 IgG and resolved by 12% SDS-PAGE before transferred to nitrocellulose
membrane. p21 was detected by immunoblotting with "-p21 IgG. Immunoprecipitated Chk1
was detected by immunoblotting with "-Chk1 IgG (In collaboration with Prof. David
'())*+,(*$+ group) (Data provided by Mary Scott).
A
F igu re 3.13 A schematic illust r ation of docking mechanisms in p rotein-subst r ate
recognition.
(A) -.*/0*1(23 456*)7. In this model, the docking motif (orange triangle) serves to tether the
substrate to the enzyme with no or little influence on the enzyme structural changes or kinase
activity. Substrate tethering can be inhibited in the presence of competitive docking ligands,
leading to poor catalytic activity towards the substrate. (B) -8))5+/*1(9 456*)7. In this model,
docking ligand (orange triangle) binding to the docking groove (orange cleft) induces kinase
conformational changes that allow better substrate accessibility to the active site (green pit).
Adapted from RE M E NYI, A., G O O D , M. C . & LIM, W. A. (2006) Docking interactions in





F igure 3.14 Recombinant human C h k1 activity towa r ds recombinant human p21 can be
stimulated by p21 docking peptide.
(A) Kinase reactions containing 100 ng of Chk1 and 0.6 #g of p21 with or without 5 #g of p21
peptide were assembled in the presence of [!32P]-ATP. The reaction products were resolved by
12% SDS-PAGE and [!32P] incorporation into p21 was visualised by autoradiography.
[!32P] p21
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F igu re 3.15 Recombinant human C h k1 activity towar ds recombinant human p21 is
stimulated by p21 peptide 4.
(A) Kinase reactions containing 100 ng of Chk1 and titration of p21 peptide 4 (0.625 #g to 5
#g) were assembled in the presence of [!32P]ATP. The reaction products were resolved in 10%
SDS-PAGE. [!32P] incorporation into Chk1 was visualised by autoradiography. (B) Kinase
reactions containing 100ng of Chk1, 1 #g of p21 and titration of p21 peptide 4 (1.25 #g to 5
#g) were assembled in the presence of [!32P]ATP. The reaction products were resolved by





F igu re 3.16 p21 peptide 4 binds to recombinant human C h k1 in an A T P-dependent
manner .
(A) Kinase reactions containing 100 ng of Chk1 and 5 #g of p21 peptide 4 were assembled in
the presence or absence of 1 mM unlabelled ATP. The reactions were stopped by addition of
sample buffer (without SDS/DTT) before resolved by 10% or 15% non-denaturing PAGE
(without SDS) and transferred to nitrocellulose membrane. Biotinylated p21 peptide 4 was






















F igu re 3.17 p21 peptide 4 can stimulate r ecombinant human C h k1 activity towa r ds the
N-ter minal domain of recombinant human p53 (N1-66) and recombinant human C dc25 C .
(A) Kinase reactions containing 100 ng of Chk1 and 100 ng of p53 N1-66 or Cdc25C with or
without 5 #g of p21 peptide 4 were assembled in the presence of [!32P]ATP. The reaction
products were resolved by 12% SDS-PAGE. [!32P] incorporation into p53 N1-66 and Cdc25C










F igure 3.18 p21 peptide 4 can alloster ically stimulate r ecombinant human C h k1 but not
recombinant human D A P K 1 and C h k2 activity.
(A) Kinase reactions containing 100 ng of DAPK1 core/Chk1/Chk2 and 0.6 #g of p21 with or
without 5 #g of p21 peptide 4 were assembled in the presence of [!32P]ATP. The reaction
products were resolved by 12% SDS-PAGE. [!32P] incorporation into p21 was visualised by
autoradiography.
A
F igu re 3.19 p21 phosphor ylation p rofile is not affected by p21 peptide 4.
(A) Kinase reaction containing 60 ng of Chk1, 1 #g of indicated p21 peptide, 5 #g of p21
peptide 4 and [!32P]ATP were assembled. DMSO was used as negative control in the absence
of p21 peptide 4. The reaction products were resolved by 15% SDS-PAGE and [!32P]
incorporation into p21 peptides were visualised by autoradiography, quantified by
phosphorimager and normalised to DMSO control. (B) Western blot analysis of p21
phosphorylation. Kinase reaction containing 60 ng of Chk1 and 1 #g of p21 with/without 5 #g
of p21 peptide 4 in the presence of unlabelled ATP were assembled. The reaction products
were resolved by 12% SDS-PAGE and transferred to nitrocellulose. Phosphorylation was
detected using "-p21 phospho-Thr145 IgG and "-p21 phospho-Ser146 IgG. Total p21 level was

































































F igu re 3.20 Identification of cr itical residues involved in p21 alloster ic docking.
(A) Indication of the positioning of alanine mutation made within p21 peptide 4. (B) Kinase
reactions containing 100 ng of Chk1, 0.6 #g of p21 and 5 #g of indicated peptide 4 were
assembled in the presence of [!32P]-ATP. (-) indicates DMSO control, (+) indicates wild-type
p21 peptide 4 and the amino acid letter represents the alanine mutation in place of that residue.





















Peptide 4 Alanine scan
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F igu re 3.21 K inetic constant for recombinant human C h k1 with respect to recombinant
human p21.
(A and B) Kinase reactions containing 100 ng of Chk1 and (A) p21 in the range of 0.28 #M to
8.83 #M or (B) p21 peptide 10 in the range of 2.065 #M to 165 #M were assembled in the
presence of [!32P]ATP. The reaction products containing p21 were resolved by 12% SDS-
PAGE and reaction products containing p21 peptide 10 were spotted onto p81 chromatography
paper. [!32P] incorporation were quantified using phosphorimager. The Michaelis-Menten
parameters were fitted via the Hanes plot using hyperbolic regression software (Hyper.version















































F igu re 3.22 Pu r ification of recombinant human H is-tagged full length p21 and p21 !"#.
(A) Schematic diagram of full-length p21 and p21 ;<. mutant where the first 65 amino acids
from the N-terminal end is deleted. (B) Two-step purification of His-tagged full-length p21
and p21 ;<.. p21 proteins were purified from inclusion bodies before passing through the Ni-
NTA agarose column. Fractions obtained from the Ni-NTA agarose column were analysed on
a 12% SDS-PAGE gel stained by coomassie brilliant blue or subjected to "-His IgG
immunoblotting. Lanes: 1, Flow-through; 2, Wash I fraction; 3, Wash II fraction; 4, Wash III




















#l 0 0.1 0.2 0.5 1
p21 FL (R.L.U) 0.00405 0.024 0.5888 1.3885 2.6615
$%&'()*'+,-.-/0 0.0027 0.02405 0.12325 0.34085 0.77235
1 Thus, using the equation,
2-33%45'+,-.-/0'67'$%&'()*'8'%9-:';<
F igu re 3.23 Nor malisation of recombinant human H is-tagged full length p21 and p21
!"#.
(A) The concentration of His-tagged full length p21 and p21 ;<. were normalised using the
ELISA fomat as described in the Materials and Methods 2.7.1. The relative light units values
obtained for full-length p21 were computed to construct a XY scatter plot. From the plot, an
equation is derived and used to calculate the concentration for p21 ;<.. Calculations were
written above.



































p21 peptide 4+ +- -
Full Length p21$%&'()*
[!32P] p21
F igu re 3.24 Recombinant human C h k1 is less active towa r ds recombinant human p21
!"# mutant
(A) Kinase reactions containing 100 ng of Chk1 and full length p21 or p21 ;<. in the range of
0 ng to 120 ng were assembled in the presence of [!32P]ATP. The reaction products were
resolved in 12% SDS-PAGE and [!32P] incorporation into p21 were visualised by
autoradiography and quantified using phosphorimager. (B) Kinase reactions containing 100ng
Chk1 and 80 ng of either full length p21 or p21 ;<. were assembled in the presence of
[!32P]ATP with or without 5 #g of p21 peptide 4. The reaction products were resolved in 12%





F igu re 3.25 A schematic illust r ation of p rotein-subst r ate recognition mechanism.
(A) Protein kinases and substrates have acquired a number of motifs that can aid in protein-
substrate recognition. The substrate phosphorylation site motif is targeted by the *2=>4*$+
active site while globular domain helps to tether the substrate to its canonical kinase. Substrate
docking motif that fits into the kinase docking groove also helps to achieve a more stringent
substrate selectivity and may function in the allosteric regulation of the enzyme. Adapted from
RE ME NYI, A., G O O D , M. C . & LIM, W. A. (2006) Docking interactions in protein kinase and











F igu re 3.26 Sequence alignment of C laspin and B R C A 1 with p21 peptide 4.
(A and B) Sequence alignment identified p21 peptide 4 homology to the C-terminal domain of
Claspin (A) and N-terminal domain of BRCA1 (B). Conserved residues are coloured red.
RERWNFDFVTETPLEGDFAW
RNSRNFVFHTLSPVKAEAAK













F igu re 3.27 Sequence alignment of p21 peptide 4 region with p27 and p57.
(A) Identical residues in all three sequences are shaded magenta. Identical residues in two
sequences are shaded blue while similar residues are shaded green.
Q R K W N F D F Q N H K P L E G - - K Y E W
R E R W N F D F V T E T P L E G - - D F A W





F igu re 3.28 O verexp ression of exogenous C h k1 leads to decreased endogenous p21 level
(A) Hela cells were grown to 90% confluency before mock transfected or transfected with
vector encoding 3xFLAG-myc-Chk1 (0.5 #g to 3 #g) for 24 hours. Cells were harvested and
lysed. 50 #g of lysates were resolved by 10% or 12% SDS-PAGE before transferred to
nitrocellulose membrane. Chk1 was detected using mouse "-Chk1 IgG and p21 was detected
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A
F igu re 3.29 Schematic model of a C h k1-dependent pathway in P C N A -dependent D N A
repai r
(A) In response to replicative stress, a stable Chk1-Claspin complex together with Timeless
protein is required for PCNA monoubiquitination, leading to efficient DNA repair. Chk1 could
also signal to p21 Ser146 to mediate ubiquitin-dependent degradation of p21. Downregulation
of p21 then facilitates PCNA monoubiquitination. The dotted line and question mark denote














     
CHAPTER 4: CHARACTERISATION OF ALLOSTERIC 
REGULATION OF CHK1             
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4.1 Introduction 
In the last chapter, a peptidomimetic ligand based on a p21 N-terminal region was 
able to function as a substrate docking site and allosterically modulate Chk1 
catalytic activity. However the mechanistic basis of the allosteric action on Chk1 
is not clear. This chapter identifies an N-terminal Chk1 region that has homology 
to the stimulatory p21 peptide 4 and also exhibits activating effect on Chk1 
function. Furthermore, the allosteric mechanism of activating peptides on Chk1 
catalytic activity is examined here. Therefore, I will give a brief introduction to the 
structural model of Chk1 and the functions of its domains.   
4.1.1   Chk1 structural model 
Chk1 is a nuclear protein made up of 476 amino acids (Sanchez et al., 1997). It 
mainly consists of a well-conserved N-terminal kinase domain (1-265 amino 
acids), a flexible linker region (~ 50 residues) and a less conserved C-terminal 
regulatory domain which includes an SQ/TQ region recognised by ATR (Chen et 
al., 2000, Katsuragi and Sagata, 2004) (Figure 1.3).   
4.1.2 Chk1 N-terminal domain 
The crystal structure of the Chk1 N-terminal domain has been elucidated and it has 
a canonical kinase two-fold lobe (N-terminal -lobe and C-terminal -lobe) with 
an ATP-binding site in-between. The kinase domain appears to adopt an active 
conformation with the activation loop stabilised by its secondary structure and side 
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chain interactions (Chen et al., 2000). This mechanism of Chk1 is unlike the 
activation of many other kinases where phosphorylation of the activation loop is 





activation loop are required for activity (Lee and Chung, 2001, Ahn et al., 2002); 
however there is no equivalent threonine residue in the activation loop of the Chk1 
kinase domain. The amino acid sequences of the activation loop also suggested 
that it is more flexible in yeast Chk1 proteins compared to human Chk1, which 
may explain the different substrate preferences (Chen et al., 2000). Kinetic 
analyses have shown that the conserved kinase domain in isolation is 20-fold more 
active than full-length Chk1, suggesting that the C-terminal domain negatively 
regulates Chk1 kinase activity. It is also suggested that the kinase domain may 
exhibit a structural basis for substrate selectivity based on the crystal structure 





in the Chk1 kinase domain are important for substrate selectivity. 
In addition, the hydrophobic side chain at P-5 and P+1 positions, arginine at P+3 
position and the steric restriction at P-2 position of the Cdc25C peptide substrate 
are also critical for Chk1 substrate specificity  (Chen et al., 2000).  




in response to genotoxic stress. It 
was shown that deletion of the Chk1 kinase domain resulted in a strong Ser
345 
phosphorylation on the C-terminal domain in the absence of genotoxic stress, 
leading to the suggestion that the Chk1 kinase domain may sterically inhibit ATR-
dependent phosphorylation on Ser
345 
and therefore the interaction with other 
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proteins or phosphorylation at sites other than Ser
345 
may be the initial activation 
event of Chk1 (Ng et al., 2004).  
Genetic analysis showed that CHK1 frameshift mutations in genetically unstable 
colorectal and endometrial cancers resulted in truncated protein of 243 and 238 
amino acids, affecting the N-terminal kinase domain. This could result in an 
inactive enzyme, thus leading to attenuation of cell cycle arrest and giving the 
tumours a growth advantage (Bertoni et al., 1999).   
4.1.3 Chk1 C-terminal domain 
It is noted that many protein kinases contain regulatory domains that may function 
to interact with other proteins or to activate/inhibit its kinase domain by an 
intramolecular mechanism (Ng et al., 2004). The Chk1 C-terminal region contains 
several motifs which are conserved across species but exhibits no sequence 
homology to other proteins. It has been suggested that the C-terminal domain can 
negatively regulate the access of substrate to the kinase domain by interacting with 
the substrate-binding site at the front of  the N-terminal region (Chen et al., 2000). 
An example of such an auto-inhibitory function is observed with several kinases 
including titin (Mayans et al., 1998). However the direction of the C-terminal 
linker showed that the C-terminal domain is more likely to interact with the back 
of the kinase domain, limiting the kinase lobe movement; a negative regulatory 
mechanism which has been observed in the regulation of Src family kinase activity 
(Chen et al., 2000). In any case, the interaction between the kinase domain and the 
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regulatory domain is likely to be intra-molecular (Katsuragi and Sagata, 2004). 
This autoinhibition mechanism prevents spurious activation of Chk1 signalling 
pathway.   
It was observed that truncation of the C-terminal domain resulted in strong Chk1 
kinase activity compared to full-length Chk1 (Oe et al., 2001). However in another 
report, weak kinase activity is observed when the whole C-terminal domain is 
deleted, in stark contrast to the Chk1 crystal structure data where Chk1 kinase 
domain by itself is 20-fold more active than full-length Chk1 (Chen et al., 2000, 
Ng et al., 2004). This suggested that the Chk1 C-terminal domain could also have 
an activating function on the N-terminal kinase domain.  
A bipartite nuclear localisation sequence (NLS) was identified within the C-









) and an essential internal sequence in between which 
are fairly conserved among species. Interestingly, deletion or mutation of the NLS 
caused a significant activation of the kinase which is not due to cytoplasmic 
localisation of the mutants. This prompted suggestion that the auto-inhibitory 
region may overlap with the NLS (Katsuragi and Sagata, 2004).   
Phosphorylation at the SQ/TQ motifs of xChk1 appears to play a role in relieving 
auto-inhibition as it prevented regulatory domain and kinase domain interactions. 
This suggests that phosphorylation of the SQ/TQ motifs might induce a 
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conformational change in the C-terminal regulatory domain, causing a release of 
its auto-inhibitory function on the kinase domain (Katsuragi and Sagata, 2004).   
   
4.1.4 Objectives 
In the last chapter, p21 was characterised as a potential novel Chk1 substrate in 
vitro with Ser
146 
as the major phospho-acceptor site and this could be 
physiologically relevant. However the significance of it is largely outwith the 
scope of this project. On the other hand, p21 was shown to contain an N-terminal 
allosteric docking site for Chk1 and this positively modulated Chk1 catalytic 
activity. The mechanism of how Chk1 autoinhibition is counteracted has been 
elusive. Elucidating the mechanism will help towards designing better non-ATP 
Chk1 inhibitors. Therefore in this chapter, I want to use p21 as a tool to delineate 
the allosteric activation of Chk1 mechanism.            
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4.2 Results 
Chk1 is an autoinhibited protein. However the mechanism of how Chk1 
autoinhibition is relieved or reinforced has not been elucidated. There are 
numerous mechanisms by which autoinhibition can be relieved. The most common 
regulation is the displacement of the inhibitory domain by an interacting protein. 
Other mechanisms include post-translational modifications, leading to the 
displacement of the inhibitory domain or proteolysis of the inhibitory domain or 
allosteric action of a binding protein partner (Pufall and Graves, 2002). Defining 
such an autoinhibitory mechanism will guide towards the discovery of better 
designed non-ATP Chk1 inhibitors. In the last chapter, p21 was shown to contain 
an allosteric signal for Chk1 catalytic activity. Therefore I am interested in using 
p21 as a model substrate in understanding the allosteric regulation of Chk1 
function.   
4.2.1 Identification of an allosteric activating peptide within the F 
region of Chk1 N-terminal kinase domain 
In the last chapter, I demonstrated that Chk1 utilised a docking interaction to 
enhance substrate recognition of p21 as a substrate. Studies with other kinases 
have shown that docking interactions not only function to tether the substrate to 
Chk1 but also appear to allosterically affect the enzyme leading to enhanced 
catalytic activity (Remenyi et al., 2006). The N-terminal domain and C-terminal 
domain of Chk1 have been shown to interact intramolecularly leading to 
autoinhibition of Chk1 catalytic activity (Katsuragi and Sagata, 2004). In turn, this 
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leads to the idea that p21 may disrupt binding of the C-terminal domain to a 
pseudo-docking site in the N-terminal kinase domain of Chk1. It is possible that 
p21 or p21 peptide 4 would act as a competitive inhibitor to disrupt intramolecular 
Chk1 interactions between the kinase and the regulatory domain (Figure 4.1). To 
test this I first carried out a sequence alignment between p21 peptide 4 and full-
length Chk1, this highlighted a potential homology between p21 peptide 4 and the 
F region (amino acids 189 to 208) of the Chk1 N-terminal catalytic domain 
(Figure 4.2A). Sequence alignment also revealed that the F region of Chk1 is 
fairly conserved across the species (Figure 4.2B), suggesting that it may have an 
important role in the regulation of Chk1 activity. Thus it is possible that the N-
terminal F region of Chk1 forms the intramolecular binding interface with the C-
terminal domain. Peptidomimetic ligands which share the critical amino residues 
required for this interface are then able to compete for binding to the C-terminal 
domain, leading to the disruption of intramolecular interaction. Using a more 
neutral experimental approach to identify a potential pseudo-docking site, a 
library of overlapping biotinylated 20-mer peptides spanning across the whole 
length of Chk1 was synthesised (Figure 4.3A). In addition, a peptide equivalent to 
the full sequence of p21 peptide 4 was synthesised (Chk1 peptide 32). Each Chk1 
peptide was analysed for its ability to allosterically stimulate Chk1 activity 
towards p21 in [
32
P]-ATP kinase assays (Figure 4.3B). Interestingly, only Chk1 
peptide 14 and peptide 32, both of which share homology with p21 peptide 4 and 
form part of the F region, displayed a positive allosteric effect on Chk1 activity 
towards p21. Chk1 peptide 14, which encodes most of the p21 peptide 4 sequence, 
showed a higher stimulating effect than peptide 32 which covers the full homology 
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sequence. This suggested that peptides based on the F-region of Chk1 which 
shared homology with p21 peptide 4 were able to allosterically activate Chk1, 
whereas peptides from other regions of Chk1 had no effect on activity or were 
inhibiting. As Chk1 peptide 14 showed greater stimulation of Chk1 activity 
towards p21, further studies were undertaken. Figure 4.4 shows that Chk1 peptide 
14 stimulated Chk1 activity towards p21 (Figure 4.4A) and Chk1 
autophosphorylation (Figure 4.4B) in a concentration-dependent manner, similar 
to that observed for p21 peptide 4 in chapter 3 (Figure 3.5B and C).   
4.2.2 Cellular Chk1 activity can be modulated by docking peptides  
I have shown that recombinant human Chk1 purified from insect cells can be 
stimulated allosterically by p21 peptide 4 and Chk1 peptide 14. However it is not 
clear if cellular Chk1 is amenable to the effects of peptidomimetic ligands. 
Furthermore, whether the p21 status of the cells used will affect the ability of the 
peptidomimetic ligands to activate Chk1 is not clear. In order to address those 
questions, I first characterised the stability and aphidicolin-dependent activation of 
Chk1 using isogenic HCT116 wild-type (p21
+/+
) and HCT116 p21
-/- 
cells. The 
possible effect of p21 status on the stability of Chk1 in HCT116 wild-type and 
HCT116 p21
-/- 
cells was assessed in the presence of translation inhibitor 
cycloheximide. Cycloheximide was added to the cells and the decay of Chk1 due 
to protein degradation was determined by immunoblot. Figure 4.5 showed that 
levels of Chk1 protein were stable in both cell lines up to 4 hours, suggesting that 
p21 does not affect the stability of Chk1 protein or the steady state levels of the 
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Next both HCT116 wild-type and p21
-/- 
cells were either transfected with C-
terminally V5-tagged Chk1 (V5-Chk1) or mock transfected with empty vector. In 
the previous chapter, I showed that aphidicolin treatment lead to the appearance of 
a slower-mobilised form of Chk1 protein; however immunoprecipitation of the 
endogenous Chk1 protein does not capture the slower-mobilised form. This form 
was thought to be the activated Chk1. Therefore to overcome the IP problem, a 
V5-tagged-Chk1 vector was made. After 24 hours, the transfected cells were 
treated with either 20 M of aphidicolin or ethanol before harvested and lysed 
after 4 hr. Figure 4.6 showed the presence of V5-tagged Chk1 in transfected cells 
using -V5 IgG (lower panel; lane 5 to 8). V5-tag adds a few kDa to the molecular 
weight of the Chk1, so the exogenous V5-Chk1 appeared as slower mobilised 
form of Chk1 on the immunoblot with -Chk1 IgG (Figure 4.6; upper panel; 
compare lane 1 and 5). This should not be confused with activated form of Chk1 
protein when cells were treated with DNA damaging agents (Figure 4.6; upper 
panel; compare lane 2 and 5). Immunoblots of the lysates showed that Chk1 
protein was activated after aphidicolin treatment by the appearance of slow-
mobilised form of Chk1 protein (Figure 4.6; upper panel; lane 2, 4, 6, 8). This 
form was not detected when the cells were treated with ethanol (Figure 4.6; upper 
panel lane 1, 3, 5, 7). Interestingly, the slow-mobilised, activated forms were not 
detected in aphidicolin-treated V5-Chk1 (Figure 4.6; lower panel; compare lane 5 
to 6). This may suggest that either V5-Chk1 is not activated in response to 
  
- 122 -  
aphidicolin-treatment or it is already activated regardless of genotoxic stress. The 
data showed that p21 status of the cells does not affect the steady-state levels of 
Chk1, the aphidicolin activation of Chk1 and also the expression levels of 
exogenous V5-Chk1.   
The lysates were subjected to Chk1 immunoprecipitation using either sheep -
Chk1 IgG for endogenous Chk1 or -V5 IgG for exogenous Chk1 and 
immunoprecipitated Chk1 was immunoblotted (Figure 4.7). Interestingly, it 
showed that significantly more endogenous Chk1 protein was immunoprecipitated 
from HCT116 p21
-/- 
cells than from HCT116 wild-type cells (Figure 4.7A; 
compare lane 1 and 2 to 3 and 4), although the total levels of Chk1 protein in 
whole cell lysate were the same (Figure 4.6; upper panel; lane 1 to 4). It should be 
noted that the band detected at around 50 kDa was of Chk1 and not the IgG heavy 
chain. Figure 4.7B showed that immunoprecipitated samples from HCT116 cells 
using either sheep -Chk1 IgG for endogenous Chk1 or mouse -V5 IgG for 
exogenous Chk1 were resolved in 10% SDS-PAGE before transferred to 
nitrocellulose membrane. The membrane was detected for the presence of Ig light 
and heavy chain by using either rabbit -mouse secondary IgG or rabbit -sheep 
secondary IgG. The result showed that only the IgG light chain was detected, but 
not the heavy chain, suggesting that the bands detected at around 50 kDa was that 
of Chk1 and not the IgG heavy chain (Figure 4.7A and B). Therefore the 
differential level of immunoprecipitated Chk1 may suggest differences in the 
conformation, modification status or Chk1 interacting proteins in HCT116 wild-
type and HCT116 p21
-/- 
cells, leading to a difference in the exposure of antigen 
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epitope. The immunoblot also showed that the activated forms of endogenous 
Chk1 were not immunoprecipitated (Figure 4.7A; compare lane 1 and 3 to lane 2 
and 4).  
In contrast, less exogenous V5-Chk1 was immunoprecipitated from HCT116 p21
-/- 
cells than from HCT116 wild-type cells (Figure 4.7A; compare lane 5 and 6 to 7 
and 8), even though the total levels of V5-Chk1 protein in whole cell lysate were 
the same (Figure 4.6; lower panel; lane 5 to 8). This again suggested differences in 
the conformation, modification status or Chk1 interacting proteins in HCT116 
wild-type and HCT116 p21
-/- 
cells, leading to a difference in the exposure of 
antigen epitope.        
To test whether cellular Chk1 is amenable to the effects of docking peptides, 
immunoprecipitated Chk1 was subjected to [
32
P]-ATP kinase assay with or 
without p21 peptide 4 (P) or Chk1 peptide 14 (C) using Chktide as a substrate 
(Figures 4.8 and 4.9). These experiments were repeated twice with consistent 
results. Chktide is a Cdc25C-derived peptide 
(KKKVSRSGLYRSPSMPENLNRPR) targeted by Chk1.  The results showed that 
the activity of endogenous Chk1 in both HCT116 wild-type and HCT p21
-/- 
cells 
can be stimulated by both peptidomimetic ligands. There was only a marginal 
increase of aphidicolin-treated Chk1 compared to ethanol-treated Chk1 (Figure 4.8; 
lane 1, 4, 7, 10). Chk1 peptide 14 stimulated endogenous HCT116 wild-type Chk1 
activity with a 8-fold increase compared to control while p21 peptide 4 stimulated 
endogenous HCT116 wild-type Chk1 activity with a 3-fold increase compared to 
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control (Figures 4.8; lane 1 to 6). Endogenous HCT116 p21
-/- 
Chk1 was also 
stimulated by Chk1 peptide 14 with a 14-fold increase compared to control while 
p21 peptide 4 stimulated endogenous HCT116 p21
-/- 
Chk1 by 5-fold compared to 
control (Figure 4.8; lane 7 to 12). Overall, endogenous Chk1 immunoprecipitated 
from HCT116 p21
-/- 
cells were stimulated better by activating peptides (Chk1 
peptide 14 and p21 peptide 4) as compared to endogenous Chk1 
immunoprecipitated from HCT116 wild-type cells  
Interestingly, exogenous V5-Chk1 activity from HCT116 wild-type cells was not 
amenable to the stimulating effects of p21 peptide 4 and Chk1 peptide 14 (Figures 
4.9; lane 1 to 6), with only marginal increase of activity in the presence of 
peptidomimetic ligands. In contrast, exogenous V5-Chk1 activity from HCT116 
p21
-/- 
cells could be modulated by the stimulating effects of peptidomimetic 
ligands. The discrepancy would be even more pronounced if normalised to 
immunoprecipitated protein. Chk1 peptide 14 stimulated HCT116 p21
-/- 
V5-Chk1 
activity with a 6-fold increase compared to control while p21 peptide 4 stimulated 
HCT116 p21
-/- 
V5-Chk1 activity with a 2-fold increase compared to control 
(Figures 4.9; lane 7 to 12). Consistent with the endogenous Chk1 activity data, 
Chk1 peptide 14 stimulated V5-Chk1 activity better than p21 peptide 4. Overall 
the data suggested that immunoprecipitated Chk1 from HCT116 p21
-/- 
cells are 
more amenable to the stimulating effects of the peptides and Chk1 peptide 14 
stimulated cellular Chk1 better than p21 peptide 4.  
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One interest to note is that in the HCT116 wild-type cells, Chk1 
immunoprecipitates contained a high molecular weight phospho-protein which 
migrated at about 50 kDa (Figure 4.8A and 4.9A; lane 1 to 6). This could be Chk1 
autophosphorylation or an unknown co-immunoprecipitated substrate of Chk1. 
Interestingly this was not detected in the HCT116 p21
-/- 
Chk1 
immunoprecipitation sample (Figure 4.8A and 4.9A; lane 7 to 12). To test whether 
this phosphorylated protein could be autophosphorylated Chk1 protein, 
endogenous and exogenous V5-Chk1 was immunoprecipitated from aphidicolin-
treated or ethanol-treated HCT116 wild-type cells and subjected to a kinase assay 
with or without unlabelled ATP. Chktide was used as a substrate. The reaction 
products were resolved in 10% SDS-PAGE before transferred to nitrocellulose 
membrane. Chk1 protein was detected using mouse -Chk1 antibodies. The 
rationale is that if cellular Chk1 undergoes autophosphorylation in the IP-kinase 
assay, it will migrate more slowly in the presence of ATP due to incorporation of 
phosphates. If not, Chk1 protein in the presence of ATP will migrate at the same 
molecular weight as Chk1 protein in the absence of ATP. Immunoblotting for 
immunoprecipitated endogenous Chk1 and V5-Chk1 in the kinase assay showed 
that in the presence of ATP, Chk1 migrated at the same molecular weight (Figure 
4.10; lane 1, 2, 5, 6) with Chk1 in the absence of ATP (Figure 4.10; lane 3, 4, 7, 8). 
This suggested that immunoprecipitated V5-Chk1 did not autophosphorylate itself 
in the IP-kinase assay and that the high molecular weight phosphorylated protein 
observed in the autoradiography (Figure 4.8A and 4.9A; lane 1 to 6) was not due 
to autophosphorylation of Chk1 protein but could be a co-immunoprecipitated 
substrate of Chk1 in HCT116 wild-type cells. This further suggested that p21 may 
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play a role in the regulation of Chk1 protein. The unknown phospho-protein will 
be subjected to mass spectrometry analysis but in the meantime I decided to focus 
on biochemical approach to delineate the mechanistic basis of allosteric regulation 
of Chk1.   
4.2.3 Characterisation of Chk1 (Ser Ala317/345) and Chk1 C70 
mutants  
We have hypothesised that stimulation of Chk1 catalytic activity by Chk1 peptide 
14 and p21 peptide 4 is mediated by the disruption of intramolecular interaction 
between the Chk1 autoinhibitory C-terminal domain and its N-terminal kinase 
domain. To further analyse the effects of intrasteric regulation of Chk1 by 
activating peptides, two Chk1 mutants were generated (Figure 4.11).   
1. Chk1 (Ser Ala
317/345
) where the ATR-phosphorylation sites were 





are thought to enhance Chk1 kinase activity, suggesting a 
coupling of ATR phosphorylation sites and the enzymatic mechanism 




phosphorylation were thought to disrupt intramolecular interaction of the 
Chk1 C-terminal domain and N-terminal domain, therefore leading to 
enhanced catalytic activity (Katsuragi and Sagata, 2004). 
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2. Chk1 C70 where the last 70 amino acids of the C-terminal domain are 
deleted. Deletion of this autoinhibitory region has been shown to give an 
increase in kinase activity (Katsuragi and Sagata, 2004).  
The desired mutations were made in the Bacmid vector and Chk1 baculovirus 
were then generated using methods outlined in Chapter 2 and titrated before 
studies were carried out to determine optimal expression conditions for parameters 
such as viral dilution (multiplicity of infection) and incubation time (data not 
shown). Using these optimal conditions, His-tagged Chk1 wild-type and mutant 
proteins were expressed in Sf9 insect cells system by infecting with Chk1 
baculovirus. The expressed proteins were purified using the Ni-NTA columns. A 
coomassie blue stained gel showed that the purified Chk1 fraction was 
approximately 90 % pure and an immunoblot confirmed the presence of Chk1 
protein in the fraction (Figure 4.12A; Lane 7). Infection of Sf9 insect cells must 





. This was not observed when Chk1 
(Ser Ala
317/345
) mutant was analysed (Figure 4.12B). However it should be noted 






To ensure that equal amounts of Chk1 wild-type and mutant proteins were tested, 
the concentrations of the purified Chk1 wild-type and mutant proteins were 
normalised against the known concentration of Chk1 wild-type protein in an 
ELISA format (Figure 4.13). First, I analysed the activity of normalised Chk1 
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proteins in a [
32
P]-ATP kinase assay using p21 as substrate (Figure 4.14). As 
expected, deletion of the autoinhibitory region in Chk1, C70, displayed a two-
fold increase in catalytic activity as compared to the Chk1 wild-type protein. 
Interestingly, mutation at the ATR phosphorylation sites, Chk1 (Ser Ala
317/345
), 
did not affect catalytic activity and activity was comparable to the Chk1 wild-type 
protein. This could indicate that phosphorylation at the ATR sites does not affect 
intrinsic Chk1 kinase activity but more likely to affect Chk1 function in cells by 
regulating its interaction with other proteins or Chk1 localisation. However it is 
also possible that only 1% of the Chk1 WT protein population was phosphorylated 
at the ATR sites, leading to no discernible differences between Chk1 WT and 
Chk1 (Ser Ala
317/345
) catalytic activity. [
32
P] incorporation into p21 was 
confirmed to be mediated by Chk1 rather than any contaminating kinases, as 
addition of debromohymenialdisine (DBH), an inhibitor of Chk1 and Chk2 
(Curman et al., 2001), attenuate [
32
P]-ATP incorporation by more than 90%.   
To analyse Chk1 wild-type and mutant protein catalytic activity further, the kinetic 
constants for Chk1 with respect to p21 were measured (Figure 4.15). Experiments 
were repeated in triplicate and the kinetics constants were calculated as the mean ± 
standard deviation. In agreement with the earlier kinase assay (Figure 4.14), Chk1 
C70 exhibited about three-fold increase in Vmax as compared to wild-type, while 
Chk1 (Ser Ala
317/345
) displayed a slightly lower activity than the wild-type 
enzyme yet not significant. However the Kcat/Km values indicated that although 
Chk1 C70 had higher catalytic activity compared to Chk1 wild-type, it was about 
2.5-fold less efficient than Chk1 wild-type in phosphorylating p21. Chk1 
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(Ser Ala
317/345
) was also less efficient with 1.5-fold inefficiency compared to 





influence catalytic activity. The disparate difference in Kcat/Km between Chk1 
wild-type and Chk1 C70 could be attributable to the high Km value of Chk1 
C70 where it is almost 5-fold higher than that of Chk1 wild-type protein, 
implying that the last 70 amino acids of Chk1 C-terminal domain might be 
important for substrate recognition/docking or stabilisation of the kinase domain.   
4.2.4 Recombinant Chk1 C70 is refractory to the stimulatory effects 
of activating peptides 
After the kinetic constants for Chk1 wild-type and mutants proteins were analysed, 
I wanted to further delineate the effects of p21 peptide 4 and Chk1 peptide 14 on 
the activity of the recombinant Chk1 mutant proteins. Kinase reactions containing 
p21 and activating peptide were assembled and [
32
P] incorporation into p21 in the 
presence of increasing concentrations of Chk1 was determined. As expected, the 
peptides exhibited a stimulating effect on the Chk1 wild-type protein, with p21 
peptide 4 having a greater positive effect than Chk1 peptide 14 (Figure 4.16). This 
is in contrast to the data obtained for cellular Chk1 where Chk1 peptide 14 
stimulated Chk1 catalytic activity better than p21 peptide 4 (Figures 4.8 and 4.9). 
This suggested that cellular Chk1 could carry post-translational modifications or 
interacting proteins that lead to the observed differential stimulating effects. For 
the recombinant human Chk1 expressed from insect cells, the stimulating effect 
seemed to plateau off at the highest enzyme concentration though probably due to 
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over-saturating amount of enzyme. Similarly, Chk1 (Ser Ala
317/345
) mutant 
protein activity was enhanced in the presence of the peptides, though the 
stimulating effect was not as pronounced as that observed with Chk1 wild-type 
protein. p21 peptide 4 was shown to be a better stimulator for Chk1 
(Ser Ala
317/345
) mutant compared to Chk1 peptide 14. Interestingly, Chk1 C70 
mutant activity was refractory to the effect of the peptides with little difference in 
p21 phosphorylation in the presence or absence of activating peptides. In fact, the 
addition of Chk1 peptide 14 seemed to inhibit Chk1 C70 mutant activity. This 
suggested that the last 70 amino acids of Chk1 C-terminal domain are displaced by 
the activating peptides (p21 peptide 4 and Chk1 peptide 14) in Chk1 wild-type or 
Chk1 (Ser Ala
317/345
) mutant. It also further suggested that this region is either 
required or is sufficient for activating peptides binding.    
4.2.5 p21 peptide 4 stimulation enhances Chk1 enzymatic efficiency 
Both p21 peptide 4 and Chk1 peptide 14 were able to stimulate Chk1 activity in a 
concentration-dependent manner; however these observations did not provide an 
insight as to whether allosteric activation of Chk1 will affect Chk1 enzymatic 
efficiency with regard to substrate utilisation. To test whether allosteric activation 
makes Chk1 a more efficient enzyme, the kinetics of p21 substrate utilisation by 
Chk1 were analysed in the presence or absence of either Chk1 peptide 14 and p21 
peptide 4 (Figure 4.17). Chk1 wild-type (WT) was found to have a Km of 3.06. In 
the presence of p21 peptide 4, Chk1 catalytic activity was clearly stimulated as 
seen by a decrease in Km from 3.06 to 1.06 compared to in the absence of peptide. 
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Data showed that the presence of p21 peptide 4 influenced catalytic efficiency of 
Chk1 with a 3-fold higher Kcat/Km value than unstimulated Chk1. This showed that 
p21 peptide 4 stimulation of Chk1 led to a much more efficient utilization of p21 
as a substrate, keeping in line with findings of Figure 4.16.  
Strikingly, in the presence of Chk1 peptide 14, Chk1 displayed an increased Km 
from 3.06 to 5.19 compared to unstimulated Chk1. In contrast to p21 peptide 4, 
Chk1 displayed lower Kcat/Km value in the presence of Chk1 peptide 14 compared 
to unstimulated Chk1, suggesting that Chk1 is not as efficient with Chk1 peptide 
14. This is surprising as Chk1 peptide 14 showed the greatest stimulation of Chk1 
activity towards p21 in Figure 4.16. Therefore the data showed that p21 peptide 4 
makes Chk1 a more efficient enzyme, however Chk1 is less efficient in the 
presence of Chk1 peptide 14.   
4.2.6 Binding of p21 peptide 4 to recombinant Chk1 C70 mutant 
protein 
In chapter 3, I demonstrated that binding of p21 peptide 4 to Chk1 wild-type was 
ATP-dependent (Figure 3.16). To test whether Chk1 peptide 14 binds to Chk1 and 
if the interaction is also ATP-dependent, Chk1 wild-type protein kinase was 
assembled with Chk1 peptide 14 with or without ATP in unlabelled kinase assay. 
The reaction products were resolved by 15 % non-denaturing PAGE (without SDS) 
and transferred to nitrocellulose membrane. Biotinylated Chk1 peptide 14 was 
detected with HRP-conjugated streptavidin whilst recombinant Chk1 protein was 
  
- 132 -  
detected with -Chk1 IgG (Figure 4.18A). A band with a molecular weight of 10 
kDa was observed when samples were probed with HRP-conjugated streptavidin, 
this represents unbound peptides. An additional band with a molecular weight of 
55 kDa was also observed. This was thought to represent Chk1 peptide 14 bound 
to Chk1. This band was present in samples treated with or without ATP. Sample 
was migrated slower in the presence of ATP which was thought to represent Chk1 
peptide 14 bound to autophosphorylated Chk1. The retarded mobility of 
autophosphorylated Chk1 was confirmed by immunoblot analysis with -Chk1 
antibodies. Data showed that Chk1 peptide 14 does indeed bind to Chk1 yet in 
contrast to p21 peptide 4, this interaction is not dependent or influenced by the 
presence of ATP.  
Figure 4.16 showed that recombinant Chk1 C70 protein was refractory to the 
stimulating effects of p21 peptide 4 and Chk1 peptide 14, leading to the possibility 
that the last 70 amino acids of the C-terminal domain may contain a potential 
docking site for the activating peptides. To test this possibility, Chk1 C70 was 
assembled with the p21 peptide 4 in unlabelled kinase assay with or without ATP 
and resolved by non-denaturing gel electrophoresis. Interestingly, the HRP-
conjugated streptavidin blot showed that p21 peptide 4 bound to Chk1 C70 in an 
ATP-dependent manner (Figure 4.18B), where a band corresponding to the 
molecular weight of Chk1 C70 was observed in the absence of ATP but not in 
+ATP conditions. The data suggested that although Chk1 C70 activity was 
refractory to the stimulating effects of activating peptides, p21 peptide 4 could 
indeed bind to Chk1 C70 protein. 
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4.2.7 Disruption of intramolecular interaction between Chk1 N-
terminal and C-terminal domains by the activating peptides 
I have demonstrated that p21 peptide 4 and Chk1 peptide 14 could bind to Chk1 
protein. To test the possibility that activating peptides could disrupt the 
intramolecular interaction between Chk1 N-terminal and C-terminal domains, the 
chick Chk1 system of Prof Gillespie group was employed. The Gillespie group has 
generated the following mutants (Figure 4.19):  
1. chick Chk1 C76 where the last 76 amino acids of C-terminal domain 
was deleted. 
2. chick Chk1 C166 where the last 166 amino acids of C-terminal 
domain was deleted. 
3. chick Chk1 C-terminal domain lacking the majority of the kinase 
domain.  
Cos1 cells were co-transfected with either chick Chk1 C76 and chick Chk1 C-
terminal domain or chick Chk1 C166 and chick C-terminal domain for 24 hours 
and then harvested and lysed. Exogenous Chk1 was then immunoprecipitated from 
lysate with -chick Chk1 C-terminal IgG and then immunoprecipitated chick Chk1 
complexes were incubated with either p21 peptide 4 or Chk1 peptide 14. Then the 
supernatant was removed before the immunoprecipitated products were resolved 
by 10 % SDS-PAGE and transferred to nitrocellulose membrane. Chick Chk1 
C76 and Chk1 C166 were detected using -Chk1 IgG that recognises Chk1 N-
terminal domain epitope. 
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Immunoprecipitated chick Chk1 was not detected when pcDNA empty vector was 
co-transfected with the chick Chk1 C-terminal domain (Figure 4.20A; lane 1 to 3). 
This showed that the immunoblotting -Chk1 IgG only recognises chick Chk1 N-
terminal domain. The IP-kinase assay also showed that transfecting chick Chk1 C-
terminal domain alone did not yield any activity (Figure 4.20B). Figure 4.20A also 
showed that the immunoprecipitation -chick Chk1 C-terminal IgG only 
recognises chick Chk1 C-terminal domain as chick Chk1 was not detected when 
chick Chk1 C76 or Chk1 C166 were transfected into Cos1 cells alone (Figure 
4.20A: lane 4 and 10). Furthermore little or no activity was detected when chick 
Chk1 C166 alone was transfected into Cos1 cells (Figure 4.20B).   
When chick Chk1 C76 or Chk1 C166 were co-transfected with chick Chk1 C-
terminal domain, chick Chk1 C76 or Chk1 C166 mutant protein was co-
immunoprecipitated in a chick Chk1 C-terminal domain IP-kinase assay (Figure 
4.20A; lane 7 and 11). This suggested that chick Chk1 C-terminal domain interact 
with the kinase domain constructs. In addition, kinase activity was detected from 
IP-kinase of co-transfected cells and interestingly, slightly lower catalytic activity 
was observed with chick Chk1 C76 + C-terminal domain compared to chick 
Chk1 C166 + C-terminal domain (Figure 4.20B). However following the 
addition of p21 peptide 4 or Chk1 peptide 14 to the IP-kinase assay, lower amount 
of co-immunoprecipitated chick Chk1 C76 and chick Chk1 C166 were detected 
(Figure 4.20A; lane 8, 9, 12 and 13) and higher Chk1 catalytic activity was 
detected (Figure 4.20B). Interestingly, as observed in Figures 4.8 and 4.9, Chk1 
peptide 14 stimulated cellular chick Chk1 catalytic activity better than p21 peptide 
  
- 135 -  
4, which is in stark contrast to the recombinant human Chk1 data (Figure 4.16), 
This again suggested that cellular Chk1 could carry post-translational 
modifications or interacting proteins that lead to the differential stimulating effects. 
Overall the data suggested that p21 peptide 4 and Chk1 peptide 14 could disrupt 
the intramolecular interaction between chick Chk1 C-terminal domain and chick 
Chk1 C76 or Chk1 C166, leading to enhanced catalytic activity.   
4.2.8 Mutation of conserved Tryptophan residues in the Chk1 N-
terminal F region resulted in loss of allosteric stimulation of 
catalytic activity 
Chk1 N-terminal kinase domain and C-terminal regulatory domain are involved in 
intra-molecular interaction (Katsuragi and Sagata, 2004). Addition of Chk1 
peptide 14 from the F region of Chk1 kinase domain was able to abrogate this 
intra-molecular interaction and stimulate Chk1 activity towards p21. This 
suggested that the F region could be involved in the association of the Chk1 N-
terminal and C-terminal domains. To determine whether the F region is crucial 




) within F region were mutated to alanine (Figure 4.21B). The two 
tryptophan residues were chosen because they are conserved throughout the 
species of Chk1 (Figure 4.21A) and furthermore alanine mutation of Trp
65 
within 
the p21 peptide 4, which was shown to align to Chk1 Trp
208
, attenuate Chk1 
stimulation (Figures 3.20 and 4.2).   
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Baculovirus carrying Trp Ala
192/208 
mutation were produced and used to infect 
insect cells. N-terminally His-tagged Chk1 (Trp Ala
192/208
) mutant protein was 
expressed in Sf9 insect cells and purified using the Ni-NTA column (Figure 
4.22A). Surprisingly, immunoblotting analysis revealed that the recombinant Chk1 
(Trp Ala
192/208
) mutant appeared to be cleaved, migrating at about 30 kDa 
(Figure 4.22A; right panel; lane 5) as compared to Chk1 wild-type which migrated 
at about 50 kDa (Figure 4.22A; left panel; lane 5). The Chk1 (Trp Ala
192/208
) 
mutant form that appeared on the immunoblot reflected a C-terminal truncation 
because the antibodies (mouse monoclonal -Chk1 IgG, Santa Cruz) used in this 
assay recognised the N-terminal Chk1 peptide. To assess whether cleavage of 
Chk1 (Trp Ala
192/208
) mutant protein happened intracellularly or if it occurred 
during the infected Sf9 insect cells lysis procedure, direct lysis of the infected cells 
in SDS-PAGE sample buffer was analysed (Figure 4.23A). The immunoblot 
showed that the Chk1 (Trp Ala
192/208
) mutant cleavage happened during protein 




makes Chk1 protein 
susceptible to proteolytic cleavage. The Chk1 (Trp Ala
192/208
) mutant form 
detected on the immunoblot seemed to represent the kinase domain as it migrated 
at approximately 30 kDa which is similar to the predicted molecular weight of the 
Chk1 kinase domain.  
Longer exposure of the immunoblot did reveal however the presence of a small 
population of full-length Chk1 (Trp Ala
192/208
) mutant protein (data not shown). 
As the sample was contaminated with cleaved Chk1 (Trp Ala
192/208
) mutant 
protein, I wanted to separate the full-length protein from the cleaved protein and 
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test whether the full length Chk1 (Trp Ala
192/208
) mutant protein catalytic activity 





are involved at the intramolecular binding interface, 
mutation at these residues would be expected to disrupt Chk1 C-terminal-mediated 
autoinhibition of the kinase domain, leading to enhanced catalytic activity. 
Therefore, the purified recombinant Chk1 (Trp Ala
192/208
) fraction was subjected 
to gel filtration using the Superdex 200 column to separate the higher molecular 
weight full-length Chk1 (Trp Ala
192/208
) mutant protein from the lower molecular 
weight cleaved Chk1 (Trp Ala
192/208
) mutant protein form (Figure 4.23B). 
However, the immunoblot analysis revealed that the full-length Chk1 
(Trp Ala
192/208
) mutant protein which migrated at about 50 kDa co-eluted from 
the gel-filtration column with the cleaved form which migrated at about 30 kDa 
(Figure 4.23B; lane 4 to 7), suggesting that the full-length Chk1 formed complexes 
with the cleaved Chk1.   
Having failed to purify the full-length Chk1 (Trp Ala
192/208
) mutant protein from 




residues on Chk1 catalytic activity by transfecting C-terminally tagged V5-Chk1 
wild-type and Chk1 (Trp Ala
192/208
) mutants into HCT116 wild-type cells. 
Immunoblotting for V5-Chk1 protein showed that exogenous V5-Chk1 
(Trp Ala
192/208
) mutant protein was not cleaved as in the insect cells and it also 
migrated slower than the exogenous V5-Chk1 wild-type protein (Figure 4.24; 
lower panel; compare lane 2, 4, 6, 8 to lane 1, 3, 5, 7). Interestingly, as noticed in 
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were not detected on the immunoblot (Figure 4.24; lower panel). This  again 
suggested that that either V5-Chk1 is not activated in response to aphidicolin-
treatment or it is already activated regardless of genotoxic stress.   
Exogenous V5-tagged Chk1 proteins were immunoprecipitated from the cellular 
lysates. The immunoprecipitated sample was assembled with Chktide as substrate 
in the presence or absence of activating peptides in the [
32
P]-ATP kinase assay. 
The reaction products were resolved by 15 % SDS-PAGE and [
32
P] incorporation 
into Chktide was visualised by autoradiography (Figure 4.25A) and quantified by 
phosphorimager (Figure 4.25B). The data showed that both V5-Chk1 wild-type 
and V5-Chk1 (Trp Ala
190/208
) were active (Figure 4.25A; lane 1 to 4). 
Interestingly, ethanol-treated V5-Chk1 wild-type displayed 3-fold increased 
activity than aphidicolin-treated V5-Chk1 wild-type (Figure 4.25A; lane 1 and 2). 
However, there was no difference in catalytic activity between aphidicolin-treated 
V5-Chk1 (Trp Ala
192/208
) and ethanol-treated V5-Chk1 (Trp Ala
192/208
) (Figure 
4.25A; lane 3 and 4). As expected, immunoprecipitated V5-Chk1 wild-type 
catalytic activity could be greatly stimulated by Chk1 peptide 14 (Figure 4.25A; 
compare lane 1 and 2 to lane 9 and 10), however in contrast, immunoprecipitated 
V5-Chk1 (Trp Ala
192/208
) catalytic activity was only mildly stimulated by Chk1 
peptide 14 (Figure 4.25A; compare lane 3 and 4 to lane 11 and 12). p21 peptide 4 
was shown to have a stimulating effect on V5-Chk1 (Trp Ala
192/208
) catalytic 
activity though the it was not as pronounced as on V5-Chk1 wild-type (Figure 
4.25A; compare lane 5 and 6 to lane 7 and 8).  Therefore the data suggested that 
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residues of Chk1 resulted in loss of allosteric 
stimulation by the activating peptides.  
Peptidomimetic ligand based on the Chk1 F region was able to abrogate 
intramolecular interaction between Chk1 N-terminal domain and its C-terminal 





in the Chk1 F region will displaced the C-terminal 




mutation led to cleavage susceptibility in insect cells-expressed Chk1 
(Trp Ala
192/208
) protein, appearance of slow-mobilised form of Chk1 
(Trp Ala
192/208





may have a destabilising effect on Chk1 conformation. The destabilising effect 
could not be rescued by the activating peptides as transfected Chk1 
(Trp Ala
192/208
) from HCT116 wild-type cells was refractory to allosteric 
stimulation compared to transfected Chk1 wild-type protein.       
4.2.9 Allosteric activation of Chk1 resulted in lower requirement for 
arginine residue at P-3 position 
Studies on p38 protein kinase showed that allosteric docking by peptidomimetic 
ligand induced conformational changes in the active site, which suggested the 
possibility that allosteric regulation could change the specificity of substrate 
recognition (Chang et al., 2002). To examine whether recombinant Chk1 wild-type 
protein allosterically activated by Chk1 peptide 14 and loss of autoinhibitory 
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region (Chk1 C70 mutant protein) could result in change of substrate recognition 
specificity, [
33
P]-ATP kinase assay with Chk1 wild-type protein or Chk1 wild-
type protein allosterically activated by Chk1 peptide 14 or Chk1 C70 mutant 
protein were performed using PepChip microarray. This microarray slide 
contained duplicate sets of 192 different peptides with a median length of nine 
amino residues, based on known phosphorylation sites in the PhosphoBase 
database (Figure 4.26). [
33
P]-ATP was used to reduce the background signal. 
Kinase buffer was also optimised for this assay by ensuring that Chk1 catalytic 
activity and allosteric stimulation by Chk1 peptide 14 are not affected by the 
addition of Brij-35 which was used to reduce background signal. After the 
conditions were optimised, kinase reactions containing either Chk1 wild-type, 
Chk1 wild-type + Chk1 peptide 14 or Chk1 C70 were assembled in the presence 
of [
33
P]. The PepChip microarrays were incubated with the kinase reactions for 3 
hours at 30
o
C in a humidity chamber. After incubation, the kinase reactions were 
washed off and [
33
P] incorporation into the peptide substrates on the microarray 
slides were visualised by autoradiography. The spot signals were correlated with 
the peptide sequences using the grid and spreadsheet provided by the manufacturer.  
Positive hits were tabulated and organised in a table format (Appendix 1). The 
data showed that all three forms of Chk1 protein shared some substrate peptides 
(coloured in yellow in Appendix 1). Interestingly, the microarray data showed that 
24 substrate peptides were phosphorylated only in the presence of the Chk1 
protein stimulated by Chk1 peptide 14 (not coloured in Appendix 1) (Figure 4.27). 
Although there were no substrate peptide phosphorylated exclusively by Chk1 
C70, it shared 10 common substrate peptides with allosterically activated Chk1. 
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Therefore, the data suggested that loss of autoinhibitory region (Chk1 C70) and 
allosteric activation of Chk1 (Chk1 stimulated by Chk1 peptide 14) can lead to 
change in substrate specificity, allowing Chk1 to target substrates that do not fit 
with Chk1 consensus substrate specificity. 10 common peptide substrates 
phosphorylated by Chk1 C70 and allosterically activated Chk1 suggested that 
deletion of the last 70 amino acids of Chk1 C-terminal domain may constitute the 
same effects as allosterically activated Chk1.         
To further confirm that allosteric activation would allow Chk1 to tolerate substrate 
specificity changes, I selected 13 peptide substrates for further analysis (Figure 
4.28). As shown in the earlier microarray data, among these 13 peptide substrates, 
peptides 1 to 7 were phosphorylated exclusively by allosterically activated Chk1 
whilst peptides 11 and 12 were targeted by all three forms of Chk1. As some of the 
peptide substrates were found in species other than human, I also want to test 
whether the human equivalent of the substrate peptides can be phosphorylated by 
Chk1 as this might be a way of identifying potential novel substrates. Peptides 8 to 
10 were human forms of peptide 2, 5 and 7 respectively, while peptide 13 is the 
human equivalent of peptide 12. The substrate peptides were assembled with 
either Chk1 wild-type protein or Chk1 wild-type stimulated by Chk1 peptide 14 in 
a [
32
P]-ATP kinase assay (Figure 4.29). The data showed that Chk1 wild-type 
protein as well as allosterically activated Chk1 phosphorylated peptides 11 and 12, 
which has arginine residue in the P-3 position. Peptides 1 to 10 showed no [
32
P] 
incorporation when assembled with Chk1 wild-type protein alone, in agreement 
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incorporation in the presence of allosterically activated Chk1. In the presence of 
stimulatory Chk1 peptide 14, Chk1 activity towards peptide 12 was about 4.5 fold 
higher than in the absence of stimulatory peptide while allosterically activated 
Chk1 activity towards peptide 11 was about 2.5 fold higher as compared to non-
activated Chk1. The data confirmed that allosteric activation could modulate Chk1 
activity towards non-consensus peptide substrates.          
4.2.10 Recombinant Chk1 is active towards Interleukin-1
Using the PepChip microarray, Chk1 was shown to be active towards several 
novel substrates such as mouse Interleukin-1 . Furthermore, some of these novel 
substrates such as human Signal transducer and activator of transcription 1 
(STAT1) are only targeted by Chk1 stimulated by the activating peptide.   
To further characterise Chk1 activity towards these novel substrates, Chk1 protein 
kinase was assembled with titrating amounts of human interleukin-1 protein 
(Sigma Aldrich) or STAT1 protein (Biomol) for [
32
P]-ATP kinase assay. The 
assay showed [
32
P] incorporation into human interleukin-1 (Figure 4.30A) but 
not human STAT1 (Figure 4.30B). This suggested that interleukin-1 could be a 
novel Chk1 substrate. Although, STAT1 was not phosphorylated in this kinase 
assay, the microarray data showed that STAT1 peptide could only be 
phosphorylated in the presence of Chk1 stimulated by activating peptide (Figure 
4.27).  
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To test whether stimulation of Chk1 by peptide 4 could enhance catalytic activity 
towards interleukin-1 and also switch substrate specificity towards STAT1, Chk1 
was assembled with interleukin-1 or STAT1 for [
32
P]-ATP kinase assay in the 
presence or absence of Chk1 peptide 14. Figure 4.31A showed that Chk1 catalytic 
activity towards interleukin-1 was only slightly enhanced in the presence of 
activating peptide (compare lane 2 and 3). In contrast to the Pepchip microarray 
data, no detectable [
32
P] incorporation into STAT1 was observed despite the 
stimulation of Chk1 by activating peptide (Figure 4.31B; lane 2 and 3). The data 
indicated that Chk1, whether allosterically activated or not, is not active towards 
human STAT1 protein. In contrast, human interleukin-1 could represent a 
potential novel substrate for Chk1.              
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4.3 Discussion 
4.3.1 An allosteric activating motif is located within the F region of 
Chk1 N-terminal kinase domain 
It was hypothesised that p21 or p21 peptide 4 would act as a competitive inhibitor 
to disrupt intramolecular binding of Chk1 C-terminal regulatory domain to a 
pseudo-docking site in the Chk1 N-terminal kinase domain (Figure 4.1). To test 
this, sequence alignment showed that the F region of the Chk1 N-terminal kinase 
domain shared sequence similarity to stimulatory p21 peptide 4. Furthermore, 
Chk1 F region is conserved across species, suggesting that this region might be 
important for the regulation of Chk1 activity (Figure 4.2). Kinase assays with 
peptides spanning across the whole length of Chk1 showed that only 
peptidomimetic ligands based on the F region (Chk1 peptide 14 and 32) were 
able to stimulate Chk1 activity towards p21, whereas most of the peptides 
demonstrated a negligible or an inhibitory effect on Chk1 catalytic activity (Figure 
4.3B). Kinase assays on Chk1 immunoprecipitated from HCT116 wild-type and 
HCT116 p21
-/- 
cells also showed that cellular Chk1 can be modulated by p21 
peptide 4 and Chk1 peptide 14 (Figures 4.8 and 4.9). An interest to note is that 
immunoprecipitated Chk1 from HCT116 p21
-/- 
cells were stimulated better by the 
activating peptides compared to immunoprecipitated Chk1 from HCT116 wild-
type cells (Figures 4.8 and 4.9). Furthermore, the IP-kinase assay also detected the 
presence of an unknown phospho-protein from the HCT116 wild-type Chk1 
immuno-complex but this was not detected from the HCT116 p21
-/- 
immuno-
complex (Figure 4.8 and 4.9). Therefore the data suggests that there may be a 
difference in the conformation, modification status or Chk1 interacting proteins in 
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HCT116 wild-type and HCT116 p21
-/- 
cells. Tools such as mass spectrometry may 
be exploited to examine the differences of Chk1 modification status in +/- p21 
background. In addition, it would be interesting to investigate the possibility that 
p21 might function as a regulatory molecule for Chk1 catalytic activity in vivo by 
transfecting p21 back into the HCT116 p21
-/- 
cells.    
Biochemical analysis has suggested that Chk1 autoinhibition is dependent on the 
association of the Chk1 C-terminal regulatory domain with its N-terminal kinase 
domain (Katsuragi and Sagata, 2004). In this study, I have demonstrated that this 
could occur through the F region in the N-terminal kinase domain forming a 
crucial intramolecular binding interface with the C-terminal regulatory domain. 
Chk1 peptide 14 based on the Chk1 F region is able to bind to Chk1 which is not 
dependent or influenced by ATP (Figure 4.18). This is in stark contrast to p21 
peptide 4 binding to Chk1 which is ATP-dependent (Figure 3.16). Data has also 
showed that peptidomimetic ligands based on the Chk1 F region are able to 
disrupt intramolecular interaction between the Chk1 C-terminal domain and its N-
terminal domain (Figure 4.20). This most likely results in the displacement of the 
inhibitory C-terminal domain from the kinase domain, leading to increased Chk1 
catalytic activity.      
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4.3.2 Differential activity of Chk1 mutant proteins 
To further characterise the effects of Chk1 peptide 14, two Chk1 mutants were 
synthesised (Figure 4.11): 
1. Chk1 (Ser Ala
317/345
) where the ATR phosphorylation sites were mutated 
to alanine residues.  
2. Chk1 C70 where the last 70 amino acids of the C-terminal regulatory 
domain were deleted.  
Kinase assays confirmed that Chk1 C70 exhibited higher catalytic activity 
(approximately two-fold) than Chk1 wild-type protein (Figure 4.14) due to the loss 
or partial loss of autoinhibitory region, which is in line with reported observation 
(Katsuragi and Sagata, 2004). Autoinhibition often involves the presence of a 
pseudosubstrate domain located in the regulatory region. The above data suggested 
that a pseudosubstrate region might be located on the last 70 amino acids of Chk1. 
The pseudosubstrate region normally contains the substrate consensus sequence 
with a non-phosphorylatable residue in place of Ser/Thr residue. However 
sequence alignment of the p21 phosphorylation motif (alanine residue was in place 
of Ser
146 
residue) with full-length Chk1 has identified a potential pseudosubstrate 
region within the C-terminal domain (amino acids 371 to 381) but not within the 
last 70 amino acids (Figure 4.32). Interestingly, mutation of Xenopus Chk1 at 
Thr
377 
within the TRF motif led to enhanced catalytic activity (Wang and Dunphy, 
2000) and this TRF motif is located within the potential pseudosubstrate region, 
suggesting that mutation of Thr
377 
might disrupt the intramolecular interaction 
between the potential pseudosubstrate region and the active site. Interestingly, the 
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TRF motif is conserved across the species of Chk1, implying that this motif may 
be important for Chk1 regulation. One possibility is that the last 70 amino acids 
are required to anchor the pseudosubstrate to the active site. The second possibility 
is that a pseudosubstrate region that does not conform to the Chk1 substrate 
consensus sequence resides within the last 70 amino acid. Therefore, more 
experiments are needed to confirm the presence of a pseudosubstrate region within 
Chk1 protein.   
Although, Chk1 C70 displayed a two-fold higher catalytic activity than Chk1 
wild-type, kinetic analysis showed that Chk1 C70 demonstrated about 2.5-fold 
lower Kcat/Km than Chk1 wild-type. This illustrated that Chk1 C70 was a less 
efficient enzyme than Chk1 wild-type in utilising p21 (Figure 4.15). This was due 
to an observed 5-fold higher Km for Chk1 C70 as compared to Chk1 wild-type. 
The high Km value suggests that p21 could not docked properly to Chk1 C70 and 
a crucial p21 docking groove was located along the last 70 amino acids. In the 
absence of a potential p21 docking groove, the substrate may diffuse away easily 
before they get phosphorylated by Chk1, thus leading to the higher Km.    
Chk1 activation induced by DNA damage has been reported to involve ATR-




and these phosphorylations are 
thought to enhance catalytic activity (Zhao and Piwnica-Worms, 2001). However, 
in our assays, the Chk1 (Ser Ala
317/345
) mutant demonstrated similar catalytic 
activity to Chk1 wild-type, suggesting that phosphorylation at the ATR sites does 
not confer higher catalytic activity (Figure 4.14). It is also possible that only 1% of 
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the Chk1 WT protein population was phosphorylated ATR sites, therefore leading 
to minimal differences in activity between Chk1 WT and Chk1 (Ser Ala
317/345
). 
Gel filtration analysis by Zhao and Piwnica-Worms, 2001, showed that 




in HeLa cells eluted at 
higher molecular weight and had a higher catalytic activity, with Chk1 
(Ser Ala
317/345
) mutant which eluted at lower molecular weight exhibiting poor 




per se does not confer enhanced catalytic activity but may result in association 
with cellular activator molecule which leads to higher kinase activity.    
4.3.3 Chk1 C70 mutant protein was refractory to the stimulating 
effects of the activating peptides 
The Chk1 kinase assays with activating peptides showed that Chk1 
(Ser Ala
317/345
) catalytic activity can be stimulated by p21 peptide 4 and Chk1 
peptide 14, albeit with a slightly lower activating effect as compared to Chk1 wild-
type protein (Figure 4.16). Interestingly, Chk1 C70 was refractory to the effect of 
the activating peptides. This data suggests that the last 70 amino acids can form a 
docking groove for the activating peptides which explains the loss of peptide-
activating effect on Chk1 C70. However, peptide-binding assay using non-
denaturing gel electrophoresis showed that the p21 peptide 4 was capable of 
associating with Chk1 C70 in an ATP-dependent manner (Figure 4.18B), 
suggesting that loss of the last 70 amino acids was not crucial to activating 
peptides docking but was crucial to the activating peptide-mediated allosteric 
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stimulation. Using the chick Chk1 system in collaboration with Prof Gillespie 
group, a domain comprising the last 70 amino acids was not able to initiate 
intramolecular interaction with Chk1 N-terminal kinase domain (MT Scott, 
personal communication); however, a full complement of the Chk1 C-terminal 
domain was able to intramolecularly interact with the Chk1 N-terminal domain 
(Figure 4.20A). Furthermore, addition of the activating peptides was able to 
disrupt the intramolecular interaction (Figure 4.20A), leading to enhanced Chk1 
catalytic activity (Figure 4.20B). The above data suggested that the activating 
peptides could bind to a region outwith the last 70 amino acids of the Chk1 C-
terminal domain (C70) and possibly allosterically displace C70 from the Chk1 
kinase domain through conformational change and/or modifications. Preliminary 
data have showed that a Chk1 peptide corresponding to amino acids 406 to 420 
within C70 was autophosphorylated by Chk1 itself (Figure 4.33A). Mass 
spectrometry has indicated that Chk1 Ser
407 
is the major phospho-acceptor site 
(Figure 4.33B). Therefore it is possible that post-translational modification of 
Chk1 Ser
407 
is required to stabilise Chk1 C70 displacement from the kinase 
domain.  
Data has showed that p21 peptide 4 stimulated recombinant Chk1 catalytic activity 
better than Chk1 peptide 14 (Figure 4.16). This is in stark contrast to the data 
obtained for cellular Chk1 where Chk1 peptide 14 stimulated Chk1 catalytic 
activity better than p21 peptide 4 (Figures 4.8 and 4.9). One explanation for this 
discrepancy is that cellular Chk1 protein is in complex with additional co-factors 
or regulatory proteins that results in better activation by Chk1 peptide 14 than p21 
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peptide 4 or that the post-translational modification status of cellular Chk1 differs 
from the insect cell expressed protein. Kinetic analysis indicated that recombinant 
human Chk1 was a far more efficient enzyme in the presence of p21 peptide 4 due 
to a lower Km value (Figure 4.17). Surprisingly, Chk1 was less efficient 
enzymatically when incubated with Chk1 peptide 14 due to a low Km value 
(Figure 4.17). The reason for this is not clear. To elucidate the effects of activating 
ligands on Chk1 structural conformation and dynamics, biophysical experiments 
such as NMR spectroscopy would be needed.   
4.3.4 Mutation at conserved tryptophan residues within the Chk1 N-
terminal F region destabilised Chk1 kinase domain structure 
Ligands based on Chk1 N-terminal -F region were able to stimulate Chk1 activity 
but were ineffective towards Chk1 C70. One possible mechanism is that Chk1 
F region forms a binding interface with the C-terminal domain and sterically 
blocks substrate access to the active site through the action of the last 70 amino 
acids of the C-terminal domain. Ligands based on the -F region were able to 
compete for the intramolecular binding interface, thus removing the steric block 
on the active site, leading to enhanced catalytic activity. To test that the F region 





) were mutated to alanine residues. The two tryptophan 
residues were chosen because they are conserved throughout the species of Chk1 
(Figure 4.21A) and furthermore alanine mutation of Trp
65 
within the p21 peptide 4, 
which was shown to align to Chk1 Trp
208
, attenuate Chk1 stimulation (Figures 
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3.20 and 4.2). Recombinant Chk1 (Trp Ala
192/208
) mutant protein was shown to 
be susceptible to C-terminal cleavage in the Sf9 insect cells system and a small 
population of the full length mutant was found to associate with the cleaved 
protein (Figure 4.22 and 4.23).   
Immunoprecipitated exogenous V5-Chk1 (Trp Ala
192/208
) mutant from HCT116 
wild-type cells revealed that the Chk1 (Trp Ala
192/208
) mutant protein could 
retain intrinsic catalytic activity but was refractory to the stimulating effect of the 
activating peptides (Figures 4.24 and 4.25). The crystal structure of Chk1 kinase 









form van der Waals contact with the hydrophobic core of the kinase domain C-
terminal lobe, which could stabilise the hydrophobic pocket important for 





integrity of Chk1 kinase domain structure is greatly destabilised. This could be the 
reason why insect cell-expressed Chk1 (Trp Ala
192/208
) was susceptible to 
cleavage. Destabilisation of the Chk1 (Trp Ala
192/208
) mutant protein also means 
that the activating peptides have little effect on Chk1 (Trp Ala
192/208
) catalytic 





is critical to intramolecular interaction 
between the Chk1 C-terminal domain and its N-terminal domain. Perhaps the best 
way forward is to make single alanine mutation across the conserved residues in 
the Chk1 F region and biochemically assess its effect on catalytic activity.   
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4.3.5 Allosteric activation resulted in Chk1 substrate specificity 
change 
The presence of a consensus phosphorylation site in a protein does not ensure that 
the protein is a substrate in vivo. Furthermore, authentic phosphorylation sites do 
not always fit with the consensus sequence, suggesting that allosteric regulation is 
often involved in substrate recognition (Ubersax et al., 2003). Indeed allosteric 
docking by peptidomimetic ligand has been shown to induce conformational 
changes in the p38 protein kinase active site (Chang et al., 2002). To assess 
whether Chk1 substrate recognition can be altered by allosteric activation and loss 
of the autoinhibitory region (Chk1 C70), PepChip microarray analysis was 
performed with Chk1 wild-type protein +/- activating Chk1 peptide 14 or Chk1 
C70. The data showed that 18 peptide substrates were phosphorylated by all 
three forms of Chk1. Sequences of these common substrate peptides were fed into 
Weblogo program (University of California, Berkeley) to generate consensus logo 
which revealed that Chk1 had a strong preference for arginine residue in the P-3 
position (Figure 4.34A), that is in line with the published data (O'Neill et al., 2002).  
It was further shown that allosterically activated Chk1 was able to phosphorylate 
34 peptide substrates not recognised by Chk1 wild-type protein in the absence of 
Chk1 peptide 14 (Appendix 1). The consensus sequence of these peptide 
substrates revealed that allosterically activated Chk1 had less preference for the 
arginine residue in P-3 position and it was able to phosphorylate tyrosine residue 
in addition to serine and threonine residues (Figure 4.34B). Determination of 
substrate motifs for Chk1 by oriented-peptide library approach showed that Chk1 
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preferentially phosphorylated tyrosine over serine and threonine residues (O'Neill 
et al., 2002). Furthermore, analysis of yeast protein kinases showed several 
examples of Ser/Thr kinases that can phosphorylated tyrosine residue to some 
extent (Zhu et al., 2000).  
There were no peptide substrate phosphorylated exclusively by Chk1 C70, 
however it shared 10 common peptide substrates with allosterically activated Chk1. 
The consensus sequence of these 10 common peptide substrates showed that Chk1 
C70 protein also had less preference for the arginine residue in P-3 position 
(Figure 4.34C). Therefore, the data suggested that loss of the autoinhibitory region 
(Chk1 C70) and allosteric activation of Chk1 (Chk1 stimulated by Chk1 peptide 
14) can lead to change in substrate specificity, allowing Chk1 to target substrates 
that do not fit with Chk1 consensus substrate specificity. This was confirmed in 
Figure 4.29 where allosterically activated Chk1 was active towards peptides 1 to 
10 and 13 which lack the arginine residue at P-3 position, although the presence of 
arginine residue at P-3 position (peptide 11 and 12) mediated better peptide 
substrates utilisation by allosterically activated Chk1. Modelling study of Chk1 
with peptide substrate revealed that Chk1 also preferred a hydrophobic amino 
residue at P+1 position (Chen et al., 2000). This might explained the 2-fold 
increase of [
32
P] incorporation into peptide 12 which has a hydrophobic 
phenylalanine residue at P+1 position as compared to peptide 11.   
Overall, the data showed that allosteric stimulation may change Chk1 substrate 
specificity towards non-consensus sequence. Although Chk1 C70 and peptide-
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stimulated Chk1 has similar effect, allosteric activation and deletion of the 
regulatory domain are not equivalent suggesting that Chk1 C70 is not in an 
active conformation. Physiologically, this could suggest that although Chk1 has a 
strong preference for substrates with a Rxx(S/T)- motif, allosteric stimulation 
may change Chk1 substrate specificity towards non-consensus sequence, thus 
widening the pool of physiological substrates. In addition, we could also 
potentially activate Chk1 activity towards a certain biochemical pathway by a 
specific allosteric peptide.     
4.3.6 Additional determinant(s) needed for Chk1 substrate recognition 
In the PepChip microarray, human STAT1 peptide (KGTGYIKTE) was found to 
be phosphorylated only by stimulated Chk1 in the presence of Chk1 peptide 14 
(Appendix 1). To test for this, human STAT1 protein was assembled with Chk1 
wild-type protein kinase for [
32
P]-ATP kinase assay in the presence or absence of 
Chk1 peptide 14. However, the autoradiography only showed [
32
P] incorporation 
into Chk1 and no detectable [
32
P] incorporation into STAT1 (Figures 4.30B and 
4.31B). This suggested that Chk1 protein kinase is not active towards human 
STAT1 protein, even under stimulating conditions. In contrast, mouse interleukin-
1 peptide (KRRLSFSET) was determined to be phosphorylated by Chk1 protein 
kinase in PepChip microarray (Appendix 1). Further [
32
P]-ATP kinase assays 
showed [
32
P] incorporation into the human form of interleukin-1 protein 
(Figures 4.30A and 4.31B), suggesting that human interleukin-1 could form as a 
novel in vitro Chk1 substrate. Although the human interleukin-1 contains a 
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slightly different phosphorylation motif (KRRLSLSQS) from the mouse 
interleukin-1 peptide (KRRLSFSET), the Chk1 consensus substrate sequence 
(RxxS/T) is represented in both forms of interleukin-1 . In contrast, four Rxx(S/T) 
phosphorylation motifs are found in human STAT1, however, [
32
P]-ATP kinase 
assays showed that human STAT1 protein was not phosphorylated by Chk1. This 
could suggest that either the human STAT1 Rxx(S/T) motifs are not exposed to 
Chk1 or that the Rxx(S/T) motif is not the sole requirement for Chk1 substrate 
recognition and other determinant such as a distinct docking/allosteric site is 
needed.       
4.4 Conclusions 
In this chapter, I have showed that Chk1 also contains an allosteric signal (Chk1 
peptide 14) within the N-terminal F region which shared sequence similarity with 
activating p21 peptide 4. These activating peptides (p21 peptide 4 and Chk1 
peptide 14) could modulate the activity of recombinant human and chick Chk1 and 
cellular Chk1 by disrupting the intramolecular interaction between the Chk1 C-
terminal domain and N-terminal domain. However recombinant human insect cell-
expressed Chk1 C70 mutant protein (deletion of the last 70 amino acids of Chk1 
C-terminal domain) which retained binding to p21 peptide 4 proved to be 
refractory to the stimulating effects of the activating peptides. It was shown that 
additional determinant(s) other than a consensus substrate sequence is required for 
Chk1 substrate recognition and indeed allosteric activation of Chk1 could result in 
phosphorylation of non-consensus substrate specificity. Mutation of conserved 
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Trp
192/208 
destabilises Chk1 conformation, leading to cleavage susceptibility. 
Furthermore, the activating peptides failed to stimulate Chk1 (Trp Ala
192/208
) 








F igu re 4.1 A simple illust r ation of p21 peptide 4-dependent alloster ic stimulation of
C h k1.
(A) This hypothetical model shows that Chk1 protein kinase adopts a !"#$%&'( conformation
for autoinhibition of catalytic activity. Allosteric activation by p21 peptide 4 prevents
autoinhibition by stimulating Chk1 to adopt an !$)&*( conformation.
A
F igure 4.2 Sha red homology of p21 docking peptide with C hk1 N-ter minal region.
(A) A schematic diagram of Chk1 structure. p21 peptide 4 sequence was aligned to a sub-
region spanning amino acids 189 to 208 within Chk1 N-terminal kinase domain using
EMBOSS Pairwise Alignment Algorithms. SQ represents the ATR phosphorylation motif
(SQ). (B) ClustalW sequence alignment of Chk1 kinase domains of human (hs), mouse (mm),
Xenopus (xl), D rosophila (dm), C . elegans (ce), S. cerevisiae (sc) and S. pombe (sp).
Secondary structural elements of human Chk1 are shown above the alignment. The numbers of
amino acids are shown on the right. Invariant residues of Chk1 among these species are in red
and human Chk1 residues that are also conserved in other species are in cyan. The shared
homology region with p21 docking peptide is boxed within red dotted line. This diagram is














F igu re 4.3 Recombinant human C h k1 activity towa r ds recombinant human p21 can be
stimulated by N-ter minal C h k1 peptide.
(A) Biotinylated overlapping Chk1 20-mer peptides with SGSG spacing were resuspended in
DMSO. (B) Kinase reactions containing 60 ng of Chk1, 1 +g of p21, 1 mM of indicated Chk1
peptides in the presence of [,32P]ATP were assembled. DMSO was used as a control in the
absence of Chk1 peptides. The reaction products were resolved in 12% SDS-PAGE and [,32P]












































































F igu re 4.4 Recombinant human C h k1 activity towa r ds recombinant human p21 is
stimulated by C h k1 peptide 14.
(A) Kinase reactions containing 100 ng of Chk1, 1 +g of p21 and titration of Chk1 peptide 14
(0.625 +g to 2.5 +g) were assembled in the presence of [,32P]ATP. The reaction products were
resolved in 12% SDS-PAGE. [,32P] incorporation into p21 was visualised by autoradiography
and quantified by phosphorimager. (B) Kinase reactions containing 100ng of Chk1 and
titration of Chk1 peptide 14 (0.625 +g to 2.5 +g) were assembled in the presence of [,32P]ATP.
The reaction products were resolved by 10% SDS-PAGE. [,32P] incorporation into Chk1 was















F igu re 4.5 p21 status of H C T116 cell line does not affect the half-life of endogenous C h k1.
(A) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluency before treated with
30 +g/ml of cycloheximide. The cells were harvested at the indicated time point and 0 min
refers to untreated cells. 50 +g of whole cell lysates were resolved by 10% or 12% SDS-PAGE
before transferred to nitrocellulose membranes. Chk1 protein was detected using mouse --
Chk1 IgG and p21 protein was detected with mouse --p21 IgG.
A
F igu re 4.6 I mmunoblot of endogenous or exogenous C h k1 p rotein f rom H C T116 wild-
type or p21-/- cells (+/- aphidicolin t reatment).
(A) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluence before transfected
with C-terminally V5-tagged Chk1 wild-type or mock-transfected with empty vector. After 24
hrs, the cells were either treated with 20 +M aphidicolin or ethanol as control for 4 hrs. The
cells were harvested and 50 +g of whole cell lysates were resolved by 10% SDS-PAGE before
transferred to nitrocellulose membranes. Chk1 protein was detected using mouse --Chk1 IgG
and exogenous V5-tagged Chk1 protein was detected using mouse --V5 tag IgG.
<-Chk1 IgG
<-V5 IgG
1 2 3 4 5 6 7 8
Lane Cell line Endogenous or V5-Chk1 Aphidicolin treatment
1 HCT116 wild type Endogenous -
2 HCT116 wild type Endogenous +
3 HCT116 p21-/- Endogenous -
4 HCT116 p21-/- Endogenous +
5 HCT116 wild type V5-Chk1 WT -
6 HCT116 wild type V5-Chk1 WT +
7 HCT116 p21-/- V5-Chk1 WT -
















+ + + +- - - - (Aphidicolin)
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F igu re 4.7 I mmunop recipitation of endogenous or exogenous C h k1 p rotein f rom H C T116
wild-type and H C T116 p21-/- cells.
(A) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluency before transfected
with C-terminally V5-tagged Chk1 wild-type or mock-transfected with empty vector. After 24
hrs, the cells were either treated with 20 +M aphidicolin or ethanol for 4 hours. 1 mg of lysate
was used for Chk1 immunoprecipitation using either sheep --Chk1 IgG or mouse --V5 tag
IgG and Protein G sepharose beads. Unbound proteins were washed off before bound proteins
were eluted off the IgG-beads with SDS-sample buffer. The immunoprecipitated proteins were
resolved by 10% SDS-PAGE before transferred to nitrocellulose membrane. Chk1 protein was
detected using either mouse --Chk1 IgG or sheep --Chk1 IgG. (B) HCT116 WT cells were
transfected with C-terminally V5-tagged Chk1 wild-type or mock-transfected with empty
vector. 1 mg of lysate was then used for Chk1 immunoprecipitation using either sheep --Chk1
IgG or mouse --V5 tag IgG and Protein G sepharose beads. The immunoprecipitated proteins
were resolved by 10% SDS-PAGE before transferred to nitrocellulose membrane. Ig light
chains and heavy chains were detected using rabbit --mouse secondary IgG (left panel) or
rabbit --sheep secondary IgG (right panel).
Immunoblot with 
sheep <-chk1 IgG
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+ -
(Peptide)
HCT116 WT HCT116 p21
-/-
A
F igu re 4.8 I mmunop recipitation-kinase assay of endogenous C h k1 p roteins f rom
H C T 116 wild-type and H C T116 p21-/- cells.
(A and B) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluency before
mock-transfected with empty vector. After 24 hrs, the cells were either treated with 20 +M
aphidicolin or ethanol for 4 hours. The cells were harvested and lysed. 1 mg of lysate was used
for Chk1 immunoprecipitation-kinase using either sheep --Chk1 IgG or mouse --V5 tag IgG
and Protein G sepharose beads. Unbound proteins were washed off. Kinase reactions
containing 0.2 mM of Chktide with or without 5 +g of p21 peptide 4 (P) or Chk1 peptide 14
(C) in the presence of [,32P]-ATP were assembled with the immunoprecipitated sample. The
reaction products were resolved by 15% SDS-PAGE. [,32P] incorporation into Chktide was
visualised by autoradiography and quantified by phosphorimager.
[(32P] Chktide
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F igu re 4.9 I mmunop recipitation-kinase assay of exogenous V 5- C h k1 p roteins f rom
H C T 116 wild-type and H C T116 p21-/- cells.
(A and B) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluency before
transfected with C-terminally V5-tagged Chk1 wild-type. After 24 hrs, the cells were either
treated with 20 +M aphidicolin or ethanol for 4 hours. The cells were harvested and lysed. 1
mg of lysate was used for Chk1 immunoprecipitation-kinase using either sheep --Chk1 IgG or
mouse --V5 tag IgG and Protein G sepharose beads. Unbound proteins were washed off.
Kinase reactions containing 0.2 mM of Chktide with or without 5 +g of p21 peptide 4 (P) or
Chk1 peptide 14 (C) in the presence of [,32P]-ATP were assembled with the
immunoprecipitated sample. The reaction products were resolved by 15% SDS-PAGE. [,32P]























F igu re 4.10 C h k1 autophosphor ylation was not detected in H C T116 wild-type C h k1 IP-
kinase assay.
(A) HCT116 WT cells were grown to >90% confluency before transfected with C-terminally
V5-tagged Chk1 wild-type. After 24 hrs, the cells were either treated with 20 +M aphidicolin
or ethanol for 4 hours. The cells were harvested and lysed. 1 mg of lysate was used for Chk1
immunoprecipitation using mouse --V5 tag IgG and Protein G sepharose beads. Unbound
proteins were washed off. Kinase reactions containing 0.2 mM of Chktide and unlabelled ATP
were assembled with the immunoprecipitated sample. The reaction products were resolved by
10% SDS-PAGE before transferred to nitrocellulose membrane. Chk1 protein was detected
























F igu re 4.11 Schematic diagr am of C h k1 wild-type and mutants.
(A) Schematic diagram of full-length Chk1 wild-type (WT), Chk1 ./&012#3317/345) mutant and
Chk1 4570 mutant where the last 70 amino acids from the C-terminal end is deleted.
A
F igu re 4.12 Pu r ification of recombinant human insect-cell exp r essed C h k1 W T and
mutants.
(A) His-tagged Chk1 wild-type (WT) and mutants were expressed in Sf9 insect cell system
and purified from the Ni-NTA agarose column. Fractions from the Ni-NTA agarose column
were analysed on a 10% SDS-PAGE gel stained by coomassie brilliant blue or subjected to --
Chk1 IgG immunoblot. Lanes: 1, uninfected cell lysate; 2, infected cell lysate; 3, Flow-through
fraction; 4, Wash I fraction; 5, Wash II fraction; 6, Wash III fraction; 7, Eluted fraction. Dotted
circle indicates Chk1 WT. (B) Immunoblot analysis of Sf9-expressed Chk1 WT and Chk1
./&012#3317/345) phosphorylation status. Titrating amounts of Chk1 were resolved in 10%
SDS-PAGE and transferred to nitrocellulose. Phosphorylation was detected using --Chk1


























F# 0 0.2 0.5 1 2
Chk1 WT (R.L.U) 0.0905 30.725 57.93 71.48 101.3
=>?@%A:72B-#4317/345) (R.L.U) 0.0882 23.16 59.73 95.53 129.3
=>?@%C=DE%AGHIHJK 0.0664 13.6 24.825 45.735 70.485
A














L Thus, using the equation,
MNHN)%AGHIHJK%"&%=>?@%A:72B-#4317/345) = 153 ng
L 1 Fl of Chk1 WT = 50 ng,
F igu re 4.13 Normalisation of H is-tagged full length C h k1 W T and C h k1 mutants.
(A) The concentration of His-tagged full length Chk1 WT and Chk1 mutants were normalised
using the ELISA assay as described in the Materials and Methods. The relative light units
values obtained for Kudos Chk1 WT were computed to construct a XY scatter plot. From the
plot, an equation is derived and used to calculate the concentration for Chk1 WT and Chk1
mutants. Calculations were written above.
A
F igu re 4.14 Recombinant human C h k1 kinase activity can be enhanced by a C -te r minal
70 amino acid deletion but not affected by mutation at A T R phosphor ylation sites.
(A) Kinase reactions containing 1 +g of p21 and [,32P]-ATP with or without 20 +M DBH were
assembled in the presence of 100 ng of Chk1 WT or Chk1 ./&012#3317/345) or Chk1 (4570).
DBH was dissolved in DMSO. The reaction products were resolved by 12% SDS-PAGE and



































Set 1 1.43 512.4 27884.30 19458.68
Set 2 1.82 457.6 24902.13 13659.97
Set 3 1.96 361.4 19667.03 10018.86
Average 1.74 443.80 24151.2 14379.2
Standard Deviation 0.27 76.44 4159.8 4760.8
F igu re 4.15 K inetic constants for recombinant human C h k1 wild-type and mutants with
respect to recombinant human p21.
(A) Kinetics data of Chk1 WT and mutants. Kinase reaction containing Chk1 WT or mutants
and full length p21 in the range of 0.28 +M to 8.83 +M were assembled in the presence of
[,32P]ATP. The reaction products were resolved on 12% SDS-PAGE and [,32P] incorporation
into p21 was quantified by phosphorimager. The Michaelis-Menten parameters were fitted via
the Hanes plot using hyperbolic regression software (Hyper,version 1.1s, J. Easterby,











Set 1 1.88 450.1 24479.59 13048.82
Set 2 1.74 244.5 13297.62 7633.54
Set 3 1.45 228.0 12400.24 8557.79
Average 1.69 307.53 16725.8 9746.7









Set 1 6.08 784.7 36355.15 5979.47
Set 2 10.10 823.6 38157.39 3777.96
Set 3 9.04 1713.0 79363.29 8775.24
Average 8.41 1107.10 51291.9 6177.6


















































F igu re 4.16 Recombinant human C h k1 !"70 is r ef r actor y to the effect of the activating
peptides.
(A) Kinase reactions containing 1 +g of p21 and titration of Chk1 WT or mutants
./&012#3317/345 or 4570) (12 to 120 ng) with or without 5 +g of p21 peptide 4 or Chk1 peptide
4 were assembled. The reaction products were resolved in 12% SDS-PAGE and [,32P]









Set 1 3.13 338.50 18416.76 5876.44
Set 2 3.29 225.80 13917.30 4228.90
Set 3 3.12 328.10 17850.92 5723.28
Set 4 2.69 674.80 36713.82 13668.59
Average 3.06 399.30 21721.70 7374.30
Standard Deviation 0.26 187.31 10191.14 4261.50
F igu re 4.17 K inetic constants for r ecombinant human C h k1 wild-type in the p resence of
peptides with respect to recombinant human p21.
(A) Kinetics data of Chk1 wild-type in the presence of p21 peptide 4 and Chk1 peptide 14.
Kinase reaction containing 100 ng/+l of Chk1 and full length p21 in the range of 0.28 to 8.83
+M and 5 +g of peptide were assembled in the presence of [,32P]ATP. The reaction products
were resolved on 12% SDS-PAGE and [,32P] incorporation into p21 was quantified by
phosphorimager. The Michaelis-Menten parameters were fitted via the Hanes plot using
hyperbolic regression software (Hyper,version 1.1s, J. Easterby, University of Liverpool) and
kinetic constants were calculated as the mean 6 standard deviation.
A










Set 1 5.00 212.70 11572.36 2315.86
Set 2 5.67 470.80 25614.80 4517.40
Set 3 4.92 917.30 49907.51 10154.12
Average 5.19 533.60 29031.56 5662.79
Standard Deviation 0.41 356.47 19394.63 4042.50








Set 1 0.75 196.20 10674.65 14215.80
Set 2 1.54 215.60 11730.14 7621.92
Set 3 1.52 302.50 16458.11 10863.44
Set 4 0.44 538.00 29270.95 66193.91
Average 1.06 313.08 17033.46 24723.77












F igu re 4.18 Non-denatu r ing gel elect rophoresis of peptides and C h k1 binding assay.
(A) Kinase reactions containing 100 ng of Chk1 WT and 5 +g of Chk1 peptide 14 were
assembled in the presence or absence of unlabelled ATP. The reactions were stopped by
addition of sample buffer (without SDS/DTT) before resolved by 10% or 15% non-denaturing
PAGE (without SDS) and transferred to nitrocellulose membrane. Biotinylated Chk1 peptide
14 was detected with HRP-conjugated streptavidin whilst Chk1 protein was detected using --
Chk1 IgG. (B) Kinase reactions containing 100 ng of Chk1 4570 and 5 +g of p21 peptide 4
were assembled in the presence or absence of unlabelled ATP. The reactions were stopped by
addition of sample buffer (without SDS/DTT) before resolved by 10% or 12% non-denaturing
PAGE (without SDS) and transferred to nitrocellulose membrane. Biotinylated p21 peptide 4



































F igu re 4.19 Schematic diagr am of chick C h k1 mutants.
(A) Schematic diagram of chick Chk1 wild-type, Chk1 4576 mutant, Chk1 45166 mutant and
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F igu re 4.20 p21 peptide 4 and C h k1 peptide 14 dissociates the int r a-molecula r inte r action
between chick C h k1 N-ter minal domain and C -ter minal domain.
(A) Cos1 cells were co-transfected with chick Chk1 4576 and chick Chk1 C-terminal domain
or chick Chk1 45166 and chick Chk1 C-terminal domain for 24 hrs. The cells were harvested
and lysed. 1 mg of lysate was subjected to Chk1 immunoprecipitation with --chick C-terminal
Chk1 IgG. Kinase reactions containing 5 +g of either p21 peptide 4 or Chk1 peptide 14 were
assembled with Chk1 immunoprecipitated sample in the presence of unlabelled ATP. The
reaction products were resolved by 10% SDS-PAGE and transferred to nitrocellulose
membrane. Chk1 protein was detected using --N-terminal Chk1 IgG. (B) Cos1 cells were co-
transfected with chick Chk1 4576 and chick Chk1 C-terminal domain or chick Chk1 45166
and chick Chk1 C-terminal domain. As control, Cos1 cells were transfected with chick Chk1
C-terminal domain or chick Chk1 45166 alone. The cells were harvested and lysed. 1 mg of
lysate was subjected to Chk1 immunoprecipitation with --chick C-terminal Chk1 IgG. Kinase
reactions containing 0.2 mM of Chktide and either p21 peptide 4 or Chk1 peptide 14 or DMSO
were assembled with Chk1 immunoprecipitated sample in the presence of [,32P]-ATP. The






































F igu re 4.21 Schematic diagr am of C h k1 mutant #$%&'()*192/208).
(A) Amino acids sequence of Chk1 -F region. Residues in red are conserved across the species


















F igu re 4.22 Pu r ification of recombinant human insect-cell exp r essed C h k1 mutant
#$%&'()*192/208).
(A) His-tagged Chk1 mutant was expressed in Sf9 insect cell system and purified from Ni-
NTA agarose column. Fractions from the Ni-NTA agarose column were resolved on a 10%
SDS-PAGE gel before transferring to nitrocellulose membrane and immunoblotted with --
Chk1 IgG. The left panel shows immunoblot of Chk1 WT purification and the right panel
shows immunoblot of Chk1 mutant .70)12#3192/208) with the full-length Chk1 and truncated
Chk1 circled respectively. Lane: 1, Flow-through fraction; 2, wash fraction I; 3, wash fraction
II; 4, wash fraction III; 5, eluted fraction.
A
F igure 4.23 M utation of C hk1 #$%&'()*192/208) render susceptibility to cleavage.
(A) Chk1 mutant .70)12#3192/208)-infected Sf9 insect cells were lysed directly with SDS-
sample buffer before a titrating amount of lysate (10 +l to 200 +l) were resolved in 10% SDS-
PAGE gel and transferred to nitrocellulose membrane. Total Chk1 level was detected using --
Chk1 IgG. (B) Chk1 .70)12#3192/208) is purified from Sf9 insect cells before loaded onto a gel
filtration column Superdex 200 (Amersham Bioscience). 10 +l of the fractions were resolved
in a 10% SDS-PAGE and transferred to nitrocellulose membrane. Total Chk1 level was
detected using --Chk1 IgG.





















F igu re 4.24 I mmunoblot of exogenous C h k1 p rotein f rom H C T116 wild-type or p21-/-
cells (+/- aphidicolin t reatment).
(A) HCT116 WT and HCT116 p21-/- cells were grown to >90% confluence before transfected
with C-terminally V5-tagged Chk1 wild-type or V5-tagged Chk1 .70)12#3192/208). After 24
hrs, the cells were either treated with 20 +M aphidicolin or ethanol as control for 4 hrs. The
cells were harvested and 50 +g of whole cell lysates were resolved by 10% SDS-PAGE before
transferred to nitrocellulose membranes. Chk1 protein was detected using mouse --Chk1 IgG
and exogenous V5-tagged Chk1 protein was detected using mouse --V5 tag IgG.
<-Chk1 IgG
<-V5 IgG




++ + +- - - - (Aphidicolin)
V5-=>?@%A.23B-#4192/208)
Lane Cell line V5-Chk1 Aphidicolin treatment
1 HCT116 wild type V5-Chk1 WT -
2 HCT116 wild type V5-=>?@%A.23B-#4192/208) -
3 HCT116 wild type V5-Chk1 WT +
4 HCT116 wild type V5-=>?@%A.23B-#4192/208) +
5 HCT116 p21-/- V5-Chk1 WT -
6 HCT116 p21-/- V5-=>?@%A.23B-#4192/208) -
7 HCT116 p21-/- V5-Chk1 WT +
8 HCT116 p21-/- V5-=>?@%A.23B-#4192/208) +
A
F igure 4.25 I mmunoprecipitation-kinase assay of exogenous V5- C hk1 W T or V5- C hk1
#$%&'()*192/208) mutant p roteins f rom H C T116 wild-type cells.
(A and B) HCT116 WT cells were grown to >90% confluency before transfected with C-
terminally V5-tagged Chk1 wild-type (W) or Chk1 .70)12#3192/208) (M). After 24 hrs, the
cells were either treated with 20 +M aphidicolin or ethanol as control for 4 hours. The cells
were harvested and lysed. 1 mg of lysate was used for Chk1 immunoprecipitation-kinase using
mouse --V5 tag IgG and Protein G sepharose beads. Unbound proteins were washed off.
Kinase reactions containing 0.2 mM of Chktide with or without 5 +g of p21 peptide 4 or Chk1
peptide 14 in the presence of [,32P]-ATP were assembled with immunoprecipitated sample.
The reaction products were resolved by 15% SDS-PAGE. [,32P] incorporation into Chktide
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M WT WTM M
p21 peptide 4 Chk1 peptide 14
HCT116 wild-type
[(32P] Chktide
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Hematopoietic lineage cell-specific protein_HumanPENDYEDVE20
DNA topoisomerase 2_YeastLSGESDLEI19
Protein phosphatase 1 regulatory subunit 1B_BovinLSEHSSPEE18
Tyrosine-protein phosphatase non-receptor type 12_HumanLRRLSTKYR17
Pyruvate kinase isozymes R/L_RatLRRASVAQL16
Epidermal growth factor receptor [Precursor]_HumanLQRYSSDPT15




RAF proto-oncogene serine/threonine-protein kinase_HumanKSRWSGSQQ10
Insulin receptor substrate 1_RatKSLNYIDLD9
Glutamate [NMDA] receptor subunit zeta-1 [Precursor]_HumanKRRRSSKDT8
Plasma membrane calcium-transporting ATPase 1_HumanKRNSSPPPS7
Histone H2B type 1-C/E/F/G/I_HumanKRKRSRKES6
Glycogen phosphorylase, muscle form_HumanKRKQISVRG5
Glycogen phosphorylase, muscle form_HumanKRKQISVR4
Protein phosphatase 1 regulatory subunit 3A_RabbitKPGFSPQPS3
Eukaryotic translation initiation factor 4E_HumanKNDKSKTWQ2
Signal transducer and activator of transcription 1-alpha/beta_HumanKGTGYIKTE1
Target ProteinSequenceS/N
F igu re 4.27 L ist of peptide sequences phosphor ylated by stimulated C h k1 exclusively in
the peptide microa r r ay.
(A) Table listing the peptides (and its sequences) which are phosphorylated exclusively by
Chk1 docking peptide-stimulated Chk1.
A
A
F igu re 4.28 L ist of peptide sequences selected for fu rther kinase assays.
(A) Biotinylated peptides were synthesised with a 8GG- spacer. Peptide 1 to 7 were identified
in the peptide microarray that were phosphorylated by Chk1 WT stimulated with Chk1 peptide
14 or Chk1 4570. Peptide 8 to 10 are human forms of peptide 2, 5 and 7 respectively whereas
peptide 11 and 12 are readily phosphorylated by all three forms of Chk1 used in the peptide
microarray. Peptide 13 is the human form of peptide 12.
(-aminobutyric acid receptor subunit (-2 (Precursor)_HumanLYQFSFVGL13
(-aminobutyric acid receptor subunit (-2 (Precursor)_BovinLRMFSFKAP12
Nitric Oxide synthase, brain_RatKRFGSKAHM11
Microtubule-associated protein Tau_HumanPAPKTPPSS10




Insulin receptor substrate 1_RatKSLNYIDLD5
MAP kinase-activated protein kinase 2_RabbitKVPQTPLHT4





F igu re 4.29 Recombinant human C h k1 activity towa r ds peptide subst r ates can be
modulated by stimulator y C h k1 peptide 14.
(A) Kinase reactions containing 100 ng of Chk1 and 0.5 +g of peptide as listed in Figure 4.17
were assembled in the presence of [,32P]-ATP with or without 5 +g of Chk1 peptide 14. The
reaction products were resolved by 12% SDS-PAGE and [,32P] incorporation into the peptides

























Chk1 WT + Chk1 
peptide 14









F igu re 4.30 Recombinant human C h k1 is active towa r ds recombinant human Inte r leu kin
1+ but not recombinant human S T A T1.
(A) Kinase reactions containing 100 ng of Chk1 WT and titration of interleukin 1- (1 to 3 ng)
were assembled in the presence of [,32P]ATP. The reaction products were resolved in 12%
SDS-PAGE. [,32P] incorporation was visualised by autoradiography. (B) Kinase reactions
containing 100 ng of Chk1 WT and titration of STAT1 (1 to 3 +g) were assembled in the
presence of [,32P]ATP. The reaction products were resolved in 10% SDS-PAGE. [,32P]
incorporation was visualised by autoradiography.
B
1 2 3 4
















F igu re 4.31 Stimulated C h k1 is not active towa r ds recombinant human S T A T1.
(A and B) Kinase reactions containing 2 ng of Interleukin 1- or 2 +g of STAT1 and 100 ng of
Chk1 with or without Chk1 peptide 14 in the presence of [,32P]ATP. The reaction products








F igu re 4.32 Sequence alignment identified a potential C h k1 pseudosubst r ate region.
(A) Pseudosubstrate region often fits the substrate consensus sequence with a non-
phosphorylatable residue in place of Ser/Thr/Tyr. Sequence alignment of p21 phosphorylation
motif (Ser146 was replaced with Ala) with full-length Chk1 has identified a potential
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Chk1 peptide (a.a 406-420)
[(32P]-Chk1 peptide (a.a 406-420)
A
F igu re 4.33 C h k1 autophosphor ylation in the C -ter minus end
(A) Kinase reactions containing 100 ng of Chk1 and a titration of Chk1 peptide (a.a 406-420)
(0.625 to 20 +g) were assembled for [,32P]-ATP kinase assay. The reaction products were
resolved by 15% SDS-PAGE. [,32P] incorporation into Chk1 peptide (a.a 406-420) was
visualised by autoradiograhpy and quantified by phosphorimager. (B) Sequence of Chk1
autophosphorylation peptide (amino acids 406-420). Mass spectrometry data have suggested





F igu re 4.34 Loss of autoinhibitor y region and alloster ic activation result in C h k1
subst r ate specificity change.
Sequences of peptides phosphorylated by Chk1 were fed into WebLogo program (University
of California, Berkeley) to generate consensus sequence logos. (A) Consensus sequence of
substrate peptides phosphorylated by Chk1 wild-type protein. (B) Consensus sequence of
substrate peptides phosphorylated only by Chk1 wild-type protein allosterically activated by
Chk1 peptide 14. (C) Consensus sequence of substrate peptides phosphorylated only by Chk1
!"70.
B
Chk1 WT substrate specificity
Change in allostercially activated Chk1 WT substrate specificity
C
!"#$%&'($'!")*'+!,-'./0.12#1&'.3&4(5(4(16
     
CHAPTER 5: CONCLUSIONS AND FUTURE 
PERSPECTIVES             
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5.1 Regulation of Chk1 enzymatic mechanism 
In this thesis, a p21 N-terminal region (p21 peptide 4) was identified to have an 
allosteric activating effect on Chk1 catalytic activity and also activated Chk1 to be 
a more efficient enzyme. Further studies showed that peptidomimetic ligands 
based on the Chk1 docking site from p21 was able to restore Chk1 catalytic 
activity towards a p21 mutant protein with an N-terminal domain deletion. This 
suggested that the peptide 4 region of p21 could function as an allosteric docking 
site for Chk1 substrate recognition. Indeed, protein kinases often recognise their 
substrates through interactions in regions distinct to the active site, in addition to a 
consensus substrate sequence (Remenyi et al., 2006, Goldsmith et al., 2007). 
These interactions involved linear docking motifs and are usually transient and 
weak (Neduva and Russell, 2005). Peptide binding assays revealed that p21 
peptide 4 bound to Chk1 protein kinase and this interaction appeared to be ATP-
dependent. Mutational analysis also identified critical residues in the p21 peptide 4 






. Interestingly, a F 
region of the Chk1 N-terminal domain has been identified to share homology with 
p21 peptide 4. Similarly, peptidomimetic ligands based on this region (Chk1 
peptide 14 and 32) were able to allosterically activate Chk1 catalytic activity. 




residues is thought to destabilise the 
kinase domain, generating a Chk1 (Trp Ala
192/208
) mutant that is refractory to the 
stimulating effects of the activating peptides (p21 peptide 4 and Chk1 peptide 14).  
Chk1 N-terminal kinase domain is constitutively active, exhibiting 20-fold more 
catalytic activity than full-length Chk1 in vitro, suggesting that the C-terminal 
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domain function to negatively regulate Chk1 activity in an autoinhibition model 
(Chen et al., 2000). Chk1 N-terminal domain and C-terminal domain has already 
been shown to interact intramolecularly (Katsuragi and Sagata, 2004). 
Intramolecular interactions between the catalytic domain and regulatory domain 
often mediate inhibition of catalytic activity by directly blocking substrate binding 
to the active site due to the presence of a pseudosubstrate or by allosterically 
inducing an inactive conformation (Huse and Kuriyan, 2002). In collaboration 
with Prof David Gillespie s group, we have shown that activating peptides were 
able to disrupt the intramolecular interaction between the chick Chk1 N-terminal 
domain and the C-terminal domain. Interestingly, a Chk1 C70 mutant where the 
last 70 amino acids of the C-terminal domain were deleted proved to be refractory 
to the stimulating effects of the activating peptides. However the last 70 amino 
acids of the C-terminal domain (C70) by itself do not mediate intramolecular 
interaction with the Chk1 N-terminal domain (MT Scott, personal communication), 
implying that the intramolecular binding interface is outwith C70 and the 
activating peptides do not function to displace C70 directly. The fact that C70 is 
required for autoinhibition suggested that the activating peptides mediate its 
allosteric stimulation effects on the displacement of C70 through unknown 
mechanism; Several questions were left unanswered and several new questions 
were raised as result of this study;- 
1. How do the last 70 amino acids of Chk1 C-terminal domain function in 
autoinhibition? 
2. Do the last 70 amino acids of Chk1 contain a pseudosubstrate? Sequence 
alignment has identified a potential Chk1 pseudosubstrate outside the last 
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70 amino acids (Figure 4.32), though it is still possible that the last 70 
amino acids harbour a potential pseudosubstrate. 
3. Where is the activating peptide docking interface and how do the activating 
peptides allosterically induce a conformational change of the last 70 amino 
acids to activate Chk1 catalytic activity? 
4. Chk1 undergoes autophosphorylation in the regulatory C-terminus end. 
Mass spectrometry data has suggested that one of the major phospho-
acceptor sites resides at Ser
407 
(data not shown). However it is not clear 
what effect autophosphorylation has on Chk1 enzymatic regulation? 
5. Is the C-terminal domain essential to the activity and/or function of Chk1? 
It has been shown recently that S.pombe Chk1 C-terminal domain contains 
both autoinhibitory and activating signal necessary for the function of 
Chk1 (Kosoy and O'Connell, 2008). Given the high degree of conservation 
in some regions of the C-terminal between S.pombe Chk1 and human Chk1, 
it is possible that human Chk1 could share similar mode of regulatory 
mechanism conferred by the C-terminal domain.  
Based on the existing data, I proposed the following hypothetical model. Chk1 
catalytic activity is autoinhibited through weak intramolecular interaction between 
the C-terminal regulatory domain and a pseudo-docking site ( F region) at the N-
terminal kinase domain. This autoinhibition requires the presence of the last 70 
amino acids of the C-terminal domain (C70) which is not involved in 
intramolecular interaction. In the response to DNA damage, Chk1 undergoes 




. This phosphorylation event 
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positively regulates Chk1 localisation and activating ligands/substrates binding. 
Activation of Chk1 protein kinase is mediated by binding to an activating 
ligand/substrate that contains a high-affinity pseudo-docking site. This high-
affinity intermolecular interaction disrupts the low-affinity intramolecular 
interaction and allosterically affects the displacement of C70 from the N-terminal 
kinase domain, resulting in an active conformation. Autophosphorylation of C70 
at Ser
407 
and other possible sites stabilises this active conformation (Figure 5.1).  
To gain valuable insight to the mechanistic basis of Chk1 allosteric activation and 
Chk1 C-terminal regulatory action, it is necessary to conduct biophysical studies 
such as NMR and more biochemical studies to ascertain the intramolecular 
interface and how allosteric regulation affects Chk1 conformational change and 
catalytic activity. Current Chk1 inhibitors studied are targeted towards the ATP-
binding site (Tse et al., 2007). However these inhibitors must compete with the 
high intracellular ATP concentrations and also differentiate between the ATP-
binding site of different protein kinases (Bogoyevitch et al., 2005). By elucidating 
the allosteric regulation mechanism, we can then design better non-ATP binding 
small-molecule inhibitors by stabilising the native autoinhibited conformation of 
Chk1 protein kinase.      
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5.2 Identifying more novel Chk1 substrates 
Chk1 is a major player in checkpoint arrest and identifying novel Chk1 substrates 
will help to further delineate checkpoint signalling pathways. In chapter 3, Chk1 
was shown to phosphorylate p21 at Ser
146 
in vitro. However more in vivo studies 
are required to confirm p21 is a novel substrate for Chk1. In chapter 4, I asked 
whether allosteric activation by the peptidomimetic ligand is able to change Chk1 
substrate specificity or modulate its activity towards substrates that do not contain 
the Chk1 consensus phosphorylation motif, Rxx(S/T). Using the PepChip 
microarray, it was shown that allosteric activated Chk1 was able to target 24 
peptide substrates not recognised by the non-allosteric activated Chk1 and Chk1 
C70 mutant protein. In contrast, further characterisation of allosteric activated 
Chk1 activity towards selected peptide substrates and STAT1 protein suggested 
that allosteric activation does not alter Chk1 substrate specificity. However it is 
still possible that allosteric regulation is required for Chk1 activity towards a 
substrate that does not contain the Chk1 consensus phosphorylation motif. Indeed 
it has been highlighted that Chk1 phosphorylates p53 Ser
20 
in vitro (Shieh et al., 
2000) and sequences around Ser
20 
(ETFSD) do not fit the Rxx(S/T) motif.  
Nevertheless the PepChip microarray does provide a useful proteomic screen for 
potential novel Chk1 substrates. Chk1 was shown in Chapter 4 to target human 
interleukin-1 protein. Interleukin-1 is a cytokine secreted by monocytes and 
macrophages and is involved in many immune responses such as inflammation 
(Dinarello, 1994). In vitro study has shown that the precursor form of interleukin-
1 is phosphorylated at Ser
90 
by an unknown kinase (Beuscher et al., 1988). 
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Sequences around interleukin-1 Ser
90 
fit within the RxxS motif and thus Chk1 
could be the protein kinase responsible for interkeukin-1 modification. 
Preliminary data from the Ball lab also indicated that Chk1 could target Interferon 
Regulatory Factor 1 (IRF1) as a substrate. Mass spectrometry and phospho-
antibodies data showed that Chk1 phosphorylated IRF1 at Ser
317 
(Figure 5.2A). 
Interestingly, sequences around IRF Ser
317 
fit within the RxxS motif (Figure 5.2B). 
Thus, IRF1 could also form as a potential novel Chk1 substrate in vivo. To identify 
more novel Chk1 substrates which do not conform to the RxxS motif, we can 
transfect mammalian cells with activating peptide to allosterically activate Chk1 
and look for changes in the phosphoproteome profile using mass spectrometry 
analysis.  
Identification of a novel phosphorylation site from in vitro/in vivo studies is 
dependent on a specific protein kinase signalling pathway, but does not provide 
definitive proof that the protein kinase phosphorylates a substrate directly in vivo 
(Berwick and Tavare, 2004). A chemical genetics approach developed by the 
Shokat lab that relies on engineering a protein kinase to accept non-natural 
synthetic ATP analogue could overcome this problem (Liu et al., 1998). The ATP 
analogue is cell permeable and can be used to label substrates targeted by the 
engineered protein kinase. Moreover attachment of ATP analogue to substrates 
means that it cannot be removed by phosphatases. Modification and optimisation 
of this technique has helped to identify many novel substrates for Cdk1-cyclin B 
and ERK (Eblen et al., 2003, Blethrow et al., 2008). So it could be possible to 










F igure 5.1 Schematic model of C hk1 autoinhibition and alloster ic activation.
(A) (Upper) The C-terminal regulatory domain autoinhibited the N-terminal kinase domain
through intramolecular interaction. The regulatory domain binds to a pseudo-docking site (blue
cylinder tube) within the kinase domain and brings C70 to a close proximity with the kinase
domain for autoinhibition. (Lower) Phosphorylation of Chk1 Ser317 and Ser345 regulates Chk1
localisation and activating ligand/substrate binding. The autoinhibitory intramolecular
interaction is disrupted by high-affinity intermolecular interaction between the Chk1 regulatory
domain and the docking site of activating ligand/substrate (yellow cylinder tube). This results
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A
F igu re 5.2 C h k1 phosphor ylates I R F 1 at Ser317 in vitro
(A) Kinase reactions containing 100 ng of Chk1 and 350 ng of GST-tagged IRF1 with/without
p21 peptide 4 (P) or Chk1 peptide 4 (C) were assembled for !"#$%& ATP kinase assay. The
reaction products were resolved by 10% SDS-PAGE before transferred to nitrocellulose
membrane. Phosphorylation was detected using sheep '-IRF phospho-Ser317 IgG and total
IRF1 was detected using mouse '-IRF1 IgG. (B) Sequences around IRF1 Ser317.
B
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312 320
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Appendix 1
List of peptides phosphorylated by Chk1 wild-type protein kinase
S/N COL ROW SEQUENCE TARGET PROTEIN
1 2 11 KKLGSKKPQ SWISS;P04775;CIN2_RAT
2 11 5 KKRLSVERI SWISS;P11388;TOPA_HUMAN
3 7 7 KNIVTPRTP SWISS;P02687;MBP_BOVIN
4 5 9 KREASLDNQ SWISS;P06593;PHY3_AVESA
5 5 13 KRFGSKAHM SWISS;P29476;NOS1_RAT
6 1 7 KRPSARAKA SWISS;P02687;MBP_BOVIN
7 1 11 KRPSDRAKA SWISS;P02687;MBP_BOVIN
8 1 15 KRPSERAKA SWISS;P02687;MBP_BOVIN
9 10 5 KRPSGRAKA SWISS;P02687;MBP_BOVIN
10 10 9 KRPTQRAKY SWISS;P02687;MBP_BOVIN
11 8 6 KRRGSVPIL SWISS;P16452;42_HUMAN
12 8 10 KRRLSFSET SWISS;P01582;IL1A_MOUSE
13 12 12 KRSGSVYEP SWISS;P12798;KPBB_RABIT
14 9 5 KYRKSSLKS SWISS;P22613;STP1_SHEEP
15 1 14 LQDDYEDMM SWISS;P02730;B3AT_HUMAN
16 5 8 LRAPSWIDT SWISS;P02510;CRAB_BOVIN
17 5 12 LRGPSWDPF SWISS;P04792;HS27_HUMAN
18 8 1 LRKVSKQEE SWISS;P50552;VASP_HUMAN
19 8 5 LRMFSFKAP SWISS;P22300;GAC2_BOVIN
20 8 9 LRRASLGAA BOS TAURUS (BOVINE) LIVER PYRUVATE KINASE (FRAGMENT)
21 1 8 RTKRSGSV phosphorylase b kinase beta regulatory chain
Peptide targeted by all three forms of Chk1 
Peptide targeted by Chk1 wild-type and Chk1 stimulated by Chk1 peptide 14
Peptide targeted by Chk1 stimulated by Chk1 peptide 14 and Chk1 C70
Appendix 1
List of peptides phosphorylated by Chk1 peptide 14-stimulated Chk1 protein kinase
S/N COL ROW SEQUENCE TARGET PROTEIN
1 8 15 KGTGYIKTE SWISS;P42224;STA1_HUMAN
2 2 11 KKLGSKKPQ SWISS;P04775;CIN2_RAT
3 11 5 KKRLSVERI SWISS;P11388;TOPA_HUMAN
4 9 14 KNDKSKTWQ SWISS;P06730;IF4E_HUMAN
5 7 7 KNIVTPRTP SWISS;P02687;MBP_BOVIN
6 7 11 KPGFSPQPS SWISS;Q00756;PPR3A_RABIT
7 5 9 KREASLDNQ SWISS;P06593;PHY3_AVESA
8 5 13 KRFGSKAHM SWISS;P29476;NOS1_RAT
9 7 12 KRKQISVR SWISS;P11217;PHS2_HUMAN
10 3 6 KRKQISVRG SWISS;P11217;PHS2_HUMAN
11 3 10 KRKRSRKES SWISS;P02278;H2B_HUMAN
12 1 3 KRNSSPPPS SWISS;P20020;ATCP_HUMAN
13 1 7 KRPSARAKA SWISS;P02687;MBP_BOVIN
14 1 11 KRPSDRAKA SWISS;P02687;MBP_BOVIN
15 1 15 KRPSERAKA SWISS;P02687;MBP_BOVIN
16 10 1 KRPSFRAKA SWISS;P02687;MBP_BOVIN
17 10 5 KRPSGRAKA SWISS;P02687;MBP_BOVIN
18 10 9 KRPTQRAKY SWISS;P02687;MBP_BOVIN
19 8 6 KRRGSVPIL SWISS;P16452;42_HUMAN
20 8 10 KRRLSFSET SWISS;P01582;IL1A_MOUSE
21 12 4 KRRRSSKDT SWISS;Q05586;P35437;NMZ1_HUMAN
22 12 12 KRSGSVYEP SWISS;P12798;KPBB_RABIT
23 4 13 KSLNYIDLD SWISS;P35570;IRS1_RAT
24 2 10 KSRWSGSQQ SWISS;P04049;KRAF_HUMAN
25 2 14 KTETSQVAP SWISS;P02699;OPSD_BOVIN
26 6 8 KTSPSSSPA SWISS;P19836;CTPT_RAT
27 6 16 KVPQTPLHT SWISS;P49139;MKK2_RABIT
28 9 5 KYRKSSLKS SWISS;P22613;STP1_SHEEP
29 9 13 LDDQYTSSS SWISS;P24604;TEC_MOUSE
30 7 14 LGGGTFDIS SWISS;P04475;DNAK_ECOLI
31 5 10 LGSPLRRR SWISS;P20152;VIME_MOUSE
32 11 8 LKLASPELE SWISS;P05412;AP1_HUMAN
33 11 12 LLPMSPEEF SWISS;P42224;STA1_HUMAN
34 3 5 LMAPSEEDH SWISS;P08833;IBP1_HUMAN
35 1 14 LQDDYEDMM SWISS;P02730;B3AT_HUMAN
36 1 4 LQRYSSDPT SWISS;P00533;P06268;EGFR_HUMAN
37 5 8 LRAPSWIDT SWISS;P02510;CRAB_BOVIN
38 5 12 LRGPSWDPF SWISS;P04792;HS27_HUMAN
39 8 1 LRKVSKQEE SWISS;P50552;VASP_HUMAN
40 8 5 LRMFSFKAP SWISS;P22300;GAC2_BOVIN
41 8 9 LRRASLGAA BOS TAURUS (BOVINE) LIVER PYRUVATE KINASE (FRAGMENT)
42 8 13 LRRASLGAF BOS TAURUS (BOVINE) LIVER PYRUVATE KINASE (FRAGMENT)
43 12 3 LRRASVAQL SWISS;P12928;P04763;Q64618;KPYR_RAT
44 12 11 LRRLSTKYR SWISS;Q05209;PTNC_HUMAN
45 10 4 LRRPSDQEV SWISS;P16236;REL_CHICK
46 2 1 LSEHSSPEE SWISS;P07516;PPR1B_BOVIN
47 2 5 LSELSRRRI SWISS;P20459;IF2A_YEAST
48 2 9 LSGESDLEI SWISS;P06786;TOP2_YEAST
49 11 3 PENDYEDVE SWISS;P14317;HCLS1_HUMAN
50 1 5 PKRGSGKDG SWISS;P02687;MBP_BOVIN
51 3 4 PPSAYATVK SWISS;P17785;ANX2_CHICK
52 10 3 PRMPSLSVP SWISS;P02719;CINA_ELEEL
53 8 16 PSPKTPPGS SWISS;P19332;TAU_RAT
54 9 15 QGTLSKIFK SWISS;P02687;MBP_BOVIN
55 1 8 RTKRSGSV phosphorylase b kinase beta regulatory chain
Peptide targeted by all three forms of Chk1 
Peptide targeted by Chk1 wild-type and Chk1 stimulated by Chk1 peptide 14
Peptide targeted by Chk1 stimulated by Chk1 peptide 14 and Chk1 C70
Appendix 1
List of peptides phosphorylated by Chk1 C70 protein kinase
S/N COL ROW SEQUENCE TARGET PROTEIN
1 2 11 KKLGSKKPQ SWISS;P04775;CIN2_RAT
2 11 5 KKRLSVERI SWISS;P11388;TOPA_HUMAN
3 7 7 KNIVTPRTP SWISS;P02687;MBP_BOVIN
4 5 9 KREASLDNQ SWISS;P06593;PHY3_AVESA
5 5 13 KRFGSKAHM SWISS;P29476;NOS1_RAT
6 1 7 KRPSARAKA SWISS;P02687;MBP_BOVIN
7 1 11 KRPSDRAKA SWISS;P02687;MBP_BOVIN
8 1 15 KRPSERAKA SWISS;P02687;MBP_BOVIN
9 10 1 KRPSFRAKA SWISS;P02687;MBP_BOVIN
10 10 9 KRPTQRAKY SWISS;P02687;MBP_BOVIN
11 8 6 KRRGSVPIL SWISS;P16452;42_HUMAN
12 8 10 KRRLSFSET SWISS;P01582;IL1A_MOUSE
13 12 12 KRSGSVYEP SWISS;P12798;KPBB_RABIT
14 6 8 KTSPSSSPA SWISS;P19836;CTPT_RAT
15 6 16 KVPQTPLHT SWISS;P49139;MKK2_RABIT
16 5 10 LGSPLRRR SWISS;P20152;VIME_MOUSE
17 11 8 LKLASPELE SWISS;P05412;AP1_HUMAN
18 11 12 LLPMSPEEF SWISS;P42224;STA1_HUMAN
19 1 14 LQDDYEDMM SWISS;P02730;B3AT_HUMAN
20 5 8 LRAPSWIDT SWISS;P02510;CRAB_BOVIN
21 8 1 LRKVSKQEE SWISS;P50552;VASP_HUMAN
22 8 5 LRMFSFKAP SWISS;P22300;GAC2_BOVIN
23 8 9 LRRASLGAA BOS TAURUS (BOVINE) LIVER PYRUVATE KINASE (FRAGMENT)
24 8 13 LRRASLGAF BOS TAURUS (BOVINE) LIVER PYRUVATE KINASE (FRAGMENT)
25 10 4 LRRPSDQEV SWISS;P16236;REL_CHICK
26 2 5 LSELSRRRI SWISS;P20459;IF2A_YEAST
27 10 3 PRMPSLSVP SWISS;P02719;CINA_ELEEL
28 1 8 RTKRSGSV phosphorylase b kinase beta regulatory chain
Peptide targeted by all three forms of Chk1 
Peptide targeted by Chk1 wild-type and Chk1 stimulated by Chk1 peptide 14
Peptide targeted by Chk1 stimulated by Chk1 peptide 14 and Chk1 C70
